

2024 ASCP ANNUAL MEETING

Innovations in Clinical Research: Broadening Clinical Trial Methods, Endpoints and Goals

MIAMI BEACH, FLORIDA

MAY 28 - 31, 2024





Dear Colleagues,

Welcome to Miami Beach and sunshine!

On behalf of the American Society of Clinical Psychopharmacology (ASCP), I am pleased to welcome you to our very exciting annual meeting. I want to thank the Program Committee for the Annual Meeting and the Review Sub-committee for their wonderful work putting together such an extraordinary meeting.



As we continue to navigate this post-Covid era, we all are learning new approaches in our professional and personal lives. Thus, the 2024 ASCP Annual Meeting theme of "Innovations in Clinical Research: Broadening Clinical Trial Methods, Endpoints and Goals" is quite timely and relevant for our attendees. The ASCP Annual Meeting has something for everyone. There are sessions that address diversity, equity, and inclusion, major mental disorders, alcohol/substance use disorders, training and career development, as well as exploring the changes in assessments, measurements, and interventions in clinical psychiatry. Our meeting also includes a very stimulating joint workshop with the American Foundation for Suicide Prevention (AFSP) and we also continue our long-standing and highly successful New Investigators' Program.

Several popular meeting events will continue this year. The ASCP Industry Advisory Council will be hosting a roundtable event led by members of the industry, in which attendees will have the opportunity to rotate between topic areas, highlighting various aspects of the industry. Additionally, the joint lunch session from the Early Career Committee, Inclusivity Committee, and Industry Advisory Council promises to be an engaging session.

We are looking forward to our plenary sessions, which include 'Clinical Updates in Neurotherapeutics,' 'Update from Federal and Other Funding Agencies,' and the 'Regulatory Plenary.' The Keynote Session, titled 'Innovations in Clinical Research,' fits our conference theme. The 'Regulatory Challenges: Ask the Experts,' a panel of FDA representatives answering your questions, is always engaging as well.

Unique to the ASCP Annual Meeting is the active participation from colleagues in government service. The Federal and Other Funding Agencies plenary will include representatives from NIMH, NIAAA, PCORI, NIDA, VA, and the DOD. Networking and learning from these professionals continues to be vital.

The ASCP Annual Meeting checks off all the boxes in our organization's strategic plan:

- Goal #1 Enhance the development of cutting-edge research in the field of clinical psychopharmacology
 and related fields by providing investigators and clinicians the opportunity to engage in the discussion,
 education, and dissemination of research findings and new methodologies
- Goal #2 Enhance ASCP's role as the preeminent leader in innovative education in clinical
 psychopharmacology and related fields to foster the development of best practices, new treatments,
 curricula, and training for all career levels
- Goal #3 Increase the leadership, membership, and participation of all underrepresented groups in the Society by cultivating inclusion to ensure that all feel welcomed, empowered, and valued
- Goal #4 Create opportunities for individuals from diverse backgrounds, such as early career members and NIA's, to stay engaged in the Society

ASCP continues to aspire to become an exemplary leader in creating an inclusive and welcoming environment wherein everyone can learn, develop, innovate, and flourish.

I hope you have a wonderful time learning, presenting, and seeing old and new friends at our annual meeting.

Joseph F. Goldberg, M.D.

President

American Society of Clinical Psychopharmacology

Welcome to the ASCP Annual Meeting

On behalf of the ASCP Program Committee for the Annual Meeting and Review Sub-Committee, we are delighted to welcome you to the ASCP Annual Meeting. The ASCP is committed to continue building on the past success of NCDEU with program innovation while preserving the rich history of this meeting. Below are some of the highlights of the 2024

The annual meeting brings together academic investigators, industry scientists, U.S. and international regulators, National Institutes of Health (NIH) and other professionals who work in drug development and clinical trials.

2024 Program Highlights

- o Tuesday, May 28th:
 - Meeting Opening
 - Career Development Luncheon (RSVP Only)
 - Pharmaceutical Pipeline
- o Wednesday, May 29th:
 - 25th Annual Fun Run/Walk
 - Regulatory Plenary: New Tools to Enable Targeted Drug Development in Psychiatry: Lessons Learned and Path
 - ASCP Lifetime Awardee Talk: Clinical Psychopharmacology of Bipolar Disorder: Selected Studies

 - Clinical Updates in Neurotherapeutics
 - Individual Research Reports
 - ASCP Reception
- o Thursday, May 30th:
- Keynote Plenary: Innovations in Clinical Research: Broadening Clinical Trial Methods, Endpoints and Goals
- Update from Federal and Other Funding Agencies Plenary
- Investigator-Industry Collaboration Session
- Poster Session II
- o Friday, May 31st:
 - Regulatory Challenges: Ask the Experts
- o The New Investigator Program
 - A closed workshop for 20 New Investigators and informal breakfast sessions
- o Workshops: 2-hour intensive interactive sessions focused on problems and solutions
 - Tuesday and Thursday Afternoons
- * Clinical Track Sessions focused on topics of immediate clinical relevance
- ~ Not Accredited Per the new ACCME guidelines, these sessions cannot be accredited
- # Child/Adolescent Track Sessions focused on topics of child and adolescent relevance
- ^ Academic Track Sessions focused on topics of academic relevance
- + DEI Track Sessions focused on topics of DEI relevance

Organization

- o The meeting is sponsored by the American Society of Clinical Psychopharmacology (ASCP).
 - The Program Committee for the Annual Meeting (PCAN) organizes the meeting.
 - The Review Sub-Committee evaluates submitted proposals and develops program innovations.
- o Federal Agency & Other Funding Agency collaborations:
 - DOD Department of Defense
 - NIAAA National Institute on Alcohol Abuse and Alcoholism
 - NIDA National Institute of Drug Abuse
 - NIMH National Institute of Mental Health
 - PCORI Patient-Centered Outcomes Research Institute
 - VA Veterans Administration
- o Regulatory agency collaborations:
 - Food and Drug Administration (FDA)
- o Society collaboration:
 - American Foundation for Suicide Prevention (AFSP)
- o Satellite Symposia provided by Clinical Care Options, LLC
- o Parthenon Management Group organizes the ASCP Annual Meeting.

And Remember

- o The Fun Run/Walk is Wednesday, May 29th at 6:30 a.m. All are welcome to join!
- o The ASCP Reception is Wednesday, May 29th from 6:00 p.m. 7:00 p.m. All are welcome to join!

The ASCP Annual Meeting is an opportunity for education and networking. We welcome your suggestions to make the event even better. Seek us out during the meeting or provide your views by completing the evaluation form.

Best Regards,

PCAN Co-Chair

M HRepapat us Mark Rapaport, M.D.

Manish Jha, M.D. Review Sub-Committee Co-Chair Tiffany Farchione, M.D. PCAN Co-Chair


Carlos Blanco, M.D.

Review Sub-Committee Co-Chair

Hotel Maps

Hotel Loews Miami Map

Second Level



Third Level




Table of Contents

ASCP

Award Winners and Featured Speakers	5
Acknowledgements2.	5
Meeting Announcements	1
Monday, May 27, 20243	7
Tuesday, May 28, 20244	1
Wednesday, May 29, 20245.	5
Thursday, May 30, 20246.	3
Friday, May 31, 20247.	3
Posters7	9
Author Index11	1

DISCLOSURES FOR ALL ASCP PRESENTERS CAN BE VIEWED AT HTTPS://ASCPP.ORG/ASCP-MEETINGS/ASCP-ANNUAL-MEETING/

Notes

Award Winners

ASCP

Recipient of the Donald Klein Lifetime Achievement Award



Ross J. Baldessarini, M.D. Harvard Medical School

Dr. Baldessarini was born in western Massachusetts in 1937 and graduated from Williams College with highest honors in chemistry in 1959. He completed medical education at Johns Hopkins School of Medicine in 1963, where he began training in

neuroscience with Professor Vernon Mountcastle in neurophysiology, as well as spending a year at the National Institutes of Health with Drs. Seymour Kety, Julius Axelrod, and Irwin Kopin in neuropharmacology. After graduation, he completed internship at Boston City Hospital in internal medicine and then returned to the NIMH for additional training in biochemical neuropharmacology in 1964–66. In 1966 he returned to Johns Hopkins Hospital for clinical training in psychiatry with Professor Joel Elkes, and was Chief Resident Psychiatrist of the Henry Phipps Psychiatric Clinic there in 1968–69.

He moved to Massachusetts General Hospital (MGH) in 1969 to help Professor Seymour Kety establish the Laboratories for Psychiatric Research (LPR), which he directed after Dr. Kety's retirement in 1983, following a move to the new Mailman Research Center at McLean Hospital in 1977. In 1988, Professor Baldessarini was named permanent Director of the LPR as well as the founding Director of a new Bipolar & Psychotic Disorders Program at McLean Hospital, where in 1989 he also became Co-Director of Psychopharmacology and Psychopharmacology Training. He founded the International Consortium for Mood & Psychotic Disorders Research there in 1995 with colleagues from the US, Canada, South America, Europe, and Asia. He has also served as consultant to numerous scientific, industrial, and clinical organizations. He was one of the founders of the International Society for CNS Drug Trials Methodology in 2005. Currently he continues to direct the International Consortium for Mood & Psychotic Disorders Research, at the Mailman Research Center of McLean Hospital. He is a tenured Professor of Psychiatry and in Neuroscience at Harvard Medical School and Senior Consulting Psychiatrist at Masschusetts General Hospital.

Award Winners

Recipient of the Paul Wender Best Paper in *The Journal of Clinical Psychiatry* Award



Michel Sabé, M.D. Geneva University Hospitals

Nominated for: Comparative Effects of 11 Antipsychotics on Weight Gain and Metabolic Function in Patients With Acute Schizophrenia: A Dose-Response Meta-Analysis

Dr. Sabé M.D. is a clinical researcher with a focus on exploring the intricacies of schizophrenia's negative

symptoms and advancing evidence-based practices in psychiatry. His expertise lies in treatment dosages, dose-response meta-analysis methodologies to examine the impact of antipsychotic doses on patient outcomes. His research group is currently working on the minimum effective treatment doses, ensuring tailored and efficacious therapies for individuals with schizophrenia.

Beyond treatment optimization, Dr. Sabé is also focusing on novel therapeutic avenues to alleviate the burdens of negative and depressive symptoms in schizophrenia. Notably, he explores innovative approaches such as the integration of serotonergic psychedelics.

Recipient of the Jonathan Cole Presidential Service Award



John Kane, M.D.

The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell

John Kane, MD served as Chair of Psychiatry at The Zucker Hillside Hospital for 34 years and Chair of Psychiatry at The Donald and Barbara Zucker School of Medicine for 12 years. He is Professor of Psychiatry and Molecular Medicine at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and

the Co-Director of the Institute for Behavioral Science at the Feinstein Institutes for Medical Research.

He earned his medical degree from New York University in New York, New York, and completed his internship and residency in Psychiatry at The Zucker Hillside Hospital. He is a Diplomate of the American Board of Psychiatry and Neurology.

Dr. Kane is the recipient of many awards, including the Lieber Prize, The APA's Kempf Award and Foundations Prize, the New York State Office of Mental Health Lifetime Achievement Award, The Dean Award from the American College of Psychiatrists. He has served as President of the American Society of Clinical Psychopharmacology, the Psychiatry Research Society, and the Schizophrenia International Research Society.

He has been a principal investigator on 23 National Institutes of Health (NIH) grants focusing on schizophrenia, psychobiology and treatment, recovery, and improving the quality and cost of care. He is the author of over 945 peer-reviewed papers and has been consistently ranked by Thomson Reuters in the top 1% of researchers in his field, based on citations of his work. Dr. Kane has served on the Board of Scientific Counselors for the National Institute of Mental Health (NIMH), chaired the Psychopharmacologic Drugs Advisory Committee of the FDA, and serves on the editorial boards of numerous journals.

Award Winners

2023-2024 ASCP Nina Schooler Early Career Research Awardee



David Adamowicz, M.D., Ph.D.Mass General Brigham

David Adamowicz completed his MD/PhD at UC San Diego, where his thesis in Rusty Gage's lab at the Salk Institute focused on hippocampal Lewy pathology in DLB. He stayed at UCSD for psychiatry residency, during which he researched inflammatory biomarkers in schizophrenia and their relation with cognitive aging under the guidance of Dilip Jeste and

Ellen Lee. Now a geriatric psychiatry fellow at Mass General Brigham, he is pursuing further work on peripheral immune changes in the context of early Alzheimer's disease with Hyun-Sik Yang. He remains very interested in how immune dysregulation in neuropsychiatric disorders may offer insight into their pathogenesis, with the hope for new types of treatments.



New Investigator Awardees

Mitchell Arnovitz, M.D.

Northwell Health

Emine Ayvaci, M.D.

University of Texas Southwestern Medical Center

Igor D. Bandeira, M.D., Ph.D. Stanford University School of

Medicine

Andrea Boscutti, M.D.

The University of Texas Health Science Center at Houston

Kyle Brown, Ph.D.

University of Maryland School of Medicine

Adam Fijtman, M.D., Ph.D. NIH/NIMH

Solomiya Gumenyuk, Pharm.D. SMPA

Robin Heider, B.S.

Mayo Clinic

Rana Jawish, M.D.

University of Utah School of Medicine

Joshua Jordan, Ph.D.

Alto Neuroscience

Yoojin Lee, Ph.D.

National Institute of Mental Health, National Institutes of Health

Benjamin Lewis, M.D.

University of Utah, Research Park, University Neuropsychiatric Institute (UNI)

Ahmed Makhlouf, M.D.

Brigham & Women's Hospital, Harvard Medical School

Renee Martin-Willett, M.A., Ph.D.

The University of Colorado Boulder

Ehsan Moazen-Zadeh, M.D., M.Sc.

Icahn School of Medicine at Mount Sinai

Tram Nguyen, M.S.

Albert Einstein College of Medicine

Mina Rizk, M.D., M.Sc.

Icahn School of Medicine at Mount Sinai

Nivedita Sriram, B.S.

University of Texas, Southwestern Medical School

Thanh Thuy Truong, M.D.

Baylor College of Medicine

Jasper van Oort, Ph.D., M.D.

Icahn School of Medicine at Mount Sinai

Taisuke Yatomi. M.D.

Keio University School of Medicine

Featured Speakers

Regulatory Plenary: New Tools to Enable Targeted Drug
Development in Psychiatry: Lessons Learned and Path
Forward

Wednesday, May 29th: 8:30 a.m. - 10:00 a.m. EDT



Tiffany Farchione, M.D.US Food and Drug Administration

Dr. Farchione received her medical degree from Wayne State University in Detroit, Michigan, and completed adult residency and child & adolescent fellowship training at the University of Pittsburgh's Western Psychiatric Institute and Clinic. Dr. Farchione is board certified in both general and child & adolescent psychiatry. Prior to joining FDA

in 2010, Dr. Farchione was affiliated with the University of Pittsburgh Medical Center, and was on the faculty of the University of Pittsburgh.

As the Director of the Division of Psychiatry in the Office of Neuroscience at FDA, Dr. Farchione is involved in the oversight of new drug review for all psychiatric drug development activities conducted under INDs, and the review of all NDAs and supplements for new psychiatric drug claims.



Teresa Buracchio, M.D.US Food and Drug Administration

Teresa Buracchio, MD, is Director of the Office of Neuroscience in the Center for Drug Evaluation and Research, Food and Drug Administration (FDA). She oversees the review of new drug programs for neurologic and psychiatric diseases. Dr. Buracchio joined FDA in 2013. Prior to joining FDA, Dr. Buracchio worked at AbbVie as an Associate Medical Director

for Neuroscience Clinical Development. Dr. Buracchio completed her medical degree and neurology residency at Rush University Medical Center in Chicago, Illinois. Dr. Buracchio completed fellowship training in geriatric neurology at Oregon Health & Science University and Veterans Affairs Medical Center in Portland, Oregon.

Featured Speakers


ASCP



Michelle Campbell, Ph.D.US Food and Drug Administration

Dr. Michelle Campbell is the Associate Director for Stakeholder Engagement and Clinical Outcomes in the Office of Neuroscience, Office of New Drugs (OND) in FDA's Center for Drug Evaluation and Research. Dr. Campbell joined the FDA in 2014 and previously was a reviewer on the Clinical Outcome Assessments (COA) Staff and Scientific Coordinator

of the COA Qualification Program in OND. Dr. Campbell's focus is in patient-focused drug development and the use of patient experience data in the regulatory setting. Prior to joining FDA, Dr. Campbell spent more than 10 years conducting research in the academic-clinical setting, including five years in a neurology and developmental medicine department. Dr. Campbell earned her BA in Biology from the College of Notre Dame, her MS in Health Science from Towson University, and her PhD in Pharmaceutical Health Services Research from the University of Maryland School of Pharmacy.



Valentina Mantua, M.D.
US Food and Drug Administration

Valentina Mantua is medical doctor and psychiatrist with a PhD in neurobiology. She has over ten years of working experience in regulatory science. Between 2013 and 2019 she served as Italian delegate to several committees and working parties of the European Medicines Agency (EMA) including the Scientific Advice Working Party, the Central Nervous

System Working Party and the European (EU) Innovation Network. Dr. Mantua moved to the US Food and Drug Administration (FDA) in 2019, where is currently serving as a clinical team leader in the Division of Psychiatry. She holds a temporary professorship at the University of Modena and Reggio Emilia in Italy.

Featured Speakers

Clinical Updates in Neurotherapeutics
Wednesday, May 29th: 1:00 p.m. – 2:30 p.m. EDT



Carlos Blanco, M.D. National Institute on Drug Abuse

Dr. Blanco is the Director of the Division of Epidemiology, Services and Prevention Research at the National Institute on Drug Abuse (NIDA). Prior to that, he was Professor of Psychiatry at Columbia University Medical Center. He is an elected member of the National Academy of Medicine.



Jeffrey Newcorn, M.D. Icahn School of Medicine at Mount Sinai

Dr. Newcorn is professor of psychiatry and pediatrics, director of the Division of ADHD and Learning Disorders at Icahn School of Medicine at Mount Sinai, and director of Pediatric Psychopharmacology for the Mount Sinai Health System. He is a highly regarded clinician - researcher with special expertise in ADHD, aggression, and child and adolescent psy-

chopharmacology, whose academic work spans both clinical and translational topics. In addition, he has studied or helped to develop many of the emerging drugs in the ADHD field. Dr. Newcorn was a member of the steering committee of the NIMH-funded multicenter study "Multimodal Treatment of Children with ADHD (MTA)" and the DSM-IV advisory committees on child and adolescent disorders and disruptive behavior disorders. He was a founding member of the board of directors of the American Professional Society for ADHD and Related Disorders (APSARD), and served as President from 2020-2022.

Featured Speakers

ASCP



Julia Riddle, M.D.
University of North Carolina at Chapel Hill

Biography Julia N. Riddle, MD is a fellowship-trained reproductive psychiatrist, Assistant Professor, and Director of Outpatient Psychiatric Services at the Center for Women's Mood Disorder at the University of North Carolina - Chapel Hill. She completed medical school, residency, and advanced reproductive psychiatry training at Johns Hopkins

School of Medicine. Dr. Riddle studies reproductive mood disorders. She is also serves on the educational board of the National Curriculum on Reproductive Psychiatry (NCRP) and facilitates a yearly practical training conference in reproductive psychiatry.

Featured Speakers



Mark Pollack, M.D. Biopharmaceutical Consulting

Dr. Mark Pollack is Professor of Psychiatry and Behavioral Science at Rush University Medical Center. Over the last 4 years he has worked at Sage Therapeutics and Myriad Neuroscience. Prior to joining Myriad in 2020, Dr Pollack was The Grainger Professor and Chairman of the Department of

Psychiatry at Rush University Medical Center, and Director of the Road Home Program for Veterans and Their Families at Rush. He received his M.D. in 1982 from New Jersey Medical School and completed residency and fellowship training in psychiatry at Massachusetts General Hospital where he served as Director of the Center for Anxiety and Traumatic Stress Disorders and Professor of Psychiatry at Harvard Medical School until 2011. 1 2024 ASCP Annual Meeting His areas of clinical and research interest include the acute and longterm course, pathophysiology and treatment of patients with anxiety disorders including panic disorder, social anxiety disorder, PTSD and generalized anxiety disorder and associated comorbidities, development of novel pharmacologic agents for mood and anxiety disorders, uses of combined cognitive-behavioral and pharmacologic therapies for treatment refractory patients, presentation and treatment of anxiety in the medical setting, and the pathophysiology and treatment of substance abuse. Dr Pollack has received federal funding from the National Institute of Mental Health (NIMH) and National Institute of Drug Abuse (NIDA) to study the longitudinal course of panic disorder, the application of cognitive-behavioral interventions for the reduction of illicit drug use in drug abusers, the impact of terrorist attacks on the development of PTSD and course of disorder in bipolar patients, changes in brain function as assessed by MR Spectroscopy and neuropsychological testing in patients on methadone maintenance, treatment response and pharmacogenetics in refractory social anxiety disorder, treatment of sleep and examination of biomarkers in PTSD and the and use of d-cycloserine to enhance the treatment efficacy of cognitivebehavioral therapy in social anxiety and panic disorder. He has published over 400 articles, reviews and chapters, and is co-editor of the books "Challenges in Clinical Practice: Pharmacologic and Psychosocial Strategies", "Panic Disorder and Its Treatment," and "Social Phobia: Research and Practice" and "Ten Minute CBT". Dr. Pollack lectures widely in national and international forum and serves on numerous editorial, federal and industry advisory boards including the Department of Defense Blue Ribbon Panel on Traumatic Brain Injury and Psychological Health Issues Among Our Nation's Warriors and the Scientific Advisory Board, for the VA Rehabilitation Research and Development TBI Center of Excellence. He is Past President of the Anxiety and Depression Association of America, and Chairman of its Scientific Advisory Board.

Featured Speakers

ASCP

Keynote Plenary: Innovations in Clinical Research:

Broadening Clinical Trial Methods, Endpoints and Goals
Thursday, May 30th: 8:15 a.m. - 9:45 a.m. EDT



Andrew Nierenberg, M.D.Massachusetts General Hospital

Andrew A. Nierenberg, MD is the Director of the Dauten Family Center for Bipolar Treatment Innovation Massachusetts General Hospital and Professor of Psychiatry, Harvard Medical School. In addition to directing the Dauten Center, Dr. Nierenberg is the co-director of Mass General's Center for Clinical Research Education and associate

director of the Depression Clinical and Research Program. He also holds the Thomas P. Hackett, MD, Endowed Chair in Psychiatry at Mass General. Dr. Nierenberg graduated from the Albert Einstein College of Medicine of Yeshiva University, Bronx, NY. After completing his residency in psychiatry at New York University/Bellevue Hospital, he studied clinical epidemiology at Yale University as a Robert Wood Johnson Clinical Scholar. Dr. Nierenberg then joined the faculty at Harvard Medical School, first at McLean Hospital in Belmont, MA and then at Massachusetts General Hospital. He is also an Honorary Professor in the School of Medicine, Faculty of Health at Deakin University, Geelong, Australia, and an Honorary Skou Professor at Aarhus University in Denmark. Dr. Nierenberg focuses on clinical trials for bipolar disorder and depression with over 595 published papers and a Google scholar h-index of 126. He has been listed among The Best Doctors or Top Doctors in America for the treatment of mood and anxiety disorders yearly since 1994. He has been honored with the ISBD Mogens Schou Award for Research and the Brain and Behavior Research 1 2024 ASCP Annual Meeting Foundation's Colvin Prize. Current projects include organizing a Bipolar Disorder Learning Health Network and leading the SMART-BD study (Sequential Multiple Assignment Randomized Treatment for Bipolar Depression).

Featured Speakers



Paul Kenny, Ph.D.
Icahn School of Medicine at Mount Sinai

Paul Kenny is the Ward-Coleman Professor and Chairman of the Nash Family Department of Neuroscience at the Icahn Schools of Medicine at Mount Sinai in New York. Dr. Kenny's research is focused on the molecular and cellular mechanisms of substance use disorders (SUDs), obesity, and schizophrenia. He is the recipient of the Annual Alton

Ochsner Award from the Ochsner Health System, the Daniel H. Efron Research Award from the American College of Neuropsychopharmacology (ACNP), the Jacob P. Waletzky Memorial Award from the Society for Neuroscience (SfN), and the Tom Connor Distinguished Investigator Award, Neuroscience Ireland. Dr. Kenny has served as a member of the Advisory Council of the National Institute on Alcohol Abuse and Alcoholism (NIAA), the Advisory Council on Drug Abuse (NACDA), and the National Institutes of Health Council of Councils (CoC). Dr. Kenny is actively involved in developing novel small molecule drugs for the treatment of brain disorders and is the co-founder of Eolas Therapeutics, Inc.



Oleg Tcheremissine, M.D. Atrium Health

Oleg V. Tcheremissine, MD, is a Professor of Psychiatry and Research Director at the Atrium Health Wake Forest University School of Medicine Department of Psychiatry. He has over 30 years of experience in human behavioral and clinical psychopharmacology and is a board-certified Psychiatrist and Clinical Research Investigator. Dr.

Tcheremissine manages a comprehensive research portfolio focused on the treatment of Alzheimer's disorder, Schizophrenia, and Affective disorders. He has received several awards, including the Established Clinical Investigator Award and the Brian R. Nagy, MD Teaching Award from the Atrium Health Wake Forest University School of Medicine. Dr. Tcheremissine has successfully combined his research interests, teaching, clinical, and administrative responsibilities while working towards eliminating external and internal barriers to novel and innovative treatments. His goal is to reduce health disparities, improve access to top-quality care, and increase the generalizability of clinical trial results.

Featured Speakers

ASCP



Martina Pavlicova, Ph.D. Columbia University Medical Center

Martina Pavlicova, PhD is an Associate Professor of biostatistics at Columbia University. Her research interests include clinical trials, generalized longitudinal mixed effect statistical models, zero-inflated models, analysis of categorical data. She is also interested in new methods of teaching statistics and biostatistics and developing new teaching approaches for non-

statistics master and Ph.D students. 9 2024 ASCP Annual Meeting Dr. Pavlicova is the director of the Statistics, Assessment and Data Management Core in HIV Center for Clinical and Behavioral Studies at the New York State Psychiatric Institute (NYSPI) and Columbia University. She is also the senior biostatistician for the Greater New York (GNY) Node of NIDA's Clinical Trials Network, for the Clinical Trials Network Coordinating Center (CTNCC) for Lyme and other Tick-Borne Diseases, and for the NYSPI STARS division, and for the Division of Behavioral Medicine, CUIMC. Dr. Pavlicova is also interested in new methods of teaching statistics and biostatistics and developing new teaching approaches for non-statistics master and Ph.D students.In 2012, she has been granted membership in ASPH/Pfizer Public Health Academy of Distinguished Teachers and in 2016, she won prestigious Presidential Teaching Award for Outstanding Teaching in Columbia University.

Featured Speakers

Update from Federal and Other Funding Agencies

Thursday, May 30th: 10:00 a.m. - 11:30 a.m. EDT



Joseph Goldberg, M.D. Icahn School of Medicine at Mount Sinai

Joseph F. Goldberg, MD is Clinical Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai. Educated at the University of Chicago and Northwestern University Medical School, he completed his psychiatry training and psychopharmacology research fellowship at the Payne Whitney Clinic, New York Presbyterian Hospital. He has published over 220 peer-reviewed papers on psychopharmacology and mood disorders, as well as

four books, most recently "Practical Psychopharmacology: Translating Findings from Evidence-Based Trials into Real-World Clinical Practice" published in 2021 by Cambridge University Press. He has served on the Board of Directors for the American Society of Clinical Psychopharmacology and is an Editor for the Journal of Clinical Psychiatry. Dr. Goldberg is a Distinguished Fellow of the American Psychiatric Association and has been listed for many years in Best Doctors in America and Castle Connolly's "America's Top Doctor."



Christopher Sarampote, Ph.D. National Institute of Mental Health

Christopher Sarampote, Ph.D., is Chief of the Biomarker and Intervention Development for Childhood-Onset Disorders Branch within the Division of Translational Research at NIMH. He has worked at NIMH for over 15 years, first serving as a Scientific Review Officer then as a Program Officer focused on child traumatic stress, research training

and career development, and pediatric mental health intervention development.

Featured Speakers

ASCP



Ivan Montoya, M.D., M.P.H. DHHS/National Institute on Drug Abuse

Dr. Montoya is the Director of the Division of Therapeutics and Medical Consequences (DTMC) of the National Institute on Drug Abuse (NIDA), which is one the institutes of the National Institutes of Health (NIH). He has a Medical Doctor and Psychiatrist degrees from the University of Antioquia in Colombia, and a Master's in Public Health from Johns Hopkins

University. He was a Fulbright-Humphrey Fellow at Johns Hopkins and Visiting Fellow at the Intramural Research Program 5 2024 ASCP Annual Meeting of NIDA. He joined NIDA's extramural program in 1999 as Medical Officer of the Clinical Trials Network, became the Deputy Director of DTMC in 2008 and the Director of DTMC in 2024. He has published extensively about treatments (pharmacological and non-pharmacological), and medical consequences of SUDs. He has received multiple awards including the NIH Director's Award and the Michael Morrison Award from CPDD. He is also Honorary Professor of the University of Valencia (Spain).



Daniel Falk, Ph.D. NIAAA/NIH

Dr. Daniel Falk is the Branch Chief of the Medications Development Branch (MDB) within the Division of Treatment and Recovery (DTR) at the National Institute on Alcohol Abuse and Alcoholism (NIAAA). At NIAAA, he directs research on pharmacotherapy for alcohol use disorder (AUD) and novel methods for clinical trials, including the evaluation of new

endpoints. Dr. Falk co-leads the NIAAA Alcohol Pharmacotherapy Evaluation Program (APEP) - a contract program which evaluates the efficacy and safety of novel and repurposed compounds to treat AUD in laboratory and randomized clinical trials. Dr. Falk is also the Coordinator of the NIAAA Data Archive, a large data repository over 400 NIAAA funded studies involving human subjects. Dr. Falk has authored a number of publications and presentations on a diverse set of alcohol-related topics, including pharmacotherapy to treat AUD, statistical methods and outcomes for alcohol clinical trials, psychiatric comorbidity of AUD, and correlates of alcohol use. Prior to joining NIAAA, he conducted epidemiologic research on AUD as a contractor for NIAAA. Dr. Falk received his Ph.D. in Clinical Psychology from the University of Miami.

Featured Speakers



Lori Davis, M.D. Veterans Affairs Medical Center

Lori Davis, MD has been a VA clinical researcher for the past 30 years and has held continuous peerreview funding with a predominance of VA awards. She has been asked to deliver this talk on behalf of the VA Office of Research and Development central office leadership.is also Honorary Professor of the University of Valencia (Spain).



Fuad Issa, M.D.Defense Health Agency

Dr. Issa has been active in clinical research for 35 years. Since January 2022 he has been the Psychological Health Research Portfolio Manager at Research & Engineering Directorate, Defense Health Agency (DHA). Prior to that Dr. Issa served as Chief of Clinical Care at DHA Psychological Health Center of Excellence since 2016. He has worked in the civilian,

military and veteran mental health arenas both in clinical and research capacities. Dr. Issa has published in peer-reviewed journals, presented at national and international conferences, and authored book 10 2024 ASCP Annual Meeting chapters. Dr. Issa is board certified in Psychiatry, distinguished life fellow of the American Psychiatric Association, member of Society of Biological Psychiatry and American Medical Association. He is a Clinical Professor of Psychiatry and Behavioral Sciences at George Washington University.

Featured Speakers

ASCP



Tracy Y. Wang, M.D., M.Sc.Patient-Centered Outcomes Research Institute (PCORI)

Tracy Y. Wang, MD, MHS, MSc, is Chief of Comparative Clinical Effectiveness Research at the Patient-Centered Outcomes Research Institute (PCORI). She is a cardiologist and clinical researcher with expertise in observational research, implementation science, and pragmatic randomized clinical trials.

Wang leads PCORI's comparative effectiveness research portfolio focused on increasing the evidence base for existing interventions and emerging innovations to improve health outcomes and health equity through multidisciplinary research. She provides strategic guidance and oversight of ongoing programs and new initiatives designed to enhance and accelerate patient-centered comparative effectiveness research.

Prior to her current role, Wang was Professor of Medicine at Duke University and led several large studies at the Duke Clinical Research Institute that have focused on comparative effectiveness and safety, health disparities, care quality assessment, and quality improvement. To date, she has published over 350 peer-reviewed manuscripts, lectured widely on pragmatic trials and the use of data to guide initiatives aimed at reducing disparities in healthcare access and outcomes. Additionally, she has evolved the platform for research to diversify site and patient recruitment, innovate longitudinal patient follow-up, enrich the collection of patient-reported outcomes, and pragmatically adjudicate clinical events of interest. She previously served as Assistant Dean of Continuing Medical Education and Director of Health Services and Outcomes Research at Duke.

Wang has served on numerous volunteer committees, tasks forces, and writing groups for the American Heart Association, American College of Cardiology, and American College of Physicians. She previously chaired the AHA Council Operations Committee (2020-22) and AHA's Quality of Care and Outcomes Research (QCOR) Council (2017-19). She is an Associate Editor of the JAMA Internal Medicine journal and serves on the editorial boards of several other high-impact journals. In 2022, she was awarded the American Heart Association QCOR Outstanding Lifetime Achievement Award, and has received multiple awards recognizing her excellence in mentorship and leadership in enhancing diversity in both research participants and workforce.

An undergraduate of Yale University, Wang received her MD from Harvard Medical School, MSc in molecular biochemistry and biophysics from Yale University, and MHS in clinical research from Duke University.

Featured Speakers

Regulatory Challenges: Ask the Experts Friday, May 31st: 10:30 a.m. – 11:30 a.m. EDT



Tiffany Farchione, M.D.US Food and Drug Administration

See Dr. Farchione's biography above.



Bernard Fischer, M.D.US Food and Drug Administration

Dr. Fischer is a psychiatrist and Deputy Director for the Division of Psychiatry in the Office of New Drugs at the U.S. Food and Drug Administration (FDA). Prior to coming to the FDA, he spent more than 10 years in academic medicine researching schizophrenia at the Maryland Psychiatric Research Center (MPRC) and the Department of Veterans Affairs. Dr. Fischer

earned his medical degree from the Medical College of Virginia. He completed a 5-year research/clinical residency in psychiatry at the University of Maryland/ Sheppard Pratt followed by a post-doctoral fellowship in schizophrenia research at the MPRC. He holds a master's degree in biomedical ethics and has been board certified in both psychiatry and addiction medicine. He has authored or co-authored over 50 scientific publications.

Featured Speakers

ASCP



Martine Solages, M.D.US Food and Drug Administration

Dr. Martine Solages is a board-certified pediatrician, general psychiatrist, and child and adolescent psychiatrist. She received her medical degree from the Yale School of Medicine. She completed pediatrics residency at Johns Hopkins Hospital, general psychiatry residency at Yale University, and child and adolescent psychiatry fellowship at

the Yale Child Study Center. Dr. Solages joined FDA in 2018 and is a Clinical Team Lead in the Division of Psychiatry. Before entering government service, Dr. Solages was on faculty at Children's National Hospital in Washington D.C., where she was the Associate Director of the Psychiatric Consultation Liaison Service and the Associate Director of the Child and Adolescent Psychiatry Fellowship Program.

ASCP Notes

Acknowledgements

ASCP

Program Committee for the Annual Meeting (PCAN) Chairs



Mark H. Rapaport, M.D.



Tiffany Farchione, M.D.

Review Sub-Committee Chairs



Carlos Blanco, M.D.



Manish Jha, M.D.

New Investigator Award Program Chairs



Mark H. Rapaport, M.D.



Christopher Sarampote, Ph.D.

Acknowledgements

Program Committee for the Annual Meeting and Review Sub-Committee Members

Scott T. Aaronson, M.D. * Sheppard Pratt

Saeed Ahmed, M.D.
Rutland Regional Medical Center

Raman Baweja, M.D.
Penn State College of Medicine

Carlos Blanco, M.D.
National Institute on Drug Abuse

Theadia L. Carey, M.D.Detroit Wayne Health Authority (Authority Health)

★ Cherise Regina Chin Fatt, Ph.D. Center for Depression Research and Clinical Care

Leslie Citrome, M.D., M.P.H. New York Medical College

Lawrence J. Cohen, B.A., Pharm.D.UNT System College of Pharmacy

M. Lynn Crismon, Pharm.D.The University of Texas at Austin

Justin Faden, D.O. Temple University

Daniel E. Falk, Ph.D. NIAAA/NIH

Marlene P. Freeman, M.D. Massachusetts General Hospital

Bradley Gaynes, M.D.*University of North Carolina

★New Investigator Alumni

Ahmad Hameed, M.D.Penn State College of Medicine

Usman Hameed, M.D.Penn State M.S. Hersey Medical Center

★ Rebecca Hendrickson, M.D., Ph.D. VA Puget Sound Health Care System

Michael Henry, M.D. Massachusetts General Hospital

★ Dan Vlad Iosifescu, M.D., M.Sc. New York University School of Medicine

★ Manish Kumar Jha, M.D.
University of Texas Southwestern
Medical Center

★ Shixie Jiang, M.D.
University of Florida, College of Medicine

★ Jordan F. Karp, M.D.
University of Arizona College of
Medicine

Susan Kornstein, M.D.Virginia Commonwealth University

Valentina Mantua, M.D.Food and Drug Administration

★ Matej Markota, M.D. Mayo Clinic

*Representing ASCP CME Committee

Acknowledgements

ASCP

Program Committee (continued)

★ Francisco Moreno, M.D. University of Arizona

★ Nicholas Murphy, Ph.D., M.Sc. Baylor College of Medicine

★ Carla Nasca, Ph.D. NYU Langone

Andrew Alan Nierenberg, M.D. Massachusetts General Hospital

Luca Pani, M.D.* University of Miami

Gerard Sanacora, M.D., Ph.D. Yale

★ Erika Fairchild Helmuth Saunders, M.D.

Penn State College of Medicine

★ Manpreet Kaur Singh, M.D., M.S.

University of California, Davis, School of Medicine

★ Jair Soares, M.D., Ph.D. University of Texas School of Medicine at Houston

Louisa Steinberg, M.D. ICON Plc

Oleg V. Tcheremissine, M.D. Atrium Health

Antonio Lucio Teixeira, M.D.
University of Texas Health Science
Center at San Antonio

Ottavio Valerio Vitolo, M.D. Cerevance

Eric Wexler, M.D., Ph.D. Modernbrains

★ Carlos Zarate, D. Phil.
National Institute of Mental Health

★ Zachary David Zuschlag, D.O. James A. Haley Veterans Hospital

★New Investigator Alumni

*Representing ASCP CME Committee

Acknowledgements

New Investigator Award Program Committee

- ★ Mahavir Agarwal, M.D., Ph.D. Centre for Addiction and Mental Health (CAMH)
- ★ Elizabeth Ballard, Ph.D.

 National Institute of Mental Health
- ★ Lori Davis, M.D.
 Veterans Affairs Medical Center
- ★ Walter Dunn, M.D., Ph.D. West Los Angeles VA Medical Center/UCLA
- **★ Tiffany Farchione, M.D.**US Food and Drug Administration

Bruce Kinon, M.D.Karuna Therapeutics

Ivan Montoya, M.D., M.P.H.
DHHS/National Institute on Drug
Abuse

★ Katharine Phillips, M.D.

Weill Cornell Medical College and NewYork-Presbyterian/Weill Cornell Medical Center

Mark Rapaport, M.D.

University of Utah Huntsman Mental Health Institute

Christopher Sarampote, Ph.D. National Institute of Mental Health

Nina Schooler, Ph.D.
SUNY Downstate Health Sciences
Center

★ Holly Swartz, M.D.
University of Pittsburgh School of Medicine

[★]New Investigator Alumni

^{*}Representing ASCP CME Committee

Acknowledgements

ASCP

ASCP Officers and Board

★ Joseph F. Goldberg, M.D.*

President Icahn School of Medicine at Mount Sinai

★ Anita H. Clayton, M.D.

President Elect University of Virginia

Leslie Citrome, M.D.

Past President New York Medical College

★ Holly Swartz, M.D.

Treasurer
University of Pittsburgh School of
Medicine

★ Dan Iosifescu, M.D.

Treasurer Elect New York University School of Medicine

Trisha Suppes, M.D., Ph.D.

Past Treasurer Stanford University

Scott Aaronson, M.D.*

Sheppard Pratt

Alexandra Aaronson, M.D., M.Sc.

Edward Hines VA Hospital

★ Mahavir Agarwal, M.D., Ph.D.

Centre for Addiction and Mental Health (CAMH)

★ Crystal Clark, M.D.*

University of Toronto, Women's College Hospital

★New Investigator Alumni

★ Christoph Correll, M.D.

The Zucker Hillside Hospital

Marlene Freeman, M.D.

Editor of the Journal of Clinical Psychiatry
Massachusetts General Hospital,
Ammon-Pinizzotto Center for
Women's Mental Health

Susan Kornstein, M.D.

Virginia Commonwealth University

Matthew Macaluso, D.O.

The University of Alabama at Birmingham

Stephen Marder, M.D.

Semel Institute at UCLA

Sanjay Matthew, M.D.

Baylor College of Medicine

★ Francisco Moreno. M.D.

Chair of the Inclusivity Committee University of Arizona

★ George Papakostas, M.D.

Massachusetts General Hospital

Gerard Sanacora, M.D., Ph.D.

Yale

★ Erika Saunders, M.D.

Penn State College of Medicine, Penn State Health

★ Carlos Zarate. M.D.

National Institute of Mental Health

*Representing ASCP CME Committee

Notes

Meeting Announcements

ASCP

Registration Desk Hours: Rotunda East - Second Level

 Monday
 1:00 p.m. - 5:00 p.m.

 Tuesday
 7:30 a.m. - 6:00 p.m.

 Wednesday
 7:30 a.m. - 7:00 p.m.

 Thursday
 7:30 a.m. - 6:00 p.m.

 Friday
 7:30 a.m. - 10:30 a.m.

Speaker Ready Room Hours:

New Yorker

Monday 1:00 p.m. – 5:00 p.m. Tuesday - Thursday 7:30 a.m. – 6:00 p.m. Friday 7:30 a.m. – 10:30 a.m.

The meeting organizers ask that all speakers upload their slides no later than 24 hours prior to their scheduled presentation time.

ASCP Wi-Fi

SSID: ASCP2024

Access PIN: ASCP2024

Americans with Disabilities Act - It is the policy of ASCP not to discriminate against any person on the basis of disabilities. If you feel you need services or auxiliary aids mentioned in this act in order to fully participate in this continuing education activity, please call the Executive Office at 615-649-3085 or send an email to info@ascpp.org.

Discounts – All ASCP meeting attendees who booked their room at the Loews Miami Beach through the ASCP website will have the following resort amenities.

- Complimentary basic wireless internet in all guest rooms
- · Fitness Center admittance

ASCP Membership - If you would like to join ASCP, you can log onto our website at https://ascpp.org/ascp-meetings/ascp-annual-meeting/ and register online. ASCP staff are available at the ASCP registration desk, located in Rotunda East - Second Level Foyer, if you have any questions. You may also contact the ASCP office at 615-649-3085.

ASCP | Meeting Announcements

Continuing Education Credits

Disclosures are available for all ASCP Annual Meeting presenters online at https://ascpp.org/ascpmeetings/ascp-annual-meeting/.

Continuing Education Credits are available for physicians, pharmacists, and psychologists. Self-assessment maintenance of certification credits are available for physicians. Applications for credit must be completed online with the meeting evaluation survey. The survey may be completed during or after the meeting at https://ascpp.org/ascpmeetings/ascp-annual-meeting/. Surveys for continuing education credit must be submitted no later than Monday, July 1, 2024. There is a \$40.00 administrative fee for CME/CE applications. It is the policy of the ASCP to require disclosure of financial relationships from individuals in a position to control the content of a CME activity; to identify and resolve conflicts of interest related to those relationships; and to make disclosure information available to the audience prior to the CME activity. Presenters are required to disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentations.

American Society of Clinical Psychopharmacology 2024 Annual Meeting May 28, 2024 – May 31, 2024 Miami Beach, FL

Joint Accreditation Statement



JOINTLY ACCREDITED PROVIDER™

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and American Society of Clinical Psychopharmacology (ASCP). Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy

Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Amedco Joint Accreditation #4008163

Physicians (ACCME) Credit Designation

This activity has been approved for *AMA PRA Category 1 Credit*™.

Nurses (ANCC) Credit Designation

This activity has been approved for ANCC contact hours.

Pharmacists and Pharmacy Technicians (ACPE) Credit Designation

This activity has been approved for ACPE contact hours.

Meeting Announcements

ASCP

Psychologists (APA) Credit Designation



This activity has been approved for APA hours.

The following state boards accept courses from APA providers for Psychologists/
Counselors: AK, AR, AZ, CA, CT, DC, DE, FL,

GA, HI, IA, ID, IL, IN, IO, KS, MA (LEP ONLY), ME, MO, NC, ND, NH, NE, NJ, NM, NV, OK*, OR, PA, RI, SC, SD, TN, TX, UT, VA, WI, WY

The following state boards accept courses approved by any other state for Psychologists/Counselors: CO, MD

MI: No CE requirements.

*OK: Accepts APA credit for live, in-person activities but not for ethics and/or online courses.

The following state boards accept courses from APA providers for MFTs: AK, AR, AZ, CA, CO, CT, DE, FL, GA, IA, ID, IN, KS, MD, ME, MO, NE, NC, NH, NJ, NM, NV, OK*, OR, PA, RI, SC, SD, TN, TX, UT, VA, WA, WDC, WI, WY AL MFTs: Credits authorized by NBCC or any other state licensing agency will be accepted.

MA MFTs: Participants can self-submit courses not approved by the MAMFT board for review.

The following state boards accept courses from APA providers for Addictions Professionals: AK, AR, CO, CT, DC, DE, GA, IA, IN, KS, LA, MD, MO, MT, NC, ND, NE, NJ, NM, NY (held outside NY *ONLY*), OK*, OR, SC, UT, WA, WI, WY

The following state boards accept courses from APA providers for Social Workers: AK, AR, AZ, CA, CO, DE, FL, GA, ID, IN, KY, ME, MN, MO, NE, NH, NM, OR, PA, VT, WI, WY

New York Board for Psychology (NY PSY)

This activity has been approved for New York Psychologists.

Full Continuing Education (CE) Language showing CE hours will be available on our website prior to the start of the meeting.

All evaluations, both Meeting and Continuing Education, must be completed by Monday, July 1, 2024.

The Meeting Evaluation Survey will be available at https://ascpp.org/ascpmeetings/ascp-annual-meeting/. We encourage all registrants to complete the evaluation. Attendees requesting CME, MOC, or CE credits are encouraged to complete the survey in order to obtain credits. There is a \$40.00 administrative fee for CME/CE applications. Your candid input on the 2024 meeting is appreciated as we strive to improve the meeting each year.

ASCP Meeting Announcements

ASCP would like to acknowledge the generosity of the following companies whose unrestricted educational grants have contributed to the overall quality of this meeting:

Neurocrine Biosciences, Inc.

2025 ASCP Annual Meeting

Save the Date





The 2025 ASCP Annual Meeting will take place May 27 - May 30, 2025, at the Fairmont Scottsdale Princess in Scottsdale, Arizona. Details regarding abstract submission for the 2025 Annual Meeting will be released in September 2024.

Sponsorships

ASCP

Thank you to our sponsors for their support.

GOLD



SILVER





ASCP

Notes

Monday

Monday, May 27, 2024

ASCP

AT-A-GLANCE

Sunday, May 26, 2024

6:00 p.m. - 7:00 p.m. New Investigator Award (NIA) Meet and Greet

(Invitation Only)

Venus

Monday, May 27, 2024

8:00 a.m. - 4:55 p.m. **NIA Workshop (Invitation Only)**

Cowrie

1:00 p.m. - 5:00 p.m. **Registration**

Rotunda East - Second Level

1:00 p.m. - 5:00 p.m. Speaker Ready Room

New Yorker

1:00 p.m. - 5:00 p.m. **ASCP Author's Nook**

Americana Foyer

ASCP

Notes

FULL SCHEDULE

Monday, May 27, 2024

8:00 a.m. - 4:55 p.m. NIA Workshop (Invitation Only)

Cowrie

Co-Chairs: Mark Rapaport, University of Utah Huntsman Mental Health Institute Chris Sarampote, National Institute of Mental Health

The ASCP Annual Meeting offers a special program for New Investigators in an effort to promote the education and training of junior investigators in psychopharmacology. Established investigators were asked to nominate individuals who may be interested in a research career in psychopharmacology for this special program. These nominees submitted an abstract describing their current research or area of research interest, a letter of recommendation from their chair or mentor, a career statement, and a curriculum vitae. The selection of awardees was based upon the scientific merit of the abstract, the level of training of the nominee and a committee of internal and external reviewers' assessment of the relative value of the specialized program to each applicant at this time in his/her career. The awardees will participate in this special educational workshop and present their posters during the scheduled poster sessions and orals during the Individual Research Reports on Wednesday, May 29, 2024. In addition, they will receive a travel expense award and a certificate acknowledging their participation in the program at an awards ceremony on Tuesday evening, May 28, 2024. This year marks the 32nd year of the New Investigator program with 20 New Investigator awardees that are indicated with a ribbon in the poster session of this program; they will also be notated with a ribbon icon in the program book.

Faculty

Mahavir Agarwal, M.D.,Ph.D. Centre for Addiction and Mental Health (CAMH)

Elizabeth Ballard, Ph.D.

National Institute of Mental Health

Lori Davis, M.D.

Veterans Affairs Medical Center

Walter Dunn, M.D., Ph.D. West Los Angeles VA Medical Center/UCLA

Tiffany Farchione, M.D.US Food and Drug Administration

Bruce Kinon, M.D.Karuna Therapeutics

Ivan Montoya, M.D., M.P.H. DHHS/ National Institute on Drug Abuse


Katharine Phillips, M.D.

Weill Cornell Medical College and NewYork-Presbyterian/Weill Cornell Medical Center

Nina Schooler, Ph.D. SUNY Downstate Health Sciences Center

Holly Swartz, M.D. University of Pittsburgh School of Medicine

ASCP Notes



Tuesday, May 28, 2024

ASCP

AT-A-GLANCE

Tuesday, May 28, 2024

7:30 a.m. - 8:30 a.m. NIA Breakfast Roundtable (Invitation Only)

Neptune

7:30 a.m. - 9:00 a.m. Morning Breakfast

Americana Foyer

7:30 a.m. - 6:00 p.m. **Registration**

Rotunda East - Second Level

7:30 a.m. - 6:00 p.m. Speaker Ready Room

New Yorker

7:30 a.m. - 6:00 p.m. **ASCP Author's Nook**

Americana Foyer

8:30 a.m. - 9:00 a.m. Meeting Opening

Salon 3

9:00 a.m. - 10:30 a.m. **Panel Sessions**

*Interventional	*Bridging the	*Revisiting	*Understanding
Options for	Gap Between	Modafinil /	Drug Safety
Treatment-	Body and Brain	Armodafinil in	Decisions as
Resistant	 Insights from 	Bipolar Disorder	New Therapies
Depression (TRD):	Translational	Targeting	Emerge: The
Lessons from	Research	Cognition,	Importance of
ASCERTAIN-TRD	on Causes,	Depression, and	Perspective
and ELEKT-D	Treatments, and	Sleep Circadian	
Studies	Outcomes	Rhythm	
Poinciana 1-2	Poinciana 3-4	Salon 1	Salon 2

10:30 a.m. - 11:00 a.m. Break

Americana Foyer

*Clinical Track, ~Not Accredited, *Child/Adolescent Track, ^Academic Track, +DEI Track

41

ASCP Tuesday, May 28, 2024

11:00 a.m. - 12:30 p.m. Panel Sessions

*The Future of Ketamine and Esketamine in Treatment- Resistant Depression: A Translational Perspective	AFSP/ASCP Session: Are We Making Progress with Anti- Suicidal Treatments and Biomarkers for Immediate Risk?	*#Fine Tuning Response in Child and Adolescent Psychopharma- cology Research and Practice	*~Navigating the Frontier of Post- Traumatic Stress Disorder Treatment: Exploring Updates in Ketamine and a Novel Therapeutic Clinical Program of Brexpiprazole in Combination with Sertraline
Poinciana 1-2	Poinciana 3-4	Salon 1	Salon 2

12:30 p.m. - 2:00 p.m. Early Career, Industry, and Inclusivity Luncheon

Cowrie

2:00 p.m. - 4:00 p.m. Pharmaceutical Pipeline Session

Salon 3

4:00 p.m. - 4:15 p.m. **Break**

Americana Foyer

4:15 p.m. - 6:15 p.m. **Workshops**

^The Next Generation ASCP Model Psychopharma-cology Curriculum: Combining Educational Technology with Content Expertise to Develop an Educational Tool for Modern Learners	*Good News/ Bad News: Precision Neuroscience and the Clinical Trials Ecosystem	*^Immune Mechanisms of Mental Illnesses: What Should Clinicians and Researchers Know?	^Early/Mid- Career Funding Workshop: Beyond NIH: Opportunities and Strategies for Foundational and Philanthropic Funding
Poinciana 1-2	Poinciana 3-4	Salon 1	Salon 2

6:30 p.m. - 8:00 p.m. New Investigator Award (NIA) Ceremony (Invitation Only)

Cowrie

^{*}Clinical Track, ~Not Accredited, #Child/Adolescent Track, ^Academic Track, *DEI Track

Tuesday, May 28, 2024

ASCP

FULL SCHEDULE

Tuesday, May 28, 2024

7:30 a.m. - 8:30 a.m. NIA Breakfast Roundtable (Invitation Only)

Neptune

7:30 a.m. - 9:00 a.m. Morning Breakfast

Americana Foyer

7:30 a.m. - 6:00 p.m. **Registration**

Rotunda East - Second Level

7:30 a.m. - 6:00 p.m. **Speaker Ready Room**

New Yorker

7:30 a.m. - 6:00 p.m. **ASCP Author's Nook**

Americana Foyer

8:30 a.m. - 9:00 a.m. Meeting Opening

Salon 3

Panel Sessions

9:00 a.m. - 10:30 a.m. *Interventional Options for Treatment-Resistant

Depression (TRD): Lessons from ASCERTAIN-

TRD and ELEKT-D Studies

Poinciana 1-2

Chair: Maurizio Fava, Massachusetts General Hospital

Co-Chair: Amit Anand, Harvard Medical School

9:09 a.m. - 9:27 a.m. Rapidity of Symptom Improvement with

Ketamine Versus ECT in Patients with

Treatment-Resistant Depression

Brittany O'Brien, Baylor College of Medicine

9:27 a.m. - 9:45 a.m. Comparative Effectiveness Research Trial for

Antidepressant Incomplete and Non-Responders

with Treatment Resistant Depression

(ASCERTAIN-TRD): Report of Primary Outcome

George Papakostas, Massachusetts General

Hospital

*Clinical Track, ~Not Accredited, *Child/Adolescent Track, ^Academic Track, *DEI Track

ASCP | Tuesday, May 28, 2024

9:00 a.m. - 10:30 a.m.

(continued)

*Interventional Options for Treatment-Resistant Depression (TRD): Lessons from ASCERTAIN-TRD and ELEKT-D Studies

*Poinciana 1-2

Baseline Features that Predict Improvement with Ketamine Versus Electroconvulsive Therapy in TRD: Findings from the ELEKT-D Study

James Murrough, Icahn School of Medicine at Mount Sinai

10:03 a.m. - 10:21 a.m.

Improvement in Suicide Risk and Propensity with Antidepressant Augmentation and Switch

Madhukar Trivedi, UT Southwestern Medical Center

Approaches in ASCERTAIN-TRD

9:00 a.m. - 10:30 a.m.

*Bridging the Gap Between Body and Brain –
Insights from Translational Research on Causes,
Treatments, and Outcomes
Poinciana 3-4

Discussant: Manish Jha, University of Texas Southwestern Medical Center

Chair: Mahavir Agarwal, Centre for Addiction and Mental Health (CAMH) **Co-Chair:** Rebecca Hendrickson, VA Puget Sound Health Care System

9:09 a.m. - 9:33 a.m. Chronic Mental and Physical Health Interactions following Repetitive Trauma Exposure in

Veterans and Mice

Katharine Liang, VA Puget Sound Health Care

System

9:33 a.m. - 9:57 a.m. **Exploring Omic' Pathways of Antipsychotic**

Treatment in Metabolic Tissues

Kyle Burghardt, Wayne State University

9:57 a.m. - 10:21 a.m. The Effect of Weight Loss on Brain Age in

Schizophrenia

Nicolette Stogios, Centre for Addiction and Mental

Health, University of Toronto

Discussant: Rebecca Hendrickson, VA Puget Sound Health Care System

*Clinical Track, ~Not Accredited, *Child/Adolescent Track, ^Academic Track, *DEI Track

Tuesday, May 28, 2024

ASCP

9:00 a.m. - 10:30 a.m.

*Revisiting Modafinil / Armodafinil in Bipolar Disorder Targeting Cognition, Depression, and

Sleep Circadian Rhythm

Salon 1

Chair: Mark Frye, Mayo Clinic

9:09 a.m. - 9:33 a.m. **Modafinil / Armodafinil in Bipolar Disorder:**

Lesson Learned, Roadmap Forward

Mark Frye, Mayo Clinic

9:33 a.m. - 9:57 a.m. A Proof-Of-Concept Study of Modafinil for

Neurocognitive Impairment in Bipolar Disorder Katherine Burdick, Brigham and Women's Hospital/

Harvard Medical School

9:57 a.m. - 10:21 a.m. How Best to Understand Sleep/Wake and

Circadian Factors in the Context of Modafinil

Treatment of Bipolar Disorder

Ellen Frank, University of Pittsburgh School of

Medicine

Discussant: Katherine Burdick, Brigham and Women's Hospital/Harvard Medical School

9:00 a.m. - 10:30 a.m.

*Understanding Drug Safety Decisions as New Therapies Emerge: The Importance of

Perspective

Salon 2

Chair: Peter Weiden, SUNY Stony Brook

Co-Chair: Joseph Goldberg, Icahn School of Medicine at Mount Sinai

9:09 a.m. - 9:27 a.m. Balancing Risks and Benefits of Psychotropic

Medications in Clinical Practice

Joseph Goldberg, Icahn School of Medicine at

Mount Sinai

9:27 a.m. - 9:45 a.m. **Drug Safety Decisions Are Not Always Rational:**

A Kahneman Perspective of Cognitive and

Emotional Biases

Peter Weiden, SUNY Stony Brook

^{*}Clinical Track, ~Not Accredited, *Child/Adolescent Track, ^Academic Track, *DEI Track

ASCP | Tuesday, May 28, 2024

9:00 a.m. - 10:30 a.m.

(continued)

*Understanding Drug Safety Decisions as New Therapies Emerge: The Importance of

Perspective

Salon 2

9:45 a.m. - 10:03 a.m. **Drug Safety Decisions During Times of Change:**

A Regulatory Perspective

Bernard Fischer, US Food and Drug Administration

10:03 a.m. - 10:21 a.m. The Role of Patient Voice in New Drug

Evaluations: Advocacy Perspectives

Gordon Lavigne, Schizophrenia and Psychosis

Action Alliance

Discussant: Nina Schooler, SUNY Downstate Health Sciences Center

10:30 a.m. - 11:00 a.m. Break

Americana Foyer

Panel Sessions

11:00 a.m. - 12:30 p.m.

*The Future of Ketamine and Esketamine in

Treatment-Resistant Depression: A Translational

Perspective 2

Poinciana 1-2

Chair: Gustavo Medeiros, University of Maryland School of Medicine

11:09 a.m. - 11:33 a.m. The Future of Ketamine and Esketamine in

Treatment-Resistant Depression: A Translational

Perspective

Gustavo Medeiros, University of Maryland School of

Medicine

11:33 a.m. - 11:57 a.m. The Future of Ketamine and Esketamine in

Treatment-Resistant Depression: A Translational

Perspective

Jennifer Vande Voort, Mayo Clinic

11:57 a.m. - 12:21 p.m. The Future of Ketamine and Esketamine in

Treatment-Resistant Depression: A Translational

Perspective

Kyle Brown, University of Maryland School of

Medicine

Discussant: Dan Iosifescu, New York University School of Medicine

😭 = New Investigator Awardee

*Clinical Track, ~Not Accredited, #Child/Adolescent Track, ^Academic Track, *DEI Track

Tuesday, May 28, 2024

ASCP

11:00 a.m. - 12:30 p.m. AFSP/ASCP Session: Are We Making Progress

with Anti-Suicidal Treatments and Biomarkers

for Immediate Risk?

Poinciana 3-4

Chair: Madhukar Trivedi, UT Southwestern Medical Center

11:09 a.m. - 11:33 a.m. What is an Anti-Suicidal Response to Treatment?

Elizabeth Ballard, National Institute of Mental

Health

11:33 a.m. - 11:57 a.m. Biomarkers of Future Mental Illness: Focus on

Postpartum Depression

Jennifer Payne, University of Virginia

11:57 a.m. - 12:21 p.m. Statewide Collaboration to Better Understand

Youth Depression and Suicide

Holli Slater, The University of Texas Southwestern

Medical Center

Discussant: Jill Harkavy-Friedman, American Foundation for Suicide Prevention

11:00 a.m. - 12:30 p.m. *#Fine Tuning Response in Child and Adolescent

Psychopharmacology Research and Practice

Salon 1

Chair: Paul Croarkin, Mayo Clinic

11:09 a.m. - 11:33 a.m. Understanding and Leveraging Placebo

Response in Pediatric Antidepressant Treatment

Jeffrey Strawn, College of Medicine, University of

Cincinnati

11:33 a.m. - 11:57 a.m. Seven Myths of Randomized Controlled Trial

Analysis in Child and Adolescent Psychiatry

Jeffrey Mills, University of Cincinnati

11:57 a.m. - 12:21 p.m. Artificial Intelligence and Digital Psychiatry: A

Frontier for Precision Medicine Paradigm in

Children and Adolescents

Arjun Athreya, Mayo Clinic

Discussant: Manpreet Singh, University of California, Davis, School of Medicine

*Clinical Track, ~Not Accredited, *Child/Adolescent Track, ^Academic Track, *DEI Track

ASCP | Tuesday, May 28, 2024

11:00 a.m. - 12:30 p.m.

*~Navigating the Frontier of Post-Traumatic Stress Disorder Treatment: Exploring Updates in Ketamine and a Novel Therapeutic Clinical Program of Brexpiprazole in Combination with Sertraline

Salon 2

Chair: Lori Davis, Veterans Affairs Medical Center

11:09 a.m. - 11:27 a.m. **Post-Traumatic Stress Disorder: Patient**

Perspectives of Unmet Care Needs

Susan Gurley, Anxiety and Depression Association

of America (ADAA)

11:27 a.m. - 11:45 a.m. Post-Traumatic Stress Disorder: An Overview of

Causes, Symptomatic Characteristics, Clinical

Challenges, and Clinical Unmet Needs Thomas Neylan, University of California, San

Francisco

11:45 a.m. - 12:03 p.m. Clinical Research on Ketamine for Post-

Traumatic Stress Disorder: Update and Future

Directions

Adriana Feder, Icahn School of Medicine at Mount

Sinai

12:03 p.m. - 12:21 p.m. Clinical Program of Brexpiprazole in

Combination with Sertraline for Patients with

Post-Traumatic Stress Disorder

Saloni Behl, Otsuka (OPDC)

Discussant: Lori Davis, Veterans Affairs Medical Center

12:30 p.m. - 2:00 p.m. Early Career, Industry, and Inclusivity Luncheon

Cowrie

^{*}Clinical Track, ~Not Accredited, *Child/Adolescent Track, ^Academic Track, *DEI Track

Tuesday, May 28, 2024

ASCP

2:00 p.m. - 4:00 p.m. Pharmaceutical Pipeline Session

Salon 3

Chair: Carlos Zarate, National Institute on Mental Health **Co-Chair:** Leslie Citrome, New York Medical College

2:00 p.m. - 2:10 p.m. A Phase 2 Randomized Proof-Of-Concept

Trial of NBI-1065846 (TAK-041) in Adults with Anhedonia Associated with Major Depressive

Disorder: Results of the Terpsis Study Shannon Benedetto, Neurocrine Biosciences

2:10 p.m. - 2:20 p.m. **Oral Prolonged-Release Adjunctive Ketamine**

(KET01): Phase 2 Trial in Treatment-Resistant Depression and Phase 1 Trial Comparing Tolerability with Intranasal Esketamine

Hans Eriksson, HMNC Brain Health

2:20 p.m. - 2:30 p.m. MM120 (Lysergide) for GAD: Results from

Mindmed's Phase 2 Trial

Paula Jacobsen, Mind Medicines Inc

2:30 p.m. - 2:40 p.m. Troriluzole, a Novel Glutamate Modulating Agent,

in Development for Obsessive-Compulsive

Disorder

Azim Munivar, Biohaven Pharmaceuticals

2:40 p.m. - 2:50 p.m. **Pro-Cognitive Pharmacodynamic Effects of**

ALTO-101: Results from Brain and Behavioral Outcomes in a Randomized, Double-Blind Phase

1 Study

Adam Savitz, Alto Neuroscience

2:50 p.m. - 3:00 p.m. **CT-155: Early Stage Evidence in the**

Development of a Prescription Digital Therapeutic to Treat Experiential Negative

Symptoms of Schizophrenia

Abhishek Pratap, Boehringer Ingelheim

Pharmaceuticals, Inc.

^{*}Clinical Track, ~Not Accredited, *Child/Adolescent Track, ^Academic Track, *DEI Track

ASCP Tuesday, May 28, 2024

2:00 p.m 4:00 p.m. (continued)	Pharmaceutical Pipeline Session Salon 3
3:00 p.m 3:10 p.m.	Glucagon-Like Peptide-1 (GLP-1) Receptor Agonism as a Potential Pharmacotherapy for Alcohol Use Disorder: Converging Evidence from Rodent and Early Human Studies Mehdi Farokhnia, Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, NIDA and NIAAA, NIH
3:10 p.m 3:20 p.m.	Efficacy and Safety of XEN1101, a Novel, Kv7 Potassium Channel Opener in Adults With Moderate to Severe Major Depressive Disorder: Results from the Phase 2 X-NOVA Study Joseph McIntosh, Xenon
3:20 p.m 3:30 p.m.	An Exploratory Comparison of Sublingual Dexmedetomidine with Quetiapine in Healthy Elderly Subjects Robert Risinger, Bioxcel Therapeutics
3:30 p.m 3:40 p.m.	Positive Results Achieved in a Phase 2b, Double-Blind, Placebo-Controlled Study for BNC210, an Alpha7 Nicotinic Receptor Negative Allosteric Modulator, for the Treatment of PTSD (ATTUNE). Spyros Papapetropoulos, Bionomics Ltd
3:40 p.m. – 4:00 p.m.	Discussion
4:00 p.m 4:15 p.m.	Afternoon Break Americana Foyer

^{*}Clinical Track, ~Not Accredited, #Child/Adolescent Track, ^Academic Track, *DEI Track

Tuesday, May 28, 2024

ASCP

Workshops

4:15 p.m. - 6:15 p.m. **^The Next Generation ASCP Model**

Psychopharmacology Curriculum: Combining Educational Technology with Content Expertise to Develop an Educational Tool for Modern

Learners *Poinciana 1-2*

Chair: Matthew Macaluso, University of Alabama at Birmingham **Co-Chair:** Richard Shelton, University of Alabama at Birmingham

4:30 p.m. - 4:45 p.m. The Next Generation ASCP Model

Psychopharmacology Curriculum: Combining Educational Technology with Content Expertise to Develop an Educational Tool for Modern

Learners

Lawrence Cohen, UNT System College of Pharmacy/ Regulatory Insurance Advisors

Discussant: Joseph Goldberg, Icahn School of Medicine at Mount Sinai

4:15 p.m. - 6:15 p.m. *Good News/Bad News: Precision Neuroscience

and the Clinical Trials Ecosystem

Poinciana 3-4

Chair: Mark Opler, WCG Inc.

4:21 p.m. - 4:40 p.m. Good News/Bad News: Precision Neuroscience

and the Clinical Trials Ecosystem
Adam Savitz, Alto Neuroscience

4:40 p.m. - 4:59 p.m. Enrichment Strategies for Clinical Trials in

Psychiatry - Symptom Scales and Objective

Measures

Seth C. Hopkins, Sumitomo Pharma America

4:59 p.m. - 5:18 p.m. Good News/Bad News: Precision Neuroscience

and the Clinical Trials Ecosystem

John Carlos Diaz, GeoSera

^{*}Clinical Track, ~Not Accredited, *Child/Adolescent Track, ^Academic Track, *DEI Track

ASCP Tuesday, May 28, 2024

4:15 p.m 6:15 p.m. (continued)	*Good News/Bad News: Precision Neuroscience and the Clinical Trials Ecosystem Poinciana 3-4
5:18 p.m 5:37 p.m.	Good News/Bad News: Precision Neuroscience and the Clinical Trials Ecosystem John Sonnenberg, Uptown Research Institute
5:37 p.m 5:56 p.m.	Performance-Based Approaches to Improve Data Quality and Signal Detection Barbara Echevarria, WCG
5:56 p.m 6:15 p.m.	Developing and Using Data-Driven Proxies to Accelerate Cns Therapeutics Development. George Garibaldi, Garibaldi Consulting GMBH
4:15 p.m 6:15 p.m.	*^Immune Mechanisms of Mental Illnesses: What Should Clinicians and Researchers Know? Salon 1

Chair: James Murrough, Icahn School of Medicine at Mount Sinai

4:25 p.m. - 4:50 p.m.

Repeated Levodopa Administration Improves
Functional Connectivity in Reward Circuity,
Motivation, and Anhedonia in Depressed
Patients with Higher Inflammation
Jennifer Felger, Emory University School of
Medicine

4:50 p.m. - 5:15 p.m. A Clinician's Perspective on Immune Mechanisms of Depression

Manish Jha, University of Texas Southwestern

Medical Center

5:15 p.m. - 5:40 p.m. **Neuroimmune Underpinning of Clinical and**

Social Factors in Cocaine Addiction

Keren Bachi, The Addiction Institute of Mount Sinai;

Icahn School of Medicine at Mount Sinai

^{*}Clinical Track, ~Not Accredited, *Child/Adolescent Track, ^Academic Track, *DEI Track

Tuesday, May 28, 2024 ASCP



4:15 p.m 6:15 p.m. (continued)	*^Immune Mechanisms of Mental Illnesses: What Should Clinicians and Researchers Know? Salon 1
5:40 p.m 6:05 p.m.	Experimental Medicine Approach for Developing Immunomodulatory Drugs as Novel Treatments for Psychiatric Disorders James Murrough, Icahn School of Medicine at Mount Sinai

Discussant: Abu Minhajuddin, The University of Texas Southwestern Medical Center

4:15 p.m 6:15 p.m.	^Early/Mid-Career Funding Workshop: Beyond NIH: Opportunities and Strategies for Foundational and Philanthropic Funding Salon 2
	Saion 2

Chair: Elizabeth Ballard, National Institute of Mental Health Co-Chair: Nicholas Murphy, Baylor College of Medicine

4:24 p.m 4:58 p.m.	Early/Mid-Career Funding Workshop: Beyond NIH: Opportunities and Strategies for Foundational and Philanthropic Funding Jill Harkavy-Friedman, American Foundation for Suicide Prevention
4:58 p.m 5:32 p.m.	Early/Mid-Career Funding Workshop:

Early/Mid-Career Funding Workshop: Beyond NIH: Opportunities and Strategies for Foundational and Philanthropic Funding Katherine Burdick, Brigham and Women's Hospital/ Harvard Medical School

5:32 p.m. - 6:06 p.m. Early/Mid-Career Funding Workshop: Beyond NIH: Opportunities and Strategies for Foundational and Philanthropic Funding Mark Rapaport, University of Utah Huntsman Mental Health Institute

Discussant: Manish Jha, University of Texas Southwestern Medical Center

^{*}Clinical Track, ~Not Accredited, *Child/Adolescent Track, ^Academic Track, *DEI Track

ASCP Tuesday, May 28, 2024

6:30 p.m. - 8:00 p.m.

New Investigator Award (NIA) Ceremony (Invitation Only)

Cowrie

Wednesday, May 29, 2024 ASCP

AT-A-GLANCE

Wednesday, May 29, 2024

6:30 a.m 8:00 a.m.	Annual ASCP Fun Run/Walk – All Attendees Welcome (No prior sign up necessary) Meet at the St. Moritz Lawn
7:30 a.m 8:30 a.m.	Inclusivity Committee Breakfast (Invitation Only) Room TBD
7:30 a.m 9:00 a.m.	Morning Breakfast Americana Foyer
7:30 a.m 6:00 p.m.	Speaker Ready Room New Yorker
7:30 a.m 7:00 p.m.	Registration Rotunda East - Second Level
7:30 a.m 7:00 p.m.	ASCP Author's Nook Americana Foyer
8:30 a.m 10:00 a.m.	Regulatory Plenary: New Tools to Enable Targeted Drug Development in Psychiatry: Lessons Learned and Path Forward Salon 3
10:00 a.m 10:15 a.m.	Break Americana Foyer
10:15 a.m 11:15 a.m.	ASCP Awards Ceremony and ASCP Lifetime Awardee Talk – Ross J. Baldessarini, M.D.: Clinical Psychopharmacology of Bipolar Disorder: Selected Studies Salon 3
11:15 a.m 1:00 p.m.	~Poster Session I with Lunch Salon 4
11:15 a.m 1:00 p.m.	Early Career Networking Tables (Open to all Attendees) Americana Foyer

ASCP Wednesday, May 29, 2024

1:00 p.m. - 2:30 p.m. *Clinical Updates in Neurotherapeutics

Salon 3

2:30 p.m. - 3:00 p.m. **Break**

Americana Foyer

3:00 p.m. - 4:30 p.m. Individual Research Reports

Individual	Individual	Individual	Individual
Research	Research	Research	Research
Reports (IRRs):	Reports (IRRs):	Reports (IRRs):	Reports
Therapeutic	Neuroscience-	Innovations in	(IRRs): Clinical
Pipeline for	Informed	Alcohol and	Outcomes in
Mood Disorders	Treatment	Substance Use	Psychiatric
	Approaches for	Disorders	Disorders
	Depression		
Poinciana 1-2	Poinciana 3-4	Salon 1	Salon 2

5:00 p.m. - 6:00 p.m. ASCP Business Meeting (ASCP Members Only)

Poinciana 3-4

6:00 p.m. - 7:00 p.m. ASCP Reception (Open to All Attendees!)

Americana Lawn

7:30 p.m. - 8:30 p.m. **Satellite Symposium:** *Cultivating Inclusivity:*

Paving the Path to Improved Diversity in Clinical

Trials Salon 3

^{*}Clinical Track, ~Not Accredited, *Child/Adolescent Track, ^Academic Track, *DEI Track

Wednesday, May 29, 2024 ASCP

FULL SCHEDULE

Wednesday, May 29, 2024

6:30 a.m. - 8:00 a.m. Annual ASCP Fun Run/Walk - All Attendees

Welcome (No prior sign up necessary)

Meet at the St. Moritz Lawn

7:30 a.m. - 8:30 a.m. Inclusivity Committee Breakfast (Invitation Only)

Room TBD

7:30 a.m. - 9:00 a.m. Morning Breakfast

Americana Foyer

7:30 a.m. - 6:00 p.m. Speaker Ready Room

New Yorker

7:30 a.m. - 7:00 p.m. **Registration**

Rotunda East - Second Level

7:30 a.m. - 7:00 p.m. **ASCP Author's Nook**

Americana Foyer

8:30 a.m. - 10:00 a.m. **Regulatory Plenary:** *New Tools to Enable*

Targeted Drug Development in Psychiatry:

Lessons Learned and Path Forward

Salon 3

Chair: Tiffany Farchione, US Food and Drug Administration

8:39 a.m. - 9:06 a.m. New Tools to Enable Targeted Drug

Development in Psychiatry: Lessons Learned

and Path Forward

Teresa Buracchio, US Food and Drug

Administration

9:06 a.m. - 9:33 a.m. New Tools to Enable Targeted Drug

Development in Psychiatry: Lessons Learned

and Path Forward

Michelle Campbell, US Food and Drug

Administration

^{*}Clinical Track, ~Not Accredited, *Child/Adolescent Track, ^Academic Track, *DEI Track

ASCP Wednesday, May 29, 2024

8:30 a.m. - 10:00 a.m. Regulatory Plenary: New Tools to Enable (continued) Targeted Drug Development in Psychiatry: Lessons Learned and Path Forward Salon 3 9:33 a.m. - 10:00 a.m. **New Tools to Enable Targeted Drug Development in Psychiatry: Lessons Learned** and Path Forward Valentina Mantua, US Food and Drug Administration 10:00 a.m. - 10:15 a.m. Break Americana Foyer 10:15 a.m. - 11:15 a.m. **ASCP Awards Ceremony and ASCP Lifetime** Awardee Talk – Ross J. Baldessarini, M.D.: Clinical Psychopharmacology of Bipolar Disorder: Selected Studies Salon 3 ~Poster Session I with Lunch 11:15 a.m. - 1:00 p.m. Salon 4 11:15 a.m. - 1:00 p.m. **Early Career Networking Tables** (Open to all Attendees) Americana Foyer 1:00 p.m. - 2:30 p.m. *Clinical Updates in Neurotherapeutics

Chair: Carlos Blanco, National Institute on Drug Abuse

Salon 3

1:09 p.m. - 1:36 p.m. ADHD Update: Current Issues and Emerging

Therapeutics

Jeffrey Newcorn, Icahn School of Medicine at

Mount Sinai

1:36 p.m. - 2:03 p.m. **Neurosteroids in Women's Mental Health Care:**

Precision Treatment for Postpartum Depression

with Brexanolone and Zuranolone

Julia Riddle, University of North Carolina at Chapel

Hill

^{*}Clinical Track, ~Not Accredited, *Child/Adolescent Track, ^Academic Track, *DEI Track

Wednesday, May 29, 2024 ASCP

1:00 p.m 2:30 p.m. (continued)	*Clinical Updates in Neurotherapeutics Salon 3
2:03 p.m 2:30 p.m.	Update on the Pharmacotherapy of Anxiety Disorders and PTSD Mark Pollack, Biopharmaceutical Consulting
2:30 p.m 3:00 p.m.	Break Americana Foyer

Individual Research Reports

3:00 p.m 4:30 p.m.	Individual Research Reports (IRRs): Therapeutic Pipeline for Mood Disorders Poinciana 1-2
3:00 p.m 3:20 p.m.	Investigational COMP360 Psilocybin Treatment for Treatment-Resistant Depression: Assessing Altered States of Consciousness Nilay Hewitt, Compass Pathfinder Ltd.
3:20 p.m 3:40 p.m.	Adjunctive Treatment with Seltorexant Improved Patient-Reported Depressive Symptoms, Insomnia Symptoms, and Overall Health in MDD with Insomnia Gahan Pandina, Johnson and Johnson, Innovative Medicine
3:40 p.m 4:00 p.m.	Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Profiles of DLX-001, A Novel Neuroplastogen Under Development for the Treatment of Major Depressive Disorder Aaron Koenig, Delix Therapeutics
4:00 p.m 4:20 p.m.	Effects of Bedtime TNX-102 SI (Sublingual Cyclobenzaprine (CBP) HCI) on Mood and Anxiety Symptoms in Fibromyalgia: Results of the Phase 3 RESILIENT Trial Seth Lederman, Tonix Pharmaceuticals

ASCP Wednesday, May 29, 2024

3:00 p.m 4:30 p.m.	Individual Research Reports (IRRs): Neuroscience-Informed Treatment Approaches for Depression Poinciana 3-4
3:00 p.m 3:20 p.m.	Unraveling the Relationships Between Childhood Adversity, Psychopathology, and the Rostral Anterior Cingulate Cortex: A Transdiagnostic Study Across Diverse Non-Psychotic Psychiatric Disorders Jasper van Oort, Icahn School of Medicine at Mount Sinai
3:20 p.m 3:40 p.m.	Similar and Unique Immune Proteomic Profiles of Major Depressive Disorder and Primary Dermatological disorders: A Potential for Novel Treatments Mina Rizk, Icahn School of Medicine at Mount Sinai
3:40 p.m 4:00 p.m.	Dysregulated Insula Connectivity and Its Association with Suicide Risk Yoojin Lee, National Institute of Mental Health
4:00 p.m 4:20 p.m.	Ketamine Outcomes and Health Care Utilization: 5 Year Experience from an Academic Ketamine Clinic Cristina Cusin, Massachusetts General Hospital
3:00 p.m 4:30 p.m.	Individual Research Reports (IRRs): Innovations in Alcohol and Substance Use Disorders Salon 1
3:00 p.m 3:20 p.m.	Pain Responses in Adolescents with Depression and Cannabis Use Tram Nguyen, Albert Einstein College of Medicine
3:20 p.m 3:40 p.m.	IL17RB Genetic Variants Are Associated with Acamprosate Treatment Response in Patients with Alcohol Use Disorder: A Multi-Omics Study Ming-Fen Ho, Mayo Clinic

Wednesday, May 29, 2024 ASCP

3:00 p.m 4:30 p.m. (continued)	Individual Research Reports (IRRs): Innovations in Alcohol and Substance Use Disorders Salon 1
3:40 p.m 4:00 p.m.	Effects of Alcohol Use Frequency and Exogenous Cannabinoids on Anandamide Levels in a Community Sample Using Cannabis for Anxiety Renee Martin-Willett, The University of Colorado Boulder
4:00 p.m 4:20 p.m.	Alcohol Craving, Cortisol Metabolism and Acamprosate Treatment Response in Patients with Alcohol Use Disorder Robin Heider, Mayo Clinic
3:00 p.m 4:30 p.m.	Individual Research Reports (IRRs): Clinical Outcomes in Psychiatric Disorders Salon 2
3:00 p.m 3:20 p.m.	Baseline Cognition is Not Associated with Depression Outcomes in Vortioxetine for Major Depressive Disorder: Findings from Placebo- Controlled Trials Joshua Jordan, Alto Neuroscience
3:20 p.m 3:40 p.m.	Can an Implantable Device Deliver a Year of Maintenance Risperidone? Results from a Phase 1 PK/Safety Study Evaluating 6- and 12-Month Versions of the DLP-114 Device in Schizophrenia Peter Weiden, SUNY Stony Brook
3:40 p.m 4:00 p.m.	Design of a Mobile Mental Health Stigma Reducing Intervention for Black Adults with Depression and Anxiety Aderonke Bamgbose Pederson, Harvard Medical School/MGH
4:00 p.m 4:20 p.m.	Localizing Heterogenous Patterns of Brain Atrophy in Schizophrenia to a Common Brain Network Ahmed Makhlouf, Brigham and Women's Hospital, Harvard Medical School

ASCP Wednesday, May 29, 2024

5:00 p.m. - 6:00 p.m. ASCP Business Meeting (ASCP Members Only)

Poinciana 3-4

6:00 p.m. - 7:00 p.m. ASCP Reception (Open to All Attendees!)

Americana Lawn

7:30 p.m. - 8:30 p.m. Satellite Symposium: *Cultivating Inclusivity:*

Paving the Path to Improved Diversity in Clinical

Trials Salon 3

This session will explore the critical importance of improving diversity and inclusivity in clinical trials, so the results are generalizable and applicable to real-world patients encountered in clinical practice. Through insightful conversations and real-world examples, we aim to inspire a shift toward greater diversity, ensuring that clinical trials reflect the rich tapestry of the patient populations being treated. Provided by Clinical Care Options, LLC in partnership with American Society of Clinical Psychopharmacology. Supported by an educational grant from Otsuka America Pharmaceutical, Inc.

Thursday, May 30, 2024

ASCP

AT-A-GLANCE

Thursday, May 30, 2024

7:00 a.m 8:00 a.m.	ASCP Committee Chair Collaboration Meeting (Invitation Only) Boardroom
7:15 a.m 8:15 a.m.	NIA Breakfast Roundtable (Invitation Only) Neptune
7:30 a.m 9:00 a.m.	Morning Breakfast Americana Foyer
7:30 a.m 6:00 p.m.	Speaker Ready Room New Yorker
7:30 a.m 6:00 p.m.	Registration Rotunda East - Second Level
7:30 a.m 6:00 p.m.	ASCP Author's Nook Americana Foyer
8:15 a.m 9:45 a.m.	Keynote Plenary: Innovations in Clinical Research: Broadening Clinical Trial Methods, Endpoints and Goals Salon 3
9:45 a.m 10:00 a.m.	Break Americana Foyer
10:00 a.m 11:30 a.m.	Update from Federal and Other Funding Agencies Salon 3
11:30 a.m 12:30 p.m.	Investigator-Industry Collaboration Session (RSVP Only) Cowrie
12:30 p.m 2:00 p.m.	Early Career Networking Tables (Open to all Attendees)

^{*}Clinical Track, ~Not Accredited, *Child/Adolescent Track, ^Academic Track, *DEI Track

Americana Foyer

ASCP Thursday, May 30, 2024

12:30 p.m. - 2:15 p.m. ~ **Poster Session II with Lunch** Salon 4

2:15 p.m. - 3:45 p.m. **Panels**

^Modern Clinical Trial Designs for Heterogeneous disorders: New Applications of Aggregated and Individual N-Of-1 Trials in Psychiatry	*#Early Results from the NIMH- Funded Early Psychosis Intervention Network (EPINET)	*The Use of Psychostimulants for the Treatment of ADHD in the Prison Setting: Balancing Benefits and Risks	*Pseudospecific Versus Transdiagnostic Symptom Targeting in Pharmacotherapy Trials: Agitation, Attention, Anhedonia, and Mood Instability
Poinciana 1-2	Poinciana 3-4	Salon 1	Salon 2

3:45 p.m. - 4:15 p.m. **Break**

Americana Foyer

4:15 p.m. - 6:15 p.m. **Workshops**

Justice, Equity, Diversity, and Inclusion in Health Research	*^Bridging the Research to Practice Gaps	*Use of Biomarkers to Identify Treatments for Psychiatric Patients: The Right Medicine for the Right Patient at the Right Time
Poinciana 1-2	Salon 1	Salon 2

^{*}Clinical Track, ~Not Accredited, *Child/Adolescent Track, ^Academic Track, +DEI Track

Thursday, May 30, 2024

ASCP

FULL SCHEDULE

Thursday, May 30, 2024

7:00 a.m. - 8:00 a.m. ASCP Committee Chair Collaboration Meeting

(Invitation Only)

Boardroom

7:15 a.m. - 8:15 a.m. NIA Breakfast Roundtable (Invitation Only)

Neptune

7:30 a.m. - 9:00 a.m. Morning Breakfast

Americana Foyer

7:30 a.m. - 6:00 p.m. Speaker Ready Room

New Yorker

7:30 a.m. - 6:00 p.m. **Registration**

Rotunda East - Second Level

7:30 a.m. - 6:00 p.m. **ASCP Author's Nook**

Americana Foyer

8:15 a.m. - 9:45 a.m. **Keynote Plenary:** *Innovations in Clinical*

Research: Broadening Clinical Trial Methods,

Endpoints and Goals

Salon 3

Chair: Andrew Nierenberg, Massachusetts General Hospital

8:24 a.m. - 8:51 a.m. **Mechanisms of Opioid Reward and Aversion**

Paul Kenny, Icahn School of Medicine at Mount

Sinai

8:51 a.m. - 9:21 a.m. Catalysts of Change: Advancing Alzheimer's

Therapeutics through Targeted Insights

Oleg Tcheremissine, Atrium Health

9:21 a.m. - 9:45 a.m. **Emerging Innovations in Clinical Trials for**

Psychiatry

Martina Pavlicova, Columbia University Medical

Center

^{*}Clinical Track, ~Not Accredited, *Child/Adolescent Track, ^Academic Track, *DEI Track

ASCP Thursday, May 30, 2024

9:45 a.m. - 10:00 a.m. **Break**

Americana Foyer

10:00 a.m. - 11:30 a.m. Update from Federal and Other Funding

Agencies Salon 3

Chair: Joseph Goldberg, Icahn School of Medicine at Mount Sinai

10:06 a.m. - 10:20 a.m. **Tailoring Treatments for Mental Illness**

Christopher Sarampote, National Institute of Mental

Health (NIMH)

10:20 a.m. - 10:34 a.m. National Institute on Drug Abuse Update

Ivan Montoya, DHHS/National Institute on Drug

Abuse (NIDA)

10:34 a.m. - 10:48 a.m. NIAAA Update: Focus on the Medications

Development ProgramDaniel Falk, (NIAAA/NIH)

10:48 a.m. - 11:02 a.m. Updates from Veterans Health Administration

Office of Research and Development

Lori Davis, Veterans Affairs Medical Center (VA)

11:02 a.m. - 11:16 a.m. Update from Defense Health Agency

Psychological Health Research Portfolio Fuad Issa, Defense Health Agency (DoD)

11:16 a.m. - 11:30 a.m. Patient-Centered Comparative Effectiveness

Research

Tracy Y. Wang, Patient-Centered Outcomes

Research Institute (PCORI)

11:30 a.m. - 12:30 p.m. Investigator-Industry Collaboration Session

(RSVP Only)

Cowrie

12:30 p.m. - 2:00 p.m. Early Career Networking Tables

(Open to all Attendees)

Americana Foyer

^{*}Clinical Track, ~Not Accredited, *Child/Adolescent Track, ^Academic Track, *DEI Track

Thursday, May 30, 2024

ASCP

12:30 p.m. - 2:15 p.m. ~ Poster Session II with Lunch

Salon 4

Panels

2:15 p.m. - 3:45 p.m. ^Modern Clinical Trial Designs for

Heterogeneous disorders: New Applications of Aggregated and Individual N-Of-1 Trials in

Psychiatry
Poinciana 1-2

Chair: Rebecca Hendrickson, VA Puget Sound Health Care System

2:24 p.m. - 2:42 p.m. **Exploring Variation in Treatment Response Using**

Aggregated N-Of-1 Clinical Trials

Nicholas Schork, The Translational Genomics

Research Institute

2:42 p.m. - 3:00 p.m. PTSD, Pupils, Prazosin, and Personalized

Medicine: Testing a Predictive Biomarker of PTSD Treatment Response Using an Aggregated

N-Of-1 Clinical Trial Design

Rebecca Hendrickson, VA Puget Sound Health Care

System

3:00 p.m. - 3:18 p.m. Estimating the Optimal Number of Treatment

Cycles for Treatment Individualization in N-Of-1

Triolo

Francisco Diaz, The University of Kansas Medical

Center

3:18 p.m. - 3:36 p.m. **Treatment of Post-Traumatic Stress Disorder**

with Associated Neurocognitive Complaints: Rationale for a Randomized N-Of-1 Trial of

Methylphenidate

Lori Davis, Veterans Affairs Medical Center

Discussant: Mark Rapaport, University of Utah Huntsman Mental Health Institute

^{*}Clinical Track, ~Not Accredited, *Child/Adolescent Track, ^Academic Track, *DEI Track

ASCP Thursday, May 30, 2024

2:15 p.m. - 3:45 p.m. *#Early Results from the NIMH-Funded Early

Psychosis Intervention Network (EPINET)

Poinciana 3-4

Chair: John Kane, The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell

2:24 p.m. - 2:48 p.m. Longitudinal Hospitalization Rates in Early

Psychosis Associated with Coordinated Specialty Care: An EPINET Assessment

Alan Breier, Indiana University School of Medicine

2:48 p.m. - 3:12 p.m. The Utilization of Long-Acting Injectable

Antipsychotics and Clozapine in Early Phase

Patients: Data from Epinet

John Kane, The Donald and Barbara Zucker School

of Medicine at Hofstra/Northwell

3:12 p.m. - 3:36 p.m. **Medication Treatment Data from a Consortium**

of 13 Clinics Providing Coordinated Specialty
Care for Individuals with First Episode Psychosis

Delbert Robinson, Hofstra NS-LIJ School of

Medicine

Discussant: Dawn Velligan, University of Texas Health Science Center

2:15 p.m. - 3:45 p.m. *The Use of Psychostimulants for the Treatment

of ADHD in the Prison Setting: Balancing

Benefits and Risks

Salon 1

Chair: Martin Katzman, START Clinic for Mood and Anxiety Disorders

2:24 p.m. - 2:48 p.m. Finding the Balance When Treating Adult

Prisoners with ADHD

Gunter Lorberg, Central North Correctional Centre

2:48 p.m. - 3:12 p.m. **Preliminary Data Examining Psychostimulant**

Therapy in Incarcerated Individuals with ADHD Martin Katzman, START Clinic for Mood and Anxiety

Disorders

^{*}Clinical Track, ~Not Accredited, *Child/Adolescent Track, ^Academic Track, *DEI Track

Thursday, May 30, 2024

ASCP

2:15 p.m. - 3:45 p.m.

(continued)

*The Use of Psychostimulants for the Treatment of ADHD in the Prison Setting: Balancing Benefits and Risks

Salon 1

3:12 p.m. - 3:36 p.m. Markers of Maladaptive Behaviour in ADHD and

Comorbid Psychopathologies

Tia Sternat, START Clinic for Mood and Anxiety

Disorders

Discussant: Larry Klassen, Eden Mental Health Centre

2:15 p.m. - 3:45 p.m. *Pseudospecific Versus Transdiagnostic

Symptom Targeting in Pharmacotherapy Trials:

Agitation, Attention, Anhedonia, and Mood

Instability
Salon 2

Chair: Joseph Goldberg, Icahn School of Medicine at Mount Sinai

2:24 p.m. - 2:42 p.m. **Do Antipsychotics Address Hostility and**

Aggressive Behavior by Managing Psychotic or Manic Symptoms. Or Is There a Specific Anti-

Hostility/Anti-Aggressive Effect?
Justin Faden, Temple University

2:42 p.m. - 3:00 p.m. Attention and Cognitive Function: Is It Specific or

Pseudospecific? Implications for Drug Discovery

and Development

Roger McIntyre, University of Toronto

3:00 p.m. - 3:18 p.m. **Targeting Anhedonia in Isolation and in Context**

Manpreet Singh, University of California, Davis,

School of Medicine

3:18 p.m. - 3:36 p.m. Mood Instability: A Symptom in Search of a

Diagnosis

Joseph Goldberg, Icahn School of Medicine at

Mount Sinai

Discussant: Tiffany Farchione, US Food and Drug Administration

^{*}Clinical Track, ~Not Accredited, #Child/Adolescent Track, ^Academic Track, *DEI Track

ASCP Thursday, May 30, 2024

3:45 p.m. - 4:15 p.m. **Break**

Americana Foyer

Workshops

4:15 p.m. - 6:15 p.m. **Justice, Equity, Diversity, and Inclusion in Health**

Research
Poinciana 1-2

Chair: Francisco Moreno, University of Arizona

4:24 p.m. - 5:01 p.m. A More Equitable Future: Improving

Representation in Clinical Research Studies

Veronica Sandoval, Genentech

5:01 p.m. - 5:38 p.m. Practical Interventions to Increase Diversity in

Trial Participation

Heather Sutton, Otsuka Pharmaceutical

Development and Commercialization, Inc. (OPDC)

5:38 p.m. - 6:15 p.m. **Diversity, Equity and Fair Inclusion in Clinical**

Research: Metrics for Success

Jennifer Miller, Yale School of Medicine

4:15 p.m. - 6:15 p.m. **Bridging the Research to Practice Gaps

Salon 1

Chair: A. Rush, Curbstone Consultant LLC

4:24 p.m. - 5:00 p.m. Advancing Psychiatric Care and Treatment

Development Through Fit-For-Purpose Curation

of EHR-Derived Real-World Data

Alex Vance, Holmusk

5:00 p.m. - 5:38 p.m. A Transdiagnostic Early Warning Score

Predicting Psychiatric Hospitalization Based on

Electronic Health Records DataMaxime Taquet, University of Oxford

5:38 p.m. - 6:15 p.m. Prediction of Major Depressive Disorder Severity

at the Time of Diagnosis Using Mental Status

Examination

Nadezda Lipunova, Holmusk

Thursday, May 30, 2024

ASCP

4:15 p.m 6:15 p.m.	*Use of Biomarkers to Identify Treatments for Psychiatric Patients: The Right Medicine for the Right Patient at the Right Time.
	Salon 2

Chair: Larry Alphs, Denovo Biopharma LLC		
4:21 p.m 4:40 p.m.	Machine Learning in Medical Applications Moses Njuguna, Princeton University	
4:40 p.m 4:59 p.m.	Precision Measures for Precision Psychiatry: Enabling Clinical Development in a New Era Gayle Wittenberg, Johnson and Johnson	
4:59 p.m 5:18 p.m.	Using Machine Learning to Identify Biomarkers for Clinical Trial Enrichment Through the Use of a Sub-Insight Learning Paradigm and Large Language Models Joseph Geraci, NetraMark Holdings	
5:18 p.m 5:37 p.m.	Use of Digital Biomarkers in Patient Selection and Follow up Christopher Chatham, Hoffman La Roche Ltd.	
5:37 p.m 5:56 p.m.	An EEG-Based, Machine Learning Biomarker to Identify Responsive vs. Non-responsive Subjects in an MDD Clinical Trial: Initial Validation Data from the EMBARC Study Database Qiang Li, Neumarker Inc.	
5:56 p.m 6:15 p.m.	Multimodal Prediction of Alzheimer's Disease – Opportunities in Nordic Registry and Biobank Data Ole Andreassen, University of Oslo, Ulleral Hospital	

ASCP Notes

Friday, May 31, 2024

ASCP

AT-A-GLANCE

Friday, May 31, 2024

7:30 a.m. - 9:00 a.m. Morning Breakfast

Americana Foyer

7:30 a.m. - 10:30 a.m. Speaker Ready Room

New Yorker

7:30 a.m. - 10:30 a.m. **Registration**

Rotunda East - Second Level

7:30 a.m. - 10:30 a.m. **ASCP Author's Nook**

Americana Foyer

8:30 a.m. - 10:00 a.m. Panels

*Evaluating the Evidence: Is There a Meaningful Clinical Difference Between Ketamine and Esketamine?	*Progress and New Developments in the Use of Neuroimaging Biomarkers in Psychiatric Clinical Trials	^Adherence	*^Insights for Advancing Translation from Bench to Clinic in Substance Use Disorders
Poinciana 1-2	Poinciana 3-4	Salon 1	Salon 2

10:00 a.m. - 10:30 a.m. Break

Americana Foyer

10:30 a.m. - 11:30 a.m. Regulatory Challenges: Ask the Experts

Salon 2

^{*}Clinical Track, ~Not Accredited, *Child/Adolescent Track, ^Academic Track, *DEI Track

ASCP Notes



Friday, May 31, 2024

FULL SCHEDULE

Friday, May 31, 2024

7:30 a.m. - 9:00 a.m. **Morning Breakfast**

Americana Foyer

7:30 a.m. - 10:30 a.m. Speaker Ready Room

New Yorker

7:30 a.m. - 10:30 a.m. Registration

Rotunda East - Second Level

7:30 a.m. - 10:30 a.m. **ASCP Author's Nook**

Americana Foyer

Panel Sessions

8:30 a.m. - 10:00 a.m. *Evaluating the Evidence: Is There a Meaningful

Clinical Difference Between Ketamine and

Esketamine? Poinciana 1-2

Chair: Samuel Wilkinson, Yale School of Medicine

8:40 a.m. - 8:56 a.m. **Comparative Effectiveness of Intravenous**

Racemic Ketamine and Intranasal Esketamine in

Adults with Treatment Resistant Depression

Roger McIntyre, University of Toronto

8:56 a.m. - 9:12 a.m. **Evaluating the Evidence: Is There a Meaningful**

Clinical Difference Between Ketamine and

Esketamine?

Lynne McInnes, Osmind

9:12 a.m. - 9:28 a.m. **Biological Plausibility and Potential Mechanistic**

Actions Underlying Clinically Relevant

Differences between Racemic I.v. Ketamine and

I.n. Esketamine

Gerard Sanacora, Yale

^{*}Clinical Track, ~Not Accredited, *Child/Adolescent Track, ^Academic Track, *DEI Track

ASCP Friday, May 31, 2024

8:30 a.m 10:00 a.m. (continued)	*Evaluating the Evidence: Is There a Meaningful Clinical Difference Between Ketamine and Esketamine? Poinciana 1-2	
9:28 a.m 9:44 a.m.	Navigating the Ketamine-Esketamine Dilemma: Choosing the Right Approach for Treatment- Resistant Depression Balwinder Singh, Mayo Clinic	
9:44 a.m 10:00 a.m.	Evaluating the Clinical Evidence: Ketamine and Esketamine Samuel Wilkinson, Yale School of Medicine	
8:30 a.m 10:00 a.m.	*Progress and New Developments in the Use of Neuroimaging Biomarkers in Psychiatric Clinical Trials Poinciana 3-4	
Chair: James Murrough, Icahn School of Medicine at Mount Sinai		
8:39 a.m 8:57 a.m.	Role of Neuroimaging in Driving Therapeutic Discovery for Mood disorders: Recent Findings from KCNQ-Targeted Clinical Trials in Depression James Murrough, Icahn School of Medicine at Mount Sinai	
8:57 a.m 9:15 a.m.	Reward-Related Behavioral and Neuroimaging Markers Predicting Treatment Response in Major Depression Peter Zhukovsky, Harvard Medical School McLean Hospital	

Affective Memories: An Experimental Medicine

Model Using fMRI in Treatment Resistant

Ketamine Rapid Effects on Neural Plasticity and

Depression

Sara Costi, University of Oxford

9:33 a.m. - 9:51 a.m. Electrophysiology, a Companion Method to

Bolster Clinical Trial Efficacy

Nicholas Murphy, Baylor College of Medicine

Discussant: Dan Iosifescu, New York University School of Medicine

*Clinical Track, ~Not Accredited, *Child/Adolescent Track, ^Academic Track, +DEI Track

9:15 a.m. - 9:33 a.m.

Friday, May 31, 2024

ASCP

8:30 a.m. - 10:00 a.m.

^Adherence

Salon 1

Chair: Molly McVoy, Case Western University School of Medicine

8:39 a.m. - 9:03 a.m. Improving Adherence in High-Risk Adolescents

and Young Adults (AYA) with Bipolar Disorder Martha Sajatovic, University Hospitals Cleveland

Medical Center

9:03 a.m. - 9:27 a.m. Moving the Needle on Medication-Taking

Behavior in Adults with Psychiatric and Medical

Comorbidities

Jennifer Levin, Case Western Reserve University

School of Medicine

9:27 a.m. - 9:51 a.m. How to Help the Kids Flourish: A Customized

Self-Management Intervention for Adolescents

and Young Adults with Attention Deficit

Hyperactivity Disorder (ADHD)

Molly McVoy, Case Western University School of

Medicine

Discussant: Martha Sajatovic, University Hospitals Cleveland Medical Center

8:30 a.m. - 10:00 a.m. **\Insights for Advancing Translation from Bench

to Clinic in Substance Use Disorders

Salon 2

Chair: Keren Bachi, The Addiction Institute of Mount Sinai; Icahn School of

Medicine at Mount Sinai

8:39 a.m. - 8:57 a.m. A Socio-Sensory Mechanism Buffering Drug

Craving

Zhengyi Sissi Huang, University of Maryland School

of Medicine

8:57 a.m. - 9:15 a.m. Stress Pathophysiology in Addiction: Bench to

Bedside Translation to Improve Substance Use

Disorder Outcomes

Rajita Sinha, Yale University School of Medicine

*Clinical Track, ~Not Accredited, *Child/Adolescent Track, ^Academic Track, *DEI Track

ASCP | Friday, May 31, 2024

8:30 a.m. - 10:00 a.m.

**Insights for Advancing Translation from Bench to Clinic in Substance Use Disorders

Salon 2

9:15 a.m. - 9:33 a.m. Cannabis Use Among Adolescents with

Depression

Vilma Gabbay, Miller School of Medicine, University

of Miami

9:33 a.m. - 9:51 a.m. **Combination Pharmacotherapy for**

Methamphetamine Use Disorder (MUD): Findings

from the ADAPT-2 Trial

Donald Egan, UT Southwestern

Discussant: Madhukar Trivedi, UT Southwestern Medical Center

10:00 a.m. - 10:30 a.m. Break

Americana Foyer

10:30 a.m. - 11:30 a.m. Regulatory Challenges: Ask the Experts

Salon 2

This session is intended to facilitate dialogue between expert regulators from the US Food and Drug Administration and conference participants with an interest in drug development and clinical research in psychopharmacology. There will be no pre-submitted questions, but rather regulators will take questions directly from the audience.

Speakers: Tiffany Farchione, US Food and Drug Administration

Bernard Fischer, US Food and Drug Administration Martine Solages, US Food and Drug Administration

11:30 a.m. Meeting Adjourns

^{*}Clinical Track, ~Not Accredited, *Child/Adolescent Track, ^Academic Track, *DEI Track

Wednesday, May 29, 2024

11:15 a.m. - 1:00 p.m. ~Poster Session I with L

~Poster Session I with Lunch Salon 4

W1. Development of a Personalized, Fast, Automated, MRI-Based Targeting Procedure for Low Intensity Focused Ultrasound Neuromodulation

Andrea Boscutti*, Richard R. Bouchard, Benson M. Irungu, Khader M. Hasan, Jair C. Soares

Andrea Boscutti, The University of Texas Health Science Center At Houston

W2. Correlates of Treatment Options in Youth with Major Depressive Disorder: Observations from the Texas Youth Depression and Suicide Research Network (TX-YDSRN)

Emine Ayvaci*, Karabi Nandy, Ryan Becker, Abu Minhajuddin, Holli Slater, Madhukar Trivedi

Emine Ayvaci, University of Texas Southwestern Medical Center

W3. Using Class-Effect Queries Defined on Established Pharmacological Classes in Clinical Development of Novel Compounds

Solomiya Gumenyuk*, Ajay Ogirala, Steven T. Szabo, Kenneth Koblan, Seth C. Hopkins

Solomiya Gumenyuk, SMPA


W4. The Brief Inventory of Psychosocial Functioning and Zarit Burden Interview Are Strongly Correlated Measures for Use in Care Partners of Civilian Individuals with Post-Traumatic Stress Disorder Jeannette Jiang, Soma Nag, Chris Holland, Bharath Ravichandran, Bradley Goodnight, Wan-Ting (Tina) Huang*, Jonathan Patterson, Lori Davis

Wan-Ting (Tina) Huang, Guidehouse

W5. Determinants of Burden and Psychosocial Functioning Among Care Partners of Civilian Patients Living with PTSD

Wan-Ting (Tina) Huang*, Soma Nag, Chris Holland, Bharath Ravichandran, Bradley Goodnight, Jeannette Jiang, Jonathan Patterson, Lori Davis

Wan-Ting (Tina) Huang, Guidehouse



Posters

W6. Longitudinal Trends in Cocaine, Methamphetamine, and Prescription Stimulant Use Disorders Across Age Groups in the United States: Findings from the National Survey on Drug Use and Health (NSDUH) from 2015-2023

Nivedita Sriram*, Sofia Alcasey, Sidarth Wakhlu, Manish Jha Nivedita Sriram, University of Texas, Southwestern Medical School

W7. Introducing the Treatment Attitude Profile (TAP) Scale for Placebo Response Persona Discovery Using Attractor AI Technologies:

Applications in Clinical Trial Patient Enrichment

Joseph Geraci*, Bessi Qorri, Larry Alphs, Luca Pani Joseph Geraci, NetraMark Holdings

W8. Cariprazine Efficacy in African American or Black Patients with Bipolar I Disorder

William Lawson, Janet Lee, Jun Yu, Huy-Binh Nguyen* Huy-Binh Nguyen, AbbVie, Florham Park, NJ, USA

W9. Negative Symptom Burden Predicts Conversion to Psychosis Among Individuals at Clinical High Risk

Mitchell Arnovitz*, Ricardo Carrión, Jean Addington, Carrie Bearden, Kristin Cadenhead, Tyrone Cannon, Matcheri Keshavan, Daniel Mathalon, Diana Perkins, William Stone, Ming Tsuang, Elaine Walker, Scott Woods, John Kane, Barbara Cornblatt Mitchell Arnovitz, Northwell Health

W10. Examining Rater Training Performance: The Rater Onboarding and Qualification Program (ROQ)

Jenicka Engler*, Cristian Sirbu, Christina Houck, Nikolina Apostolova, Sophia Nagornaya, Krishan Washington, Cynthia McNamara, Brian Saxby

Jenicka Engler, Cronos, an IQVIA Business

W11. Antidepressant Treatment After Acute/Induction Phase of Iv Ketamine/IN Esketamine in Patients with Treatment Resistant Depression

Edith Liliana Patarroyo Rodriguez*, Balwinder Singh, Simon Kung, Jennifer Vande Voort

Edith Liliana Patarroyo Rodriguez, Mayo Clinic, Dept. Psychiatry and Psychology

👰 = New Investigator Awardee 🗼 = Pharmaceutical Pipeline Presentation

W12. Safety and Tolerability of Brexpiprazole in Combination with Sertraline for Patients with Post-Traumatic Stress Disorder:
Summary of Data from Phase 2 and Phase 3 Randomized Clinical Trials

Saloni Behl, Daniel Lee, Hui Zeng, Alpesh Shah, Taisa Skubiak, Shelley Weaver, Nanco Hefting*, Klaus Groes Larsen, Pam Sheridan, Mary Hobart, Lori Davis

Nanco Hefting, H. Lundbeck A/S, Valby, Denmark

W13. Ulotaront in the Treatment of Schizophrenia: Post-Hoc Analyses of Two 6-Week, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trials

Heather Dworak, Robert Goldman, Yan Li, Kenneth S. Koblan, Armin Szegedi, Nicholas DeMartinis*

Nicholas DeMartinis, Sumitomo Pharma America, Inc.

W14. The Risk of Postpartum Hemorrhage with Selective Serotonin Reuptake Inhibitors or Serotonin Norepinephrine Reuptake Inhibitors: Preliminary Results from the National Pregnancy Registry for Psychiatric Medications

Adele Viguera, Alexia Jones, Mercedes Szpunar, Sarah Bernstein, Parker Killenberg, Ellen Sojka, Ella Rossa, Peter Gaccione, Marlene Freeman, Lee Cohen*

Lee Cohen, Massachusetts General Hospital, Ammon-Pinizzotto Center for Women's Mental Health, Boston, MA

W15. Elevated Plasma Anthranilic Acid-To-Intercellular Adhesion Molecule 1 (AA/ICAM1) Predicts Ketamine Response in Treatment-Resistant Depression (TRD)

Stephen Murata*, Zachary Madaj, Rifaat Elmallakh, Sagar Parikh, William Bobo, Fernando Goes, Jennifer Vande Voort, Balwinder Singh, Gustavo Meideros, Erik Nelson, Mark Frye, John Greden, Eric Achtyes, Lena Brundin

Stephen Murata, Pine Rest/Michigan State University

W16. Comparison of Tolerability, Safety, and Pharmacokinetics of Antidepressant Doses of Oral Ketamine Prolonged Release Tablets (KET01) and Intranasal Esketamine: A Randomized, Placebo-Controlled, Double-Blind, Cross-Over Trial

Hans Eriksson*, Christine zu Eulenburg, Karin Schmid, Ani Damyanova, Lars Arvastson, Caren Strote, Evangelos Papanastasiou Hans Eriksson, HMNC Brain Health

Posters

W17. Effects of AXS-05 (Dextromethorphan-Bupropion) in Improving Anhedonia and Interest-Activity Symptoms of MDD and the Associated Improvements in Functional Impairment

Roger S. McIntyre, Sagar Parikh*, Rakesh Jain, Candace Andersson, Zachariah Thomas, Graham Eglit, Andrew Cutler Sagar Parikh, University of Michigan, Ann Arbor

W18. Implementation and Evaluation of the Pathway Platform in a Real-World Setting: A Digitally Enabled Care Pathway to Improve Depression Management in Primary Care

Christopher Blair*, Rasha Khatib, Maggie McCue, Ben Fehnert, James King, Lara Zaki, Lambros Chrones, Anit Roy, Michael Martin, Ramona Donovan, Marybeth Ingle, Iridian Guzman, David Kemp Christopher Blair, Takeda Pharmaceuticals U.S.A., Inc.

W19. Antidepressant Changes and App Usage Improve MDD Outcomes in Study to Implement the Pathway Platform in Primary Care: A Post Hoc Subgroup Analysis

Michael Martin*, Rasha Khatib, Christopher Blair, Maggie McCue, Ramona Donovan, Marybeth Ingle, Iridian Guzman, David Kemp Michael Martin, Takeda Pharmaceuticals North America, Inc.

W20. Evaluating Safety and Tolerability of Semaglutide in Participants with Substance Use Disorder

Georgios Kostantinis, Klara Klein, Margret Powell, Ethan Campbell, Michael Bremmer, Michael Paladino, Thomas Gilmore, Robyn Jordan, Amanda Tow, Christian Hendershot, Christian Hendershot*
Christian Hendershot, UNC at Chapel Hill, Dept of Psychiatry

- W21. Maintenance Treatment with Esketamine: Insights from the 8th Largest Academic Medical Center in the United States

 Abhishek Wadhwa, Emma Cao, Cassie Wicken, Matthew Macaluso*

 Matthew Macaluso, The University of Alabama At Birmingham
- W22. Childhood Trauma and Its Association with Depression and Somatic Anxiety in Patients with Major Depression Pro Inflammatory Phenotype: A Post Hoc Analysis

Nicolas Nunez*, Dylan Gould, Pamela Schettler, Naoise Mac Giollabhui, Defne Yucebas, Grace Ding, Boadie Dunlop, Becky Kinkead, Stefania Lamon-Fava, Maurizio Fava, David Mischoulon, Mark Rapaport Nicolas Nunez, Department of Psychiatry, University of Utah

Posters

ASCP

W23. Positive Correlation Between Ampa Receptor Density and Local and Global Functional Centrality: [11C]K-2 Pet and Resting-State fMRI Study

Taisuke Yatomi*, Dardo Tomasi, Sakiko Tsugawa, Hideaki Tani, Teruki Koizumi, Nobuhiro Nagai, Shinichiro Nakajima, Yohei Ohtani, Kie Nomoto-Takahashi, Waki Nakajima, Mai Hatano, Hiroyuki Uchida, Takuya Takahashi

Taisuke Yatomi, Department of Neuropsychiatry, Keio University School of Medicine

W24. Assessing Participant Experience with Karxt Treatment Using In-Trial Qualitative Interviews: Initial Findings from a Long-Term Phase 3 Trial in Schizophrenia

William Horan*, Cory Saucier, Peter Weiden, April Foster, Colin Sauder, Katlin LaGasse, Kristi Jackson, Sloan Rucker, Inder Kaul William Horan, Karuna Therapeutics

W25. Incentive Salience of Drug Cues and Brain Reactivity in Opioid Use Disorder: Preliminary Findings from a Pharmacoimaging Trial of Cannabidiol


Ehsan Moazen-Zadeh*, Keren Bachi, George Gardner, Yasmin Hurd Ehsan Moazen-Zadeh, Ehsan Moazen

W26. First Dual Non-Sulfonamide OX1R and OX2R Agonists and Their Potential Use for the Treatment or Prevention of Neurological Diseases

Eric Konofal*, Maxime Robin, Anh-Tuan Lormier Eric Konofal, University of Paris, Robert-Debré Hospital, France

W27. AID-ME: Artificial Intelligence in Depression – Medication Enhancement: A Cluster Randomized, Patient and Rater Blinded, Active-Controlled Trial of an AI-Enabled Clinical Decision Support System in Adults with Major Depression

David Benrimoh*, Kate Whitmore, Mamta Sapra, Stefan Kloiber, Fanny Hersson-Edery, Georges-F. Pinard, Erica Moodie, Karl J. Looper, Soham Rej, Warren Steiner, Serge Beaulieu, Jordan F. Karp, Martin Enault, Sagar V. Parikh, Howard C. Margolese David Benrimoh, McGill University



Posters

W28. A Phase 2, Multicenter, Randomized, Double-Blind, Parallel-Group, Dose-Finding Trial of MM-120 (Lysergide D-Tartrate) for Treatment of Generalized Anxiety Disorder (GAD)

Daniel Karlin, Sarah Karas*, Jamileh Jemison, Jamie M. Freedman, Rob Silva, Paula L. Jacobsen, Reid Robison Sarah Karas, Mind Medicine

W29. The Impact of Cariprazine on Short- And Long-Term Disability Among Commercially-Insured Patients

Nadia Nabulsi*, Mousam Parikh, Jamie Ta, Enrico Zanardo, Dominique Lejeune, Cristina Martinez, François Laliberté Nadia Nabulsi, AbbVie, North Chicago, IL, USA

W30. The Impact of Adjunctive Cariprazine on Mental Health-Related Quality of Life in Patients with Major Depressive Disorder: A Pooled Post Hoc Analysis of Clinical Trial Data

Mousam Parikh, Tina Matthews-Hayes, Julie L. Adams, Lakshmi Kandukuri, Tracy Yee, Nadia Nabulsi* Nadia Nabulsi, AbbVie, North Chicago, IL, USA

W31. Amnesia is Associated with Antidepressant Response to Ketamine in Treatment-Resistant Major Depressive Episodes with Suicidal Ideation: A Preliminary Report

Igor D. Bandeira*, Jason Tucciarone, Ian H. Kratter, Boris D. Heifets, Alan F. Schatzberg

Igor D. Bandeira, Stanford University School of Medicine

W32. Establishment of a Digital Therapeutic Alliance in Patients Living with Negative Symptoms of Schizophrenia

Abhishek Pratap, Cornelia Dorner-Ciossek, Cassandra Snipes, Brendan D. Hare*, Olya Besedina, Thomas Mick, Eehwa Ung, Alankar Gupta, Shaheen E. Lakhan

Brendan D. Hare, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA; Click Therapeutics, Inc., New York, NY, USA (at time of study)

W33. Dysglycemia Associated with Antipsychotic Use: A Systematic Review and Meta-Analysis

Emily Smith*, Kristoffer Panganiban, Kateryna Maksyutynska, Jiwon Lee, Femin Prasad, Sandra Pereira, Jonathan Monteiro, Kaitlin Fuller, Michael McCarthy, Jacob Ballon, Tyler Prestwood, Christoph Correll, Sri Mahavir Agarwal, Zachary Freyberg, Margaret Hahn Emily Smith, Centre for Addiction and Mental Health, University of Toronto

= New Investigator Awardee 🛊 = Pharmaceutical Pipeline Presentation

Posters

ASCP

- W34. Metabolomic Signatures Differentiating Psychosis Spectrum
 Disorders from Healthy Controls and Association with Weight Gain
 Kristoffer Panganiban*, Jiwon Lee, Kenya Costa-Dookhan, Nicole
 MacKenzie, Araba Chintoh, Gary Remington, Daniel Mueller, Alla
 Karnovsky, Kathleen Stringer, Vicki Ellingrod, Ivy Tso, Stephan Taylor,
 Sri Mahavir Agarwal, Margaret Hahn, Kristen Ward
 Kristoffer Panganiban, Centre for Addiction and Mental Health,
 University of Toronto
- W35. Impact of Longer Duration of Esketamine Nasal Spray on Change in Depression Symptoms in Real-World Patients

 Lynne McInnes*, Kruti Joshi, Gary Kane, Matt Worley, Lisa Harding Lynne McInnes, Osmind
- W36. N-Methyl-D-Aspartate Receptor Uncompetitive Antagonists and Depression, from Psychopharmacology and Pathology to Physiology: A Unifying Hypothesis for the Epigenetic Code of Neural Plasticity

 Stefano Comai*, Sara De Martin, Andrea Mattarei, Clotilde Guidetti, Franco Folli, Andrea Alimonti, Marco Pappagallo, Paolo Manfredi
- Stefano Comai, University of Padua

 W37. The Association Between Adherence to Esketamine Nasal Spray
 Therapy Dosing Regimen and Changes in Depressive Symptoms

Among Patients with Treatment-Resistant Depression in the United

Carl Marci*, Kruti Joshi, Stevan Geoffrey Severtson, Manish Jha Carl Marci, OM1, Inc.

- W38. Preliminary Data from the Connex-X Extension Trial Examining the Long-Term Safety of Iclepertin (BI 425809) in Patients with Schizophrenia who Completed Phase III Connex Trials
 Corey Reuteman-Fowler, Zuzana Blahova, Stephen R. Marder, Satoru Ikezawa, Brett English*, Peter Falkai
 Brett English, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT
- W39. Healthcare Resource Utilization and Medication Patterns in a Real-World Dataset of Patients with Major Depressive Disorder
 Holly Johnson*, Andria Del Tredici, Brady DeHart, Priya Maheshwari,
 Alexander Gutin, Katie Johansen Taber, Pamela Morin, Laura Becker,
 Julia Certa, Devika Chawla, Andrew Nierenberg
 Holly Johnson, Myriad Genetics, Inc.

States

Posters

W40. Real-World AXS-05 Patient Characteristics in Major Depressive Disorder

Andrew Muzyk, Fatima Zahara Syed, Candace Andersson, Huanxue Zhou, Junjun Chong, Herriot Tabuteau, Yang Zhao* Yang Zhao, Axsome Therapeutics Inc. New York, NY, USA

W41. A Phase 3, Double-Blind, Placebo-Controlled Study for BNC210, an Alpha7 Nicotinic Receptor Negative Allosteric Modulator, for the Acute Treatment of Anxiety in Social Anxiety Disorder (AFFIRM-1)

Spyros Papapetropoulos*, Elisabeth Doolin, Michael Odontiadis, Dharam Paul, Julia Crossman, Mark A. Smith, Charles Taylor, Murray B. Stein

Spyros Papapetropoulos, Bionomics Ltd

W42. Investigating Viral Involvement in Schizophrenia

David Adamowicz*, Xin Dang, Barbara Hanson, Lina Benhaddouch, Igor Koralnik, Ellen Lee, Matthew Shtrahman David Adamowicz, Mass General Brigham

W43. Lithium Intoxication Following Gastric Balloon Bariatric Procedure: A Case Report

Melissa Ortiz-Pena*, Frances Fuster-Astor, Diana Diaz-Ramírez, Karen Martínez-González


Melissa Ortiz-Pena, University of Puerto Rico, Medical Science Campus, Department of Psychiatry

W44. The Effect of Psychedelics on Individuals with a Personality Disorder: A Prospective Cohort Analysis

Alexandra Gordon*, Brennan Carrithers, Hannes Kettner, Alessia Marrocu, Sandeep Nayak, Brandon Weiss, David Erritzoe, Robin Carhart-Harris, Daniel Roberts, Richard Zeifman Alexandra Gordon, NYU Langone Medical Center

W45. TSND-201 (Methylone) for the Treatment for PTSD: Improvement in Sleep-Related Outcomes from the Open- Label Portion of the IMPACT-1 Study

Amanda Jones*, Jennifer Warner-Schmidt, Hannah Kwak, Blake Mandell, Martin Stogniew, Paul W Miller, Iain Jordan, Sarah Kleiman, Kelly Parker-Guilbert, Terence Ching, Benjamin Kelmendi Amanda Jones, Transcend Therapeutics



W46. Determining the Exposure-Response Relationship Between Aripiprazole Once-Monthly Plasma Concentrations and Time to Recurrence of Mood Episodes in Patients Diagnosed with Bipolar I

Xiaofeng Wang*, Matt Harlin, Karimah S. Bell Lynum, Frank Larsen, Pedro Such, Jessica Madera-McDonough, Murat Yildirim, Luann Phillips, Julie Passarell, Ric M. Procyshyn, Craig Chepke Xiaofeng Wang, Otsuka Pharmaceutical Development and Commercialization, Inc. (OPDC)

W47. Clinical Profile of AXS-05 (Dextromethorphan-Bupropion) in Treating Alzheimer's Disease Agitation (ADA): Results from the Phase 2/3 Development Program

Jeffrey Cummings, George Grossberg, Candace Andersson*, Caroline Streicher, Herriot Tabuteau Candace Andersson, Axsome Therapeutics

W48. Assessment of Patient-Reported Depression Severity in Subpopulation of Escape-Trd study: Esketamine Nasal Spray **Versus Quetiapine for Treatment-Resistant Depression**

Jason Doran, Kristin Clemens, Amanda Teeple, Benoit Rive, Pushpike Thilakarathne, Yordan Godinov, Noam Kirson, Urvi Desai, Diab Eid, Alice Qu, Hannah Bowrey, Kruti Joshi*

Kruti Joshi, Janssen Scientific Affairs, LLC

W49. Lumateperone in the Treatment of Patients With Major Depressive Disorder and Bipolar Disorder With Anxious Distress and Mixed **Features**

Suresh Durgam, Susan G. Kozauer, Willie R. Earley, Jason Huo, Bradford Loo*, Gary S. Sachs Bradford Loo, Intra-Cellular Therapies, Inc.

W50. Dosing to Effect with Subcutaneous and Sublingual Buprenorphine for Opioid Use Disorder

Michelle Lofwall, Edward Nunes, Sharon Walsh, Genie Bailey, Michael Frost*, Natalie Budilovsky-Kelley, Elin Banke Nordbeck, Fredrik Tiberg Michael Frost, Wayspring

W51. Functional Remission After a Single Administration of COMP360 **Psilocybin Treatment for Treatment-Resistant Depression**

Rachael W. Taylor, Lucinda Orsini, Jamie Chai-Rees, Lindsey Marwood, Joyce Tsai*, Guy Goodwin Joyce Tsai, COMPASS Pathways Ltd.

🙎 = New Investigator Awardee 🛛 🗶 = Pharmaceutical Pipeline Presentation

Posters

W52. Characterizing the Safety Profile of Karxt Relative to Anticipated D2-Dopamine-Based Antipsychotic Medications in Faers Ian Ramsay*, Colin Sauder, Edwin Raj, Inder Kaul, Stephen K. Brannan Ian Ramsay, Karuna Therapeutics

W53. Long-Term Follow-Up of Implementation of Psychotropic Medication Utilization Parameters for Children and Adolescents in Texas Foster Care

M. Crismon*, Nina Muse

M. Crismon, The University of Texas at Austin

W54. Prevalence of Mild to Moderate Mental Illness, Correlates of Treatment Patterns, and Perceived Unmet Need among U.S. Adults: Results from the National Survey on Drug Use and Health, 2021

Valerie L. Forman-Hoffman*, Megan Flom, Andre Williams, Timothy Y. Mariano

Valerie L. Forman-Hoffman, Woebot Health

W55. Association Between Symptom Severity and Medication Adherence in Adults with Bipolar Disorder Reporting Adherence Challenges Martha Sajatovic, Farren Briggs, Mohammad Lesanpezeshki*, Jacob Koopman, Jessica Black, Celeste Weise, Clara Adeniyi, Douglas Einstadter, Nicole Fiorelli, Joy Yala, Jennifer Levin Mohammad Lesanpezeshki, Department of Psychiatry, Case Western Reserve University, MetroHealth Medical Center


W56. Layperson/Plain Language Summaries: Global Challenges and Opportunities in 2024

Charles Wilcox*

Charles Wilcox, Praxis Research Consulting

W57. Contemporary Estimates of the Direct Medical Cost Burden of Treatment-Resistant Depression

Vicki Wing*, Jason Lerner, Emma Teoh, Lucinda Orsini, Jaspreet Gill, Shane O'Connor, Rachael Taylor, Matthew Young, Steven Levine Vicki Wing, Compass Pathways



Posters

ASCP

W58. An EEG-Based, Machine Learning Biomarker to Identify Responsive Vs. Non-Responsive Subjects in an MDD Clinical Trial: Early Validation Data from the Embarc and Rottco Studies

Qiang Li, Michael Detke*, Alan Breier, William Potter, Larry Alphs, Jeff Burgdorf, Owen Wolkowitz, Larry Ereshefsky, Miaolin Fan, Fan Zhang, Ken Wang

Michael Detke, Neumarker, Inc.

W59. Effect of Lemborexant on Sleep Architecture in Adult and Elderly Participants with Moderate to Severe Chronic Obstructive Pulmonary Disease

Gary K. Zammit, Jocelyn Y. Cheng, Nancy Hall, Margaret Moline* Margaret Moline, Eisai Inc.

W60. Nonclinical Studies of Abuse Potential with Dual Orexin Receptor Antagonists: Concordance with Real-World Use

Margaret Moline*, Jocelyn Y. Cheng, Jack E. Henningfield, Mark A. Sembower, Steve Pype, August R. Buchhalter Margaret Moline, Eisai Inc.

W61. Seltorexant, Adjunctive to Antidepressants, in Adults with MDD with Insomnia Symptoms: Results of a Double-Blind, Randomized, Placebo-Controlled Study

Michael E. Thase*, Andrew D. Krystal, Ewa Wajs, Joseph M. Trombello, Ryan Kelly, Yun Zhang, Haiyan Xu, John Thipphawong, Sandra Ruschel, Yanina Flossbach, Gahan Pandina, Carla M. Canuso, Thomas Laughren, Wayne C. Drevets

Michael E. Thase, Perelman School of Medicine, University of Pennsylvania, and Corporal Michael J. Crescenz VAMC, Philadelphia, PA

W62. Bridging the Efficacy-Effectiveness Divide: Comparing Intranasal Esketamine for Treatment Resistant Depression in the Clinical Trial Versus Real World Setting

Benjamin Anderson*, Andrew Winokur, Grace Chan Benjamin Anderson, Institute of Living

W63. Analysis of Correlation of the Clinical and Patient Global Impression of Improvement Scales in Acute Schizophrenia Clinical Trials

Maria Companioni*, Judith Montero, Patricia Ruiz Maria Companioni, Cenexel_RCA

Posters

- W64. Semaglutide for the Treatment of Antipsychotic-Associated Weight Gain in Patients Not Responding to Metformin a CaseSeries Riddhita De*, Femin Prasad, Vittal Korann, Araba Chintoh, Gary Remington, Bjørn Ebdrup, Dan Siskind, Filip K Knop, Tina Villsbøll, Anders Fink-Jensen, Margaret Hahn, Sri Mahavir Agarwal Riddhita De, Centre for Addiction and Mental Health, University of Toronto
- W65. Effect of Ulotaront on Brain Dopamine Synthesis Capacity in Subjects with Schizophrenia on Stable Doses of a D2 Antipsychotic: Results of an 18F-DOPA Pet Study
 Oliver D. Howes, Luke Vano, Grazia Rutigliano, Robert McCutcheon, Robert Lew, Snezana Milanovic, Lisa Lennek, Seth C. Hopkins*, Kenneth S. Koblan

Seth C. Hopkins, Sumitomo Pharma America, Marlborough, MA, USA

- W66. Comparison of Augmentation with Aripiprazole or Repetitive Transcranial Magnetic Stimulation Versus Switching to the Antidepressant Venlafaxine on Quality of Life and Cognition in Subjects with Treatment Resistant Depression
 Clotilde Guidetti*, Madhukar Trivedi, Richard Shelton, Dan Iosifescu, Michael Thase, Manish Jha, Sanjay Mathew, Charles DeBattista, Mehmet Dokucu, Olga Brawman-Mintzer, William Vaughn McCall, Mandana Modirrousta, Thomas Carmody, Maurizio Fava, George Papakostas
 Clotilde Guidetti, Department of Psychiatry, Massachusetts General Hospital, and Harvard Medical School, Boston, MA, USA
- W67. A Phase 1 Trial of Single Ascending 24h IV Infusion Doses of EVX-301 (5-HTP) in Healthy Adult Subjects Taking Escitalopram:
 Confirmation of Target Engagement and Phase 2 Dose
 David Carpenter*, Robert Riesenberg, Maria Johnson, Leana Woodside, Jennifer Hart, Rebecca Klein, Joel Raskin, Jacob Jacobsen David Carpenter, Evecxia Therapeutics
- Metabolic Adverse Effects of Psychotropics on Patients by Co-Prescribing Semaglutide

 Aashraya Ramu*, Sasidhar Gunturu

 Aashraya Ramu, Bronxcare Health System, Icahn School of Medicine at Mount Sinai

W68. The Price to Pay for Mental Wellness: Mitigating the Cardio-

W69. Survey Study: Exploring the Feasibility and Acceptability of Transcranial Magnetic Stimulation Therapy (TMS) in Pregnant Individuals with Depression and /or Substance Use Disorder (SUD).

Rana Jawish*, Adam Gordon, Brian Mickey, Marcela Smid Rana Jawish, University of Utah School of Medicine

W70. A Case Series of Covid-Encephalopathy Imaged with fMRI and Treated with Near Infrared Light

Kevin Enemuo*, Katelyn Hoffman, Chloe Deveney, Jonathan Haroon, Kennedy Mahdavi, Margaret Zielinski, Sergio Becerra, Victoria Venkatramen, Alexander Bystritsky, Lider Chan, Barshen Habelhah, Taylor Kuhn, Sheldon Jordan

Kevin Enemuo, The Regenesis Project

W71. The Propranolol Problem: Mixed Results in the Treatment of Trauma-Related Disorders

Nikolas Cirillo*

Nikolas Cirillo, Nova Southeastern University

W72. Double-Blind, Placebo-Controlled Multiple Ascending Dose Study of BXCL501 with Concomitant Treatment with Anti-Depressant in Healthy Volunteers

Robert Risinger*, Stephen Gorny, Heather Robison, Michael De Vivo, Chetan Lathia, Adedayo Adedoyin Robert Risinger, Bioxcel Therapeutics

W73. Navacaprant, a Novel and Selective Kappa Opioid Receptor Antagonist, Improves Symptoms of Major Depressive Disorder in a Phase 2 Trial, Including in Participants with Comorbid Anxiety at Baseline

Sanjay J. Mathew, Andrew Cutler, Nicole Visitacion*, Michael Gold, Jason Yuan, Bill Aurora

Nicole Visitacion, Neumora Therapeutics, Inc.

W74. Propensity Weighted Approach to Control the Confounding Effect of Unbalanced Distribution of Placebo Responders on the Treatment Effect in Psychiatric Clinical Trials: An Artificial Intelligence Driven Trial Simulation Study

Roberto Gomeni*, Francoise Bressolle-Gomeni Roberto Gomeni, Pharmacometrica

Posters

W75. Lemborexant Augmentation of Naltrexone for Alcohol Craving and Sleep: A Randomized, Double-Blind, Placebo-Controlled Study

Thanh Thuy Truong*, Jillian Thomas

Thanh Thuy Truong, Baylor College of Medicine

W76. An Algorithmic Model for the Risk of New-Onset Schizophrenia in Young Cannabis Users

Aristomenis Alevizopoulos, Maria Alevizopoulou, Artemis Igoumenou, Georgios Alevizopoulos*

Georgios Alevizopoulos, School of Health Sciences, National and Kapodistrian University of Athens

W77. Using Experimental Data to Guide Psychotherapeutic Applications of Dissociative and Psychedelic Medications

David Mathai*

David Mathai, Department of Psychiatry, Johns Hopkins University School of Medicine

W78. Brain and Peripheral Tissue Distribution of Intranasal Radiolabeled Itruvone (PH10) in Laboratory Rats

Jo Cato*, Ross A. Baker, Louis Monti Jo Cato, Vistagen Therapeutics, Inc.

W79. Long-Term Safety and Efficacy of Esmethadone in Patients with Major Depressive Disorder: Findings from a 12-Month Open-Label Study

Maurizio Fava, Luca Pani, Sara De Martin, Andrew Cutler, Cornelia Kroger, Paggard Champasa, Clotilde Guidetti, Stefano Comai, Andrea Mattarei, Franco Folli, David Bushnell, Sergio Traversa, Charles Inturrisi, Paolo Manfredi, Marco Pappagallo*

Marco Pappagallo, Relmada Therapeutics, Inc.

W80. Efficacy and Safety of Esketamine Nasal Spray as Monotherapy in Adults with Treatment-Resistant Depression: A Randomized, Double-Blind, Placebo-Controlled Study

Adam Janik*, Xin Qiu, Rosanne Lane, Wayne C. Drevets, Carla Canuso, Dong Jing Fu

Adam Janik, Janssen Research and Development, LLC, San Diego, CA, USA

Posters

ASCP

W81. How Should We Measure Sleep and Circadian Rhythm in Adolescents and Young Adults with Psychosis Spectrum Symptoms?

Francis Ochman*, Casey Ganz-Leary, Kayla Piiwaa, Raquel Gur, Jerome H. Taylor

Francis Ochman, Psychiatry, Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA

W82. Exploring Non-US Rater Work Stress and Burnout: How Can We Do Better to Preserve Our Primary Endpoint Evaluators?

Vera Grindell, Judith Montero, Katarzyna Wyka, Howard Hassman, David Walling, Cassie Blanchard, Mark Opler, David Mischoulon, Larry Ereshefsky, Elan Cohen*

Elan Cohen, Hassman Research Institute

W83. Use of a Novel Pharmacogenomic Biomarker to Enrich Responders for Liafensine in Treatment-Resistant Depression Patients in a Phase 2b Clinical Study

Crystal Chen, Matthew Spear*
Matthew Spear, Denovo Biopharma

W84. A Review of Recent Trends in Sociodemographic Composition Among ASCP Members, Leaders, and Meeting Attendees

Gilmar Gutierrez, Brenda Cabrera Mendoza, Emily Smith, Alexander Herman, Obiora E. Onwuameze, Francisco Moreno, Andrew T. Olagunju, Nicolette Stogios*

Nicolette Stogios, Centre for Addiction and Mental Health, University of Toronto

W85. Using Active and Passive Digital Phenotyping to Augment Efficacy Assessments in an Early-Stage Drug Development Program

Philip Harvey*, Charles Nemeroff, Stephen Kanes, Steven Targum Philip Harvey, University of Miami Miller School of Medicine

W86. Low Long-Term Risk of Eps with Muscarinic Agonist Karxt (Xanomeline and Trospium)

Keisha Novak, Carolyn Watson*, Amy Claxton, Ronald Marcus, Stephen K. Brannan, Colin Sauder

Carolyn Watson, Karuna Therapeutics

W87. Oxybutynin is Effective on Methadone- Induced Hyperhidrosis treatment: A Case Report

Narges Joshaghani*, Eliseo Go Narges Joshaghani, Bronx Care Health System

Posters

W88. Does Association Between Problematic Substance Use and Suicidal Ideation in Youths Differ Based on Sex?

Sofia Alcasey*, Taylor Helmbrecht, McKenna Dougherty, Teresa Slettebo, Isabella Huddleston, Alyssa Serrano, Ann Brindley House, Elizabeth Dedrick, Sidarth Wakhlu, Abu Minhajuddin, Manish Jha, Madhukar H. Trivedi

Sofia Alcasey, The University of Texas Southwestern Medical Center, Department of Psychiatry

W89. A Randomized, Double-Blind Controlled Comparison of NRX-101 (D-cycloserine/lurasidone) to Lurasidone for Adults with Bipolar Depression and Subacute Suicidal Ideation or Behavior

Andrew Nierenberg, Michael Sapko*, Jonathan Javitt Michael Sapko, NRx Pharmaceuticals

W90. Is the Magnitude of the Psychedelic Experience Associated with Depressive Improvement?

Bryce Lund, Audrey Shoultz*, Andrew Van der Vaart, Scott Aaronson Audrey Shoultz, Sheppard Pratt Health System

W91. Ropanicant (SUVN-911), a α4β2 Receptor Antagonist: A Phase-2 Study Evaluating the Safety and Efficacy in Participants with Moderate to Severe Major Depressive Disorder

Ramakrishna Nirogi, Veera Raghava Chowdary Palacharla, Vljay Benade, Jyothsna Ravula, Satish Jetta, Vinod Kumar Goyal, Abdul Rasheed Mohammed, Ramkumar Subramanian, Santosh Kumar Pandey, Pradeep Jayarajan, Anil Shinde, Veera Raghava Chowdary Palacharla*

Veera Raghava Chowdary Palacharla, Suven Life Sciences

W92. Optimal Dosage of Psilocybin in the Treatment of Mood Disorders: A Systematic Review and Meta-Analysis

Rakesh Kumar*, Nicolas Nunez, Alessandro Miola, Anand Singh Rakesh Kumar, Mayo Clinic

W93. Beyond Response and Remission: Using Time to Discontinuation as an Outcome of Ketamine Treatment for Depression

Jacob Ellis*, Simon Kung, Jennifer Vande Voort, Vanessa Pazdernik, Balwinder Singh

Jacob Ellis, Mayo Clinic, Dept. Psychiatry and Psychology, Rochester, Minnesota, USA.

Posters

ASCP


W94. Safety and Tolerability of BHV-7000, a Novel Kv7 Potassium Channel Activator: Results from Phase 1 Single and Multiple Ascending Dose Studies

Bharat Awsare, Azim Munivar*, Eric Ashbrenner, Heather Sevinsky, Michael Bozik, Steven Dworetzky, Lia Donahue, Randall Killingsworth, Bruno Francoeur, Irfan Qureshi Azim Munivar, Biohaven Pharmaceuticals

★ W95. Two Randomized, Double-Blind, Placebo-Controlled Trials of Troriluzole, a Novel Glutamate Modulating Agent, in Obsessive-Compulsive Disorder

Azim Munivar*, Stephen Kaplita, Kimberly Gentile, Lia Donahue, Deborah Smith, Tim McCormack, Christopher Jensen, Irfan Qureshi, Vladimir Coric

Azim Munivar, Biohaven Pharmaceuticals



Posters

Thursday, May 30, 2024

12:30 p.m. - 2:15 p.m

~Poster Session II with Lunch

Salon 4

T1. Retrospective Analysis of Ketamine Intravenous Therapy Outcomes at a Large Academic Center

Michael Kritzer*, Doga Cetinkaya, Sydney Decaro, Anika Kopcznski, Isabella Henneman, Ava Licht, Lauren Fisher, Maurizio Fava, Paola Pedrelli, Cristina Cusin

Michael Kritzer, Massachusetts General Hospital

T2. Integration of Blood-Derived and Brain-Derived Biomarkers for Predicting Stage 2 Remission Status in EMBARC Study Subjects with Major Depressive Disorder

Milica Barac*, Caroline Grant, Taryn Mayes, Thomas Carmody, Abu Minhajuddin, Russell Toll, Cherise Chin Fatt, Paul Croarkin, William Bobo, Manish Jha, Arjun Athreya, Madhukar Trivedi Milica Barac, Mayo Clinic

T3. Use of Biomarkers to Identify Treatment for Pyschiatric Patients Moses Njuguna*

Moses Njuguna, Princeton University

★ T4. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonism as a Potential Pharmacotherapy for Alcohol Use Disorder: Converging Evidence from Rodent and Early Human Studies

Mehdi Farokhnia*, Leandro Vendruscolo, George Koob, Christopher Rentsch, Lorenzo Leggio

Mehdi Farokhnia, Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, NIDA and NIAAA, NIH

T5. Late Night Leads: Exploring the Relationship Between Callback Times and MDD Symptomatology for Late Night Applications and Implications for Recruitment and Placebo Response

Simon Desjardins*, Sam Toft, John Albano, Hasiba Zandi, Miriam Evans, Stephanie Ellickson, Allison Zadourian Simon Desjardins, Adams Clinical

T6. Azapirone Abuse and Misuse: A Review

Carl Zhou, Philip Yu, Andrew Olagunju* Andrew Olagunju, McMaster University

= New Investigator Awardee 🛊 = Pharmaceutical Pipeline Presentation

T7. Efficacy of Brexpiprazole in Combination with Sertraline for Patients with Post-Traumatic Stress Disorder: Summary of Data from Phase 2 and Phase 3 Randomized Clinical Trials

Saloni Behl, Daniel Lee, Hui Zeng, Taisa Skubiak, Shelley Weaver, Nanco Hefting*, Klaus Groes Larsen, Mary Hobart, Lori Davis Nanco Hefting, H. Lundbeck A/S, Valby, Denmark

T8. Ziprasidone and Pregnancy: Preliminary Data from the MGH National Pregnancy Registry for Psychiatric Medications

Marlene Freeman*, Adele Viguera, Maya Verghese, Parker Killenberg, Ellen Sojka, David Chitayat, Sonia Hernandez-Diaz, Lee Cohen Marlene Freeman, Massachusetts General Hospital, Ammon-Pinizzotto Center for Women's Mental Health

T9. The National Pregnancy Registry for Psychiatric Medications: Risk of Major Malformations Following Fetal Exposure to Second Generation Antipsychotics

Lee Cohen*, Marlene Freeman, Parker Killenberg, Ellen Sojka, Caroline Frisch, Audrey Reuman, Maya Verghese, Hannah Yoon, David Chitayat, Sonia Hernández-Díaz, Adele Viguera

Lee Cohen, Massachusetts General Hospital, Ammon-Pinizzotto Center for Women's Mental Health

T10. Effect Size Deflation as a Function of Sample Size in Adjunctive Treatment Trials for Negative Symptoms in Schizophrenia

Daniel Javitt*, Megan Mayer, Tse-Hwei Choo, Kevin Liu, Viraj Govani, Shyanne Francis, Joshua Kantrowitz
Daniel Javitt, Columbia University

T11. A Randomized, Double-Blind, Active Comparator-Controlled, Phase 3 Study to Evaluate the Long-Term Safety and Tolerability of Ulotaront in Patients with Schizophrenia

Leslie Citrome, Heather Dworak, Kenneth S. Koblan, Robert Goldman, Hailong Cheng, Alison Fitzgerald, Antony Loebel, Armin Szegedi, Nicholas DeMartinis*

Nicholas DeMartinis, Sumitomo Pharma America, Inc.

T12. Determinants of Burden and Psychosocial Functioning Among Care Partners of Civilian Patients Living with PTSD

Soma Nag, Wan-Ting (Tina) Huang*, Bharath Ravichandran, Jeannette Jiang, Chris Holland, Bradley Goodnight, Jonathan Patterson, Lori L. Davis

Wan-Ting (Tina) Huang, Guidehouse

Posters

T13. The Brief Inventory of Psychosocial Functioning and Zarit Burden Interview Are Strongly Correlated Measures for Use in Care Partners of Civilian Individuals with Post-Traumatic Stress Disorder Soma Nag, Jeannette Jiang, Bharath Ravichandran, Wan-Ting (Tina) Huang*, Chris Holland, Bradley Goodnight, Jonathan Patterson, Lori L. Davis
Wan-Ting (Tina) Huang, Guidehouse

T14. Apimostinel, A Novel Nmdar Modulator with Rapid-Acting,
Sustained Effects and Favorable Drug-Like Properties: Preclinical
Studies

Jeffrey Burgdorf*, Xiao-lei Zang, Anantha Shekhar, Patric Stanton, Ronald Burch, Joseph R Moskal, John Donello Jeffrey Burgdorf, Gate Neurosciences

T15. Impact of Time to Brexpiprazole Initiation on Healthcare Resource
Utilization and Cost for Major Depressive Disorder: – A US RealWorld Study

Shivanshu Awasthi, Dusica Hadzi Boskovic*, Shivani Kapadia Dusica Hadzi Boskovic, Otsuka Pharmaceutical Development and Commercialization, Inc., Princeton, NJ, USA

T16. Effect of Bedtime Sublingual Cyclobenzaprine (TNX-102 SL) on Pain, Sleep, Fatigue and Cognition in Fibromyalgia-Type Long COVID: Results of a Double-Blind Randomized Proof-of-Concept Phase 2 Study

Herb Harris*, Jean Engels, Ben Vaughn, Candace Flint, Seth Lederman, Gregory Sullivan

Herb Harris, Tonix Pharmaceuticals

T17. A Randomized Placebo-Controlled Double-Blind Phase 2 Trial of Adjunctive KET01 (Oral Prolonged-Release Ketamine) for Treatment-Resistant Depression

Hans Eriksson*, Christine zu Eulenburg, Karin Schmid, Ani Damyanova, Lars Arvastson, Caren Strote, Evangelos Papanastasiou Hans Eriksson, HMNC Brain Health

T18. Vortioxetine vs Other Standard of Care Antidepressants in Patients With Major Depressive Disorder: 12-Week Interim Analysis From PatientsLikeMe Survey

Mary C. Burke, Chris Blair, Sagar V. Parikh, Roger S. McIntyre, Mark Opler, Erlyn Macarayan, Jeoffrey Bispham, Alina Karim, Michael Martin, Priscilla Driscoll Shempp, Ian Robinson, Maggie McCue, Mark Opler* Mark Opler, WCG Inc.

Posters

ASCP

T19. An Open Label Pilot Study of Non-Invasive Vagal Nerve Stimulation for Treatment Resistant Major Depressive Disorder

Matthew Maceluso* Cassio Wicken, Michael Falola, Samantha White

Matthew Macaluso*, Cassie Wicken, Michael Falola, Samantha White Matthew Macaluso, University of Alabama At Birmingham

T20. Understanding Preferences for an Antipsychotic Regimen
Administered once Every 2 Months for Bipolar I Disorder: A
Qualitative, Single-Person Interview Study of Patients, Caregivers,
and Prescribers Conducted in the USA

Stephanie Loomer, Murat Yildirim*, Jessica Madera-McDonough, Arun Micheelsen, Kristine Harrsen, Bolu Oladini, Clodagh Beckham, Soma Nag, Dawn Bates, Xavier Guillaume, Pedro Such Murat Yildirim, H. Lundbeck A/S

T21. A Phase 1 Safety, Pharmacokinetics (PK) and Quantitative Electroencephalography (qEEG) Pharmacodynamics Study of Single and Multiple Ascending Doses of Intravenous Apimostinel Compared with Placebo in Healthy Volunteers


Ronald Burch*, John Donello, Jeffrey Burgdorf, Joseph R Moskal, Leonardo Trejo, Roman Rosipal, Anantha Shekhar Ronald Burch, Gate Neurosciences, Inc

T22. Neuroprotective Effect of Mazindol on Nocturnal Activity in an Orexin-B-Saporin-Induced Narcoleptic-Like Model in Sprague-Dawley Rats

Eric Konofal*, Christelle Peyron, Fabienne Massé, Anne-Laure Morel, Jean-Charles Bizot, George Apostol Eric Konofal, University of Paris, Robert-Debré Hospital, France

T23. Can Adaptive Testing Technology Lead to a Better Understanding of the Course of Ketamine Treatment Outcome?

Kimberly Frost-Pineda*, Meredith Wallace, Robert Gibbons, Jeremy Kendrick, Brian Mickey, Sarah Cote, David Kupfer, Ellen Frank Kimberly Frost-Pineda, Health Rhythms, Inc



Posters

T24. Optimizing Acute Stress Reaction (ASR) Interventions with TNX-102 SL (Sublingual Cyclobenzaprine HCI) – The OASIS Trial: Sustaining Civilian Performance Post-Trauma by Reduction of ASR and Prevention of ASD/PTSD

David Hsu*, Christopher W Jones, Laura Germine, Xinming An, Council Mintz, Christine Bizgu, Romina Soudavari, Seth Lederman, Gregory Sullivan, Samuel A McLean

David Hsu, Tonix Pharmaceuticals, Inc.

T25. Do Second Generation Antipsychotics Protect Against the Emergence of (Hypo)mania in Depressed Patients with Mixed Features?

Mark Zimmerman*

Mark Zimmerman, South County Psychiatry

T26. Early Symptom Improvement with Adjunctive Cariprazine in Patients with Major Depressive Disorder: A Post Hoc Analysis

Michael Measom*, Carra Simpson, Simranpreet Waraich, Julie L. Adams, Majid Kerolous

Michael Measom, Center For Human Potential, VOA ACT Team, New Roads Behavioral Health

T27. Assessing and Monitoring Clinical Severity in Depressive Disorders Using Automated Speech Analysis

Michael Spilka*, Mengdan Xu, Sunny Tang, Leily Behbehani, Jessica Robin, William Simpson

Michael Spilka, Cambridge Cognition

T28. Efficacy and Safety of Iclepertin (BI 425809) in Patients with Schizophrenia: CONNEX, a Phase III Randomized Controlled Trial Programme

Corey Reuteman-Fowler, Zuzana Blahova, Satoru Ikezawa, Stephen R. Marder, Peter Falkai, Brett English*, John H. Krystal Brett English, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT

T29. Acceptability, Engagement, and Outcomes with Use of a Digital Therapeutic in Patients Living with Experiential Negative Symptoms of Schizophrenia

Brendan D. Hare*, Cassandra Snipes, Eehwa Ung, Cornelia Dorner-Ciossek, Shaheen E. Lakhan

Brendan D. Hare, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA; Click Therapeutics, Inc., New York, NY, USA (at time of study)

T30. Comparative Activity of Muscarinic Agonists ML-007 and Xanomeline in Preclinical Models of Schizophrenia and Cognitive Impairment

Susmita Chatterjee, Maritza Soria, Natalie Navarro, Michael W Wood, Kimberly R. Thompson*, James Lillie, Anatol C. Kreitzer Kimberly R. Thompson, MapLight Therapeutics

T31. Comparison of Data Quality Between High and Low Recruiting Sites in Schizophrenia Clinical Trials

Alan Kott*, Xingmei Wang, David Daniel Alan Kott, Signant Health

★ T32. Positive Results Achieved in a Phase 2b, Double-Blind, Placebo-Controlled Study for BNC210, an Alpha7 Nicotinic Receptor Negative Allosteric Modulator, for the Treatment of PTSD (ATTUNE).

Spyros Papapetropoulos*, Elisabeth Doolin, Michael Odontiadis, Dharam Paul, Julia Crossman, Mark A. Smith, Paul Rolan Spyros Papapetropoulos, Bionomics Ltd

T33. The National Institute on Drug Abuse's Addiction Treatment Discovery Program: Preclinical Evaluation of Potential Pharmacotherapies for Substance Use Disorders

David White*, Carol Hubner
David White, NIH/NIDA/DTMC/MDTB

★ T34. Oral Prolonged-Release Adjunctive Ketamine (KET01): Phase 2 Trial in Treatment-Resistant Depression and Phase 1 Trial Comparing Tolerability with Intranasal Esketamine

Hans Eriksson*, Christine zu Eulenburg, Karin Schmid, Ani Damyanova, Lars Arvastson, Caren Strote, Daniel Gerlach, Katarina Maiboe, Alena Busche, Clara Engelhardt, Evangelos Papanastasiou Hans Eriksson, HMNC Brain Health

T35. Pro-Cognitive Pharmacodynamic Effects of ALTO-101: Results from Brain and Behavioral Outcomes in a Randomized, Double-Blind Phase 1 Study

Akshay Ravidran, Guhan Sundar, Samantha Goncalves, Chao Wang, Li Shen, Maimon Rose, Joshua Jordan, Sebastian Marquez, Tabitha Carrieira, Jessica Powell, Faizan Badami, Wei Wu, Amit Etkin, Adam Savitz*

Adam Savitz, Alto Neuroscience

Posters

T36. TSND-201 (Methylone) for the Treatment for PTSD: Functional and Global Improvements from the Open- Label Portion of the IMPACT-1 Study

Amanda Jones*, Jennifer Warner-Schmidt, Martin Stogniew, Blake Mandell, Hannah Kwak, Paul W Miller, Iain Jordan, Sarah Kleiman, Kelly Parker-Guilbert, Terence Ching, Benjamin Kelmendi Amanda Jones, Transcend Therapeutics

T37. Changes in Neuroplasticity Related to Nonpharmacological Interventions for Major Depressive Disorder: A Systematic Literature Review

Sandeep Vaishnavi, Alex Leow, Veronica Nguyen, Chip Meyer, Madeline Keleher, Caroline Leitschuh, Tarolyn Carlton, Veronica Nguyen* Veronica Nguyen, Otsuka (OPDC)

T38. Solriamfetol Improves Cognitive Performance in Preclinical Models of Sleep Apnea and in a Randomized Placebo-Controlled Study of Sleep Apnea Participants (SHARP)

David Gozal, Hans Van Dongen, Eileen B. Leary, Gregory Parks, Samantha Floam, Herriot Tabuteau, Samantha Floam* Samantha Floam, Axsome Therapeutics

- T39. Effect of Lemborexant on Sleep Architecture in Adult and Elderly Participants with Mild to Severe Obstructive Sleep Apnea
 Gary K. Zammit, Jocelyn Cheng, Nancy Hall, Margaret Moline*
 Margaret Moline, Eisai Inc.
- T40. Lumateperone in the Treatment of Major Depressive Disorder and Bipolar Depression With Mixed Features: Efficacy Across Symptoms

Susan G. Kozauer, Suresh Durgam, Willie R. Earley, Jason Huo, Ian D'Souza*, Lakshmi N. Yatham Ian D'Souza, Intra-Cellular Therapies, Inc.

T41. Lumateperone Treatment for Major Depressive Episodes with Mixed Features in Major Depressive Disorder and Bipolar I or Bipolar II Disorder

Suresh Durgam, Susan G. Kozauer, Willie R. Earley, Changzheng Chen, Jason Huo, Margaret Martin*, Stephen Stahl, Roger S. McIntyre Margaret Martin, Intra-Cellular Therapies, Inc.

Posters

ASCP

T42. Exploring Connections Between Childhood Maltreatment and Cognitive Performance in Patients with Bipolar Disorder and Healthy Controls: Insights into the Role of Inflammation Marzieh Maid* Jennifer Nicoloro-SantaBarbara Emma Galante, Me

Marzieh Majd*, Jennifer Nicoloro-SantaBarbara, Emma Galante, Megan Shanahan, Katherine E. Burdick

Marzieh Majd, Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, MA

T43. Transcranial Magnetic Stimulation in the Department of Veterans Affairs: Impacts of Sleep Dysfunction on the Treatment of Major Depressive Disorder

Zachary Zuschlag*, Michael Norred, Michelle Madore, Noah Philip, Sonia Rehman, F. Andrew Kozel Zachary Zuschlag, James A. Haley Veterans Hospital

T44. Early Improvement of Symptoms in Bipolar I Depression Predicts Functional Remission and Recovery: A Post Hoc Analysis

Roger S. McIntyre, Mauricio Tohen, Gregory Mattingly, Eduard Vieta, Leslie Citrome, Anita H. Clayton, Jun Yu, Huy-Binh Nguyen* Huy-Binh Nguyen, AbbVie, Florham Park, NJ, USA

T45. Placebo Response Prediction in Major Depressive Disorder Using Machine Learning

Ali Samadani, Emily Kogan, Jocelyn Wang, Yun Zhang, Shyla Jagannatha, Haiyan Xu, Qingqin Li, Yanina Flossbach, Gahan Pandina, Jen Hayden, Amin Yakubu, Ray Harvey, Gayle Wittenberg, Jennifer Hayden*

Jennifer Hayden, Johnson and Johnson

T46. Iloperidone Treatment Associated Increase in Serum Urate and Interaction with SLC2A9 Variant RS7442295

Sandra Smieszek*, Sean Chadwick, Emily Czeisler, Changfu Xiao, Rosarelis Torres, Christos Polymeropoulos, Gunther Birznieks, Mihael Polymeropoulos

Sandra Smieszek, Vanda Pharmaceuticals

T47. Key Characteristics of the Long-Acting Injectable Atypical Antipsychotic Aripiprazole Lauroxil for the Treatment of Adults with Schizophrenia

Leslie Citrome, Christoph U. Correll, Gregory W. Mattingly, Andrew J. Cutler, Amber R. Hoberg, Peter J. Weiden, Bhaskar Rege, James McGrory*, Martin Dunbar, Craig Hopkinson, David McDonnell James McGrory, Alkermes, Inc.

Posters

T48. Evaluating Functional Outcomes in Major Depressive Disorder: A Patient Interview Study

Erin Gallagher, Mousam Parikh, Kathy Vong, Harlow Sharp, Julia D'Ambrosio, Nathan Johnson, Adriana Estrada, Laure Weijers, Nadia Nabulsi*, Tina Matthews-Hayes
Nadia Nabulsi, AbbVie, North Chicago, IL, USA

T49. Long-Term Safety and Efficacy of Olanzapine/Samidorphan: Results of a 4-Year Open-Label Study

Jacob Ballon*, René Kahn, Christina Arevalo, Martin Dunbar, David McDonnell, Christoph U. Correll Jacob Ballon, Stanford University School of Medicine, Department of Psychiatry

T50. A Retrospective Study of Real-World Clinical Effectiveness of Esketamine Nasal Spray Therapy Among Patients with Treatment Resistant Depression

Lynne McInnes*, Kruti Joshi, Gary Kane, Matt Worley, Lisa Harding Lynne McInnes, Osmind

T51. A VA Interventional Psychiatry Consultation Model for Processing, Expert Evaluation, and Disposition of Interventional Referrals

Eugene Cozza*, Timothy Buckley, Elizabeth Lassen, Brian Gomoll, Piotr Czarnkowski, Rachael Olson-Marszewski, Carolyn O'Donnell, Christopher Olson, Heide Klumpp, William Gilmer Eugene Cozza, Edward Hines, Jr. VA Hospital, Hines, IL, Northwestern University Feinberg School of Medicine, Chicago, IL

T52. Treatment Patterns and Healthcare Resource Utilization Following Initiation of Aripiprazole Lauroxil Using a 1-Day Initiation Regimen Lauren Strand, Michael Doane*, James McGrory, Alejandro Hughes, John Lauriello Michael Doane, Alkermes, Inc.

T53. The Clinical Global Impression of Severity (CGI-S): Bridging the Research-Practice Gap

Joydeep Sarkar, A. Rush*, Natali Sorajja, Joshua Wong, Antonio Martinez

A. Rush, Curbstone Consultant LLC

🖹 = New Investigator Awardee 🗼 = Pharmaceutical Pipeline Presentation

T54. Does the Ketogenic Diet Improve Outcomes in Severe and Persistent Mental Illness and Neurocognitive Disorders? A Systematic Review

Kateryna Maksyutynska*, Cameron Arnold, Riddhita De, Emily Smith, Kristoffer Panganiban, Bailey Humber, Reena Besa, Stephen Cunnane, Sri Mahavir Agarwal, Margaret Hahn Kateryna Maksyutynska, Centre for Addiction and Mental Health, University of Toronto

T55. Ketamine's Influence on Magnetoencephalography Patterns During a Working Memory Task in Individuals with Treatment-Resistant Depression

Adam Fijtman*, Mani Yavi, Abigail Vogeley, Dede Greenstein, Jessica Gilbert, Carlos Zarate Adam Fijtman, NIH/NIMH

T56. A Biomarker-Based Enrichment Strategy for Neuropsychiatric Drug Development: Examples from Two Ongoing Phase 2b Studies

Michael Avissar*, Joshua Jordan, Nicholas Cooper, Maimon Rose, Chao Wang, Faizan Badami, Peter Emmel, Kaitlly Zhu, Jessica Powell, Fadi Abdel, Amit Etkin, Adam Savitz Michael Avissar, Alto Neuroscience

T57. Hippocampal Metaplastic Mechanisms Activated by Ketamine Metabolite (2R,6R)-Hydroxynorketamine Promote Long-Lasting Antidepressant-Relevant Effects

Kyle Brown*, Todd Gould Kyle Brown, University of Maryland School of Medicine

T58. Karxt (Xanomeline and Trospium) for the Treatment of Schizophrenia: Number Needed to Treat, Number Needed to Harm, and Likelihood to Be Helped or Harmed

Leslie Citrome, Nichole Neugebauer, Alicia Meli, Judith Kando, Nichole Neugebauer*

Nichole Neugebauer, Karuna Therapeutics

T59. Zonisamide Induced Neurocognitive Deficits: A Case Study Renee Bayer*

Renee Bayer, Trinity Health

T60. Ulotaront Delays Gastric Emptying Time in Schizophrenia Patients with Metabolic Syndrome (NCT05402111)

Snezana Milanovic*, Nina Dedic, Robert Lew, Kenneth S. Koblan, Michael Camilleri, Seth C. Hopkins Snezana Milanovic, Sumitomo Pharma America, Cambridge, MA

Posters

T61. Predicting Conversion to Insulin Sensitivity with Metformin in Treatment Resistant Bipolar Depression -- A Novel Clinical Tool Jessica Gannon*, Marcos Sanches, Katherine Lines, Kathleen Cairns, Claire Reardon, Roy Chengappa, Cynthia Calkin Jessica Gannon, University of Pittsburgh School of Medicine

T62. PET/CT Study of Dopamine Transporter (DAT) Binding with the Novel Triple Reuptake Inhibitor Toludesvenlafaxine in Rats and Humans

Yifeng Shen* Yifeng Shen, Shanghai Mental Health Center

- T63. Fluoxetine and Sertraline Inhibit Height Growth During Puberty
 Chadi Calarge*, Chima Amushie, Stephanie Dinh, James Mills, Sridevi
 Devaraj, Jose Garcia, Griselda Barba-Villalobos, Jacqueline Nguyen,
 Stephanie Sisley, Fida Bacha, Babette Zemel
 Chadi Calarge, Baylor Collee of Medicine
- T64. PAPR: Psilocybin-Assisted Therapy + Mindfulness-Based Stress Reduction (MBSR) for Front-Line Healthcare Provider Covid-Related Burnout and Depression

 Benjamin Lewis*, John Hendrick, Kevin Byrne, Eric Garland Benjamin Lewis, University of Utah, Research Park, University Neuropsychiatric Institute (UNI)
 - T65. A Preliminary Investigation of Transcranial Focused Ultrasound for the Treatment of Tremor

Chloe Deveney*, Kevin Enemuo, Katelyn Hoffman, Jean Surya, Jonathan Haroon, Kennedy Mahdavi, Kaya Jordan, Sergio Becerra, Taylor Kuhn, Alexander Bystritsky, Sheldon Jordan Chloe Deveney, The Regenesis Project

T66. Treating Emotional and Cognitive Disorders Linked to Traumatic Brain Damage with Transcranial Infrared Laser stimulation:
Additional Findings

Katelyn Hoffman*, Chloe Deveney, Kevin Enemuo, Jonathan Haroon, Kennedy Mahdavi, Sergio Becerra, Lider Chan, Sheldon Jordan Katelyn Hoffman, The Regenesis Project

T67. Comparative Effectiveness of Intravenous Ketamine and Intranasal Esketamine for Treatment Resistant Depression in Adults

CJ Hutchison*, Rachel Hershenberg, Anthony Chatham, Anahit Keshishyan, Brandon Kitay, Ally Mandell, Valeriya Tsigankova, Patricio Riva Posse

CJ Hutchison, Emory University School of Medicine

= New Investigator Awardee 🛊 = Pharmaceutical Pipeline Presentation

T68. Adhesion Proteins in Preclinical and Prodromal AD: A Proteomic Study.

Reem Neal*, Zhiyi Yang, Ihab Hajjar Reem Neal, University of Texas Southwestern Medical Center

T69. In a World of Rising Deltas, Review of Clinical Implication of Delta 8, 9 and 10 THC in Psychiatry

Thersilla Oberbarnscheidt*

Thersilla Oberbarnscheidt, University of Pittsburgh Medical Center, Western Psychiatric Hospital

T70. A Phase Ib/II Multicenter, Randomized, Double Blind, Placebo Controlled, Ascending Dose Finding Study of BXCL501 in Agitation Associated with Dementia

Robert Risinger*, Lavanya Rajachandran, Heather Robison Robert Risinger, Bioxcel Therapeutics

T71. LB-102, A Novel Benzamide for the Treatment of Schizophrenia: Safety and Dopamine Receptor Occupancy Data from Two Clinical Studies

Anna Eramo*, Vincent T. Grattan, Zachary Prensky, Andrew R. Vaino, Dean F. Wong, John M. Kane Anna Eramo, LB Pharmaceuticals Inc.

T72. A Randomized Placebo-Controlled Phase 2 Trial of Navacaprant, a Novel and Selective Kappa Opioid Receptor Antagonist, in Major Depressive Disorder

Sanjay Mathew, Andrew Cutler, Nicole Visitacion*, Michael Gold, Jason Yuan, Bill Aurora

Nicole Visitacion, Neumora Therapeutics, Inc.

T73. Enhancing Access to Care as Well as Patient Education for Bipolar Disorder with Group Medical Visits / Shared Medical Appointments Sagar Parikh*, Melvin McInnis, Jennifer Severe, Danielle Taubman, Megan Rush, Joshua Saunders-Lustick Sagar Parikh, University of Michigan, Ann Arbor

T74. Clinical Outcomes in the Biomarkers of Ketamine (Bio-K) Study of Open-Label Iv Ketamine for Refractory Depression

Sagar Parikh*, Jennifer Vande Voort, Anastasia Yocum, Eric Achtyes, Fernando Goes, Louis Nykamp, Balwinder Singh, Daniela Lopez, Dan Maixner, Vijay Tarnal, Jennifer Severe, Mark Frye, John Greden, William Bobo, Susannah Tye

Sagar Parikh, University of Michigan, Ann Arbor

Posters

T75. Use and Experience of European Healthcare Professionals with Aripiprazole Once-Monthly 400 mg Two-Injection Start Initiation Regimen in Adult Patients with Schizophrenia

Andrea Fagiolini, Karolina Leopold, Sofia Pappa, William Cottam, Joe Hickey, Olivia Rogerson, Murat Yildirim, Clodagh Beckham* Clodagh Beckham, Otsuka Pharmaceutical Europe Ltd

T76. Response to Karxt in Short-Term Placebo-Controlled Trials in Schizophrenia

Ian Ramsay*, Colin Sauder, Inder Kaul Ian Ramsay, Karuna Therapeutics

T77. Functional and Sexual Disability, and Quality of Life after One Dose of MM120 (Lysergide D-Tartrate) in Adults with Generalized Anxiety Disorder

Todd Solomon*, Robert Barrow, Craig Conant, Eric Foster, Jamie Freedman, Paula Jacobsen, Jamileh Jemison, Sarah Karas, Daniel Karlin, Miri Halperin Wernli, Reid Robison Todd Solomon, Mind Med

T78. Measurement of Positive and Negative Symptoms Through Speech Analysis from Panss Interview Recordings in Patients with Schizophrenia

Anzar Abbas*, Georgios Efstathiadis, Michelle Worthington, Vijay Yadav, Alan Kott, Tejendra Patel, Colin Sauder Anzar Abbas, Brooklyn Health

T79. Prevalence and Correlates of Cognitive Impairment in Depression: Findings from the Texas Resilience Against Depression Study Joshua Jordan*, Li Shen, Cherise Chin Fatt, Adam Savitz, Amit Etkin,

Joshua Jordan, Alto Neuroscience

Shani Waninger, Ulysses Neuroscience

Madhukar Trivedi

T80. α-Tubulin Post-Translational Modifications as Potential Translational Biomarkers in Major Depressive Disorder Shani Waninger*, Aimée Freeburn, John Kealy, Massimiliano Bianchi

T81. The Seattle Trauma Nightmare Index: A Novel, Quantitative Self-

Report for Trauma Nightmares and Sleep Disruptions

Aaron Rosser*, Garth Terry, Murray Raskind, Sarah Campbell, Rebecca

Hendrickson

Aaron Rosser, University of Washington School of Medicine, Dept. of Psychiatry and Behv. Sci.

👰 = New Investigator Awardee 🗼 = Pharmaceutical Pipeline Presentation

T82. Evaluation of Psychosocial and Biological Markers of Vulnerability for Depressive Symptoms During Pregnancy: Preliminary Findings from the Study Present

Maria Grazia Di Benedetto*, Lucrezia Barbato, Fabio Gamba, Francesca Pontoglio, Melissa Rosa, Annamaria Cattaneo Maria Grazia Di Benedetto, University of Milan

T83. Should Psychosis Be Treated with tPA like a Stroke? Evidence for Pathological Coagulopathy in Psychosis

Kara Miecznikowski*, Henry Nasrallah Kara Miecznikowski, University of Cincinnati College of Medicine

T84. Physical Activity in Individuals with Schizophrenia

Kate Lyden*, Shelby Bachman, Ieuan Clay, Philip Harvey, J. Cara Pendergrass Kate Lyden, VivoSense, Inc

T85. Action Plans to Promote Diversity, Equity, and Inclusion in ASCP

Brenda Cabrera Mendoza, Andrew Olagunju, Mahavir Agarwal, Gilmar Gutierrez, Emily Smith*, Alexander Herman, Nicolette Stogios, Obiora Onwuameze, Francisco Moreno Emily Smith, Centre for Addiction and Mental Health, University of

Emily Smith, Centre for Addiction and Mental Health, University of Toronto

T86. Sex Differences in the Association Between Irritability and Suicidal Ideation

Ann House*, Taylor Helmbrecht, Sofia Alcasey, Abu Minhajuddin, Cherise Chin Fatt, Madhukar Trivedi, Manish Jha Ann House, University of Texas Southwestern Medical Center At Dallas

T87. Association of Pain with Symptoms of Irritability and Anhedonia in Individuals with Major Depressive Disorder and Healthy Controls Taylor Helmbrecht*, Ann Brindley House, Sofia Alcasey, Abu Minhajuddin, Cherise Chin Fatt, Madhukar Trivedi, Manish Jha Taylor Helmbrecht, The University of Texas Southwestern Medical Center, Department of Psychiatry

T88. Examining the Association Between Altitude of Residence and the Patterns of Cigarette and Alcohol Use in the United States

Danielle Boxer*, Nicolas Nunez, Young-Hoon Sung, Deborah Yurgelun-Todd, Perry Renshaw, Douglas Kondo
Danielle Boxer, Department of Psychiatry, University of Utah

Danielle Boxer, Department of Psychiatry, University of Utah

Posters

T89. TSND-201 (Methylone) for the Treatment of PTSD, MDD, and Other CNS Disorders

Jennifer Warner-Schmidt*, Amanda Jones, Martin Stogniew, Blake Mandell, Benjamin Kelmendi Jennifer Warner-Schmidt, Transcend Therapeutics

T90. Investigating the Impact of Psychostimulants and Comorbid Disorders on Misconducts Among Individuals with Attention-Deficit/ Hyperactivity Disorder in the Prison: A Preliminary Study

Alexandria Greifenberger, Gunter Lorberg, David Runnalls, Elssa Toumeh, Kathryn Fotinos, Tia Sternat, Irvin Epstein, Martin Katzman* Martin Katzman, START Clinic for Mood and Anxiety Disorders

T91. Oxybutynin is Effective on Methadone-Induced Hyperhidrosis treatment: A Case Report

Narges Joshaghani*, Eliseo Go Narges Joshaghani, Bronx Care Health System

T92. Effect of Ropanicant (SUVN-911), an α4β2 Receptor Antagonist in Animal Models of Depression

Ramakrishna Nirogi, Renny Abraham, Vljay Benade, Venkatesh Goura, Rajesh Kallepalli, Rajesh Babu Medapati, Vinod Kumar Goyal, Ramkumar Subramanian, Shankar Reddy Gagginapally, Abdul Rasheed Mohammed, Vinod Goyal*

Vinod Goyal, Suven Life Sciences Limited

T93. Noninterventional, Retrospective, Prospective, Longitudinal Cohort Study to Assess Antidepressant Treatment Patterns and Outcomes in Individuals with Major Depressive Disorder

Maurice Ohayon, Stéphanie Duhoux, Maggie McCue, Michelle Kirby, Michael Martin, Priscilla Driscoll Shempp, Andrew Krystal, Marie-Lise Cote, Priscilla Driscoll Shempp*

Priscilla Driscoll Shempp, Takeda Pharmaceuticals North America, Inc.

★ T94. CT-155: Early Stage Evidence in the Development of a Prescription Digital Therapeutic to Treat Experiential Negative Symptoms of Schizophrenia

Abhishek Pratap*, Cornelia Dorner-Ciossek, Cassandra Snipes, Mariya Petrova, Brendan D Hare, Thomas Mick, Shaheen E Lakhan Abhishek Pratap, Boehringer Ingelheim Pharmaceuticals, Inc.

Aaronson, Alexandra	29	Baweja, Raman	26
Aaronson, Scott T.	26, 29, 94	Bayer, Renee	105
Abbas, Anzar	108	Bearden, Carrie	80
Abdel, Fadi	105	Beaulieu, Serge	83
Abraham, Renny	110	Becerra, Sergio	91, 106
Achtyes, Eric	81, 107	Becker, Laura	85
Adamowicz, David	8, 86	Becker, Ryan	79
Adams, Julie L.	84, 100	Beckham, Clodagh	99, 108
Addington, Jean	80	Behbehani, Leily	100
Adedoyin, Adedayo	91	Behl, Saloni	48, 81, 97
Adeniyi, Clara	88	Benade, Vljay	94, 110
Agarwal, Mahavir	28, 29, 39, 44, 109	Benedetto, Shannon	49
9	84, 85, 90, 105	Benhaddouch, Lina	86
Agarwal, Sri Mahavir		•	
Ahmed, Saeed	26	Benrimoh, David	83
Albano, John	96	Bernstein, Sarah	81
Alcasey, Sofia	80, 94, 109	Besa, Reena	105
Alevizopoulos, Aristomenis	92	Besedina, Olya	84
Alevizopoulos, Georgios	92	Bianchi, Massimiliano	108
Alevizopoulou, Maria	92	Birznieks, Gunther	103
Alimonti, Andrea	85	Bispham, Jeoffrey	98
Alphs, Larry	71, 80, 89	Bizgu, Christine	100
Amushie, Chima	106	Bizot, Jean-Charles	99
Anand, Amit	43	Black, Jessica	88
Anderson, Benjamin	89	Blahova, Zuzana	85, 100
Andersson, Candace	82, 86, 87	Blair, Christopher	82, 98
Andreassen, Ole	71	Blanchard, Cassie	93
An, Xinming	100	Blanco, Carlos	12, 25, 26, 58
Apostol, George	99	Bobo, William	81, 96, 107
Apostolova, Nikolina	80	Boscutti, Andrea	9, 79
Arevalo, Christina	104	Boskovic, Dusica Hadzi	98
Arnold, Cameron	105	Bouchard, Richard R.	79
Arnovitz, Mitchell	9, 80	Bowrey, Hannah	87
Arvastson, Lars	81, 98, 101	Boxer, Danielle	109
Ashbrenner, Eric	95	Bozik, Michael	95
Athreya, Arjun	47, 96	Brannan, Stephen K.	88, 93
Aurora, Bill	91, 107	Brawman-Mintzer, Olga	90
Avissar, Michael	105	Breier, Alan	68, 89
Awasthi, Shivanshu	98	Bremmer, Michael	82
Awsare, Bharat	95	Bressolle-Gomeni, Francoise	91
Ayvaci, Emine	9, 79	Briggs, Farren	88
Bacha, Fida	106	Brown, Kyle	9, 46, 105
Bachi, Keren	52, 77, 83	Brundin, Lena	81
Bachman, Shelby	109	Buchhalter, August R.	89
Badami, Faizan	101, 105	Buckley, Timothy	104
•		Budilovsky-Kelley, Natalie	
Bailey, Genie	87	Buracchio, Teresa	87 10 57
Baker, Ross A.	92	'	10, 57
Baldessarini, Ross J.	5	Burch, Ronald	98, 99
Ballard, Elizabeth	28, 39, 47, 53	Burdick, Katherine E.	45, 53, 103
Ballon, Jacob	84, 104	Burgdorf, Jeff	89
Bandeira, Igor D.	9, 84	Burgdorf, Jeffrey	98, 99
Barac, Milica	96	Burghardt, Kyle	44
Barbato, Lucrezia	109	Burke, Mary C.	98
Barba-Villalobos, Griselda	106	Busche, Alena	101
Barrow, Robert	108	Bushnell, David	92
Bates, Dawn	99	Byrne, Kevin	106

Bystritsky, Alexander	91, 106	Cohen, Lee	81, 97
Cadenhead, Kristin	80	Comai, Stefano	85, 92
Cairns, Kathleen	106	Companioni, Maria	89
Calarge, Chadi	106	Conant, Craig	108
Calkin, Cynthia	106	Cooper, Nicholas	105
Camilleri, Michael	105	Coric, Vladimir	95
Campbell, Ethan	82	Cornblatt, Barbara	80
Campbell, Michelle	11, 57	Correll, Christoph U.	29, 84, 103, 104
Campbell, Sarah	108	Costa-Dookhan, Kenya	85
Cannon, Tyrone	80	Costi, Sara	76
Canuso, Carla M.	89, 92	Cote, Marie-Lise	110
Cao, Emma	82	Cote, Sarah	99
Carey, Theadia L.	26	Cottam, William	108
Carhart-Harris, Robin	86	Cozza, Eugene	104
Carlton, Tarolyn	102	Crismon, M. Lynn	26, 88
Carmody, Thomas	90, 96	Croarkin, Paul	47, 96
Carpenter, David	90	Crossman, Julia	86, 101
Carrieira, Tabitha	101	Cummings, Jeffrey	87
Carrión, Ricardo	80	Cunnane, Stephen	105
Carrithers, Brennan	86	Cusin, Cristina	
		-	60, 96
Cato, Jo	92	Cutler, Andrew J.	82, 91, 92, 103, 107
Cattaneo, Annamaria	109	Czarnkowski, Piotr	104
Certa, Julia	85	Czeisler, Emily	103
Cetinkaya, Doga	96	D'Ambrosio, Julia	104
Chadwick, Sean	103	Damyanova, Ani	81, 98, 101
Chai-Rees, Jamie	87	Dang, Xin	86
Champasa, Paggard	92	Daniel, David	101
Chan, Grace	89	Davis, Lori L.	20, 28, 39, 48, 66, 67,
Chan, Lider	91, 106		79, 81, 97, 98
Chatham, Anthony	106	DeBattista, Charles	90
Chatham, Christopher	71	Decaro, Sydney	96
Chatterjee, Susmita	101	Dedic, Nina	105
Chawla, Devika	85	Dedrick, Elizabeth	94
Chen, Changzheng	102	DeHart, Brady	85
Chen, Crystal	93	DeMartinis, Nicholas	81, 97
Chengappa, Roy	106	De Martin, Sara	85, 92
Cheng, Hailong	97	De, Riddhita	90, 105
Cheng, Jocelyn Y.	89, 102	Desai, Urvi	87
Chepke, Craig	87	Desjardins, Simon	96
Ching, Terence	86, 102	Detke, Michael	89
Chintoh, Araba	85, 90	Devaraj, Sridevi	106
Chitayat, David	97	Deveney, Chloe	91, 106
Chong, Junjun	86	Diaz, Francisco	67
Choo, Tse-Hwei	97	Diaz, John Carlos	51
Chrones, Lambros	82	Diaz-Ramírez, Diana	86
Cirillo, Nikolas	91	Di Benedetto, Maria Grazia	109
Citrome, Leslie	26, 29, 49, 97, 103,	Ding, Grace	82
	105	Dinh, Stephanie	106
Clark, Crystal	29	Doane, Michael	104
Claxton, Amy	93	Dokucu, Mehmet	90
Clay, leuan	109	Donahue, Lia	95
Clayton, Anita H.	29, 103	Donello, John	98, 99
Clemens, Kristin	87	Donovan, Ramona	82
Cohen, Elan	93	Doolin, Elisabeth	86, 101
Cohen, Lawrence J.	26, 51	Doran, Jason	87

Dorner-Ciossek, Cornelia	84, 100, 110	Fischer, Bernard	22, 46, 78
Dougherty, McKenna	94	Fisher, Lauren	96
Drevets, Wayne C.	89, 92	Fitzgerald, Alison	97
D'Souza, lan	102	Flint, Candace	98
Duhoux, Stéphanie	110	Floam, Samantha	102
Dunbar, Martin	103, 104	Flom, Megan	88
Dunlop, Boadie	82	Flossbach, Yanina	89, 103
Dunn, Walter	28, 39	Folli, Franco	85, 92
Durgam, Suresh	87, 102	Forman-Hoffman, Valerie L.	88
Dworak, Heather	81, 97	Foster, April	83
Dworetzky, Steven	95	Foster, Eric	108
Earley, Willie R.	87, 102	Fotinos, Kathryn	110
Ebdrup, Bjørn	90	Francis, Shyanne	97
Echevarria, Barbara	52	Francoeur, Bruno	95
Efstathiadis, Georgios	108	Frank, Ellen	45, 99
Egan, Donald	78	Freeburn, Aimée	108
Eglit, Graham	82	Freedman, Jamie M.	84, 108
Eid, Diab	87	Freeman, Marlene P.	26, 29, 81, 97
Einstadter, Douglas	88	Freyberg, Zachary	84
Ellickson, Stephanie	96	Frisch, Caroline	97
Ellingrod, Vicki	85	Frost, Michael	87
Ellis, Jacob	94	Frost-Pineda, Kimberly	99
-		Frye, Mark	
Elmallakh, Rifaat	81	Fu, Dong Jing	45, 81, 107
Emmel, Peter	105	, 0 0	92
Enault, Martin	83	Fuller, Kaitlin	84
Enemuo, Kevin	91, 106	Fuster-Astor, Frances	86
Engelhardt, Clara	101	Gabbay, Vilma	78
Engels, Jean	98	Gaccione, Peter	81
Engler, Jenicka	80	Gagginapally, Shankar Reddy	110
English, Brett	85, 100	Galante, Emma	103
Epstein, Irvin	110	Gallagher, Erin	104
Eramo, Anna	107	Gamba, Fabio	109
Ereshefsky, Larry	89, 93	Gannon, Jessica	106
Eriksson, Hans	49, 81, 98, 101	Ganz-Leary, Casey	93
Erritzoe, David	86	Garcia, Jose	106
Estrada, Adriana	104	Gardner, George	83
Etkin, Amit	101, 105, 108	Garibaldi, George	52
Evans, Miriam	96	Garland, Eric	106
Faden, Justin	26, 69	Gaynes, Bradley	26
Fagiolini, Andrea	108	Gentile, Kimberly	95
Falkai, Peter	85, 100	Geraci, Joseph	71, 80
Falk, Daniel E.	19, 26, 66	Gerlach, Daniel	101
Falola, Michael	99	Germine, Laura	100
Fan, Miaolin	89	Gibbons, Robert	99
Farchione, Tiffany	10, 22, 25, 28, 39, 57,	Gilbert, Jessica	105
	69, 78	Gill, Jaspreet	88
Farokhnia, Mehdi	50, 96	Gilmer, William	104
Fatt, Cherise Chin	26, 96, 108, 109	Gilmore, Thomas	82
Fava, Maurizio	43, 82, 90, 92, 96	Giollabhui, Naoise Mac	82
Feder, Adriana	48	Go, Eliseo	93, 110
Fehnert, Ben	82	Godinov, Yordan	87
Felger, Jennifer	52	Goes, Fernando	81, 107
Fijtman, Adam	9, 105	Goldberg, Joseph F.	18, 29, 45, 51, 66, 69
Fink-Jensen, Anders	90	Goldman, Robert	81, 97
Fiorelli, Nicole	88	Gold, Michael	91, 107
			,

O D-bt-	04	Heifete Berie D	0.4
Gomeni, Roberto	91	Heifets, Boris D.	84
Gomoll, Brian	104	Helmbrecht, Taylor	94, 109
Goncalves, Samantha	101	Hendershot, Christian	82
Goodnight, Bradley	79, 97, 98	Hendrick, John	106
Goodwin, Guy	87	Hendrickson, Rebecca	26, 44, 67, 108
Gordon, Adam	91	Henneman, Isabella	96
Gordon, Alexandra	86	Henningfield, Jack E.	89
Gorny, Stephen	91	Henry, Michael	26
Gould, Dylan	82	Herman, Alexander	93, 109
Gould, Todd	105	Hernández-Díaz, Sonia	97
Goura, Venkatesh	110	Hershenberg, Rachel	106
Govani, Viraj	97	Hersson-Edery, Fanny	83
Goyal, Vinod	94, 110	Hewitt, Nilay	59
Gozal, David	102	Hickey, Joe	108
Grant, Caroline	96	Ho, Ming-Fen	60
Grattan, Vincent T.	107	Hobart, Mary	81, 97
Greden, John	81, 107	Hoberg, Amber R.	103
Greenstein, Dede	105	Hoffman, Katelyn	91, 106
Greifenberger, Alexandria	110	Holland, Chris	79, 97, 98
Grindell, Vera	93	Hopkinson, Craig	103
Grossberg, George	87	Hopkins, Seth C.	51, 79, 90, 105
Guidetti, Clotilde	85, 90, 92	Horan, William	83
Guillaume, Xavier	99	Houck, Christina	80
Gumenyuk, Solomiya	9, 79	House, Ann	94, 109
Gunturu, Sasidhar	90	Howes, Oliver D.	90
Gupta, Alankar	84	Hsu, David	100
Gur, Raquel	93	Huang, Wan-Ting (Tina)	79, 97, 98
Gurley, Susan	48	Huang, Zhengyi Sissi	77, 37, 30
Gutierrez, Gilmar	93, 109	Hubner, Carol	101
Gutin, Alexander	85	Huddleston, Isabella	94
Guzman, Iridian	82	Hughes, Alejandro	104
·	91	Humber, Bailey	105
Habelhah, Barshen			
Hahn, Margaret	84, 85, 90, 105	Huo, Jason	87, 102
Hajjar, Ihab	107	Hurd, Yasmin	83 106
Hall, Nancy	89, 102	Hutchison, CJ	
Hameed, Ahmad	26	Igoumenou, Artemis	92
Hameed, Usman	26	Ikezawa, Satoru	85, 100
Hanson, Barbara	86	Ingle, Marybeth	82
Harding, Lisa	85, 104	Inturrisi, Charles	92
Hare, Brendan D.	84, 100, 110	losifescu, Dan	26, 29, 46, 76, 90
Harkavy-Friedman, Jill	47, 53	Irungu, Benson M.	79
Harlin, Matt	87	Issa, Fuad	20, 66
Haroon, Jonathan	91, 106	Jackson, Kristi	83
Harris, Herb	98	Jacobsen, Jacob	90
Harrsen, Kristine	99	Jacobsen, Paula L.	49, 84, 108
Hart, Jennifer	90	Jagannatha, Shyla	103
Harvey, Philip	93, 109	Jain, Rakesh	82
Harvey, Ray	103	Janik, Adam	92
Hasan, Khader M.	79	Javitt, Daniel	97
Hassman, Howard	93	Javitt, Jonathan	94
Hatano, Mai	83	Jawish, Rana	9, 91
Hayden, Jen	103	Jayarajan, Pradeep	94
Hayden, Jennifer	103	Jemison, Jamileh	84, 108
Hefting, Nanco	81, 97	Jensen, Christopher	95
Heider, Robin	9, 61	Jetta, Satish	94

Jha, Manish	25, 52, 53, 80, 85, 90,	Klassen, Larry	69
	94, 96, 109	Kleiman, Sarah	86, 102
Jha, Manish Kumar	26	Klein, Klara	82
Jiang, Jeannette	79, 97, 98	Klein, Rebecca	90
Jiang, Shixie	26	Kloiber, Stefan	83
Johnson, Holly	85	Klumpp, Heide	104
Johnson, Maria	90	Knop, Filip K.	90
Johnson, Nathan	104	Koblan, Kenneth S.	79, 81, 90, 97, 105
Jones, Alexia	81	Koenig, Aaron	59
Jones, Amanda	86, 102, 110	Kogan, Emily	103
Jones, Christopher W.	100	Koizumi, Teruki	83
Jordan, lain	86, 102	Kondo, Douglas	109
Jordan, Joshua	9, 61, 101, 105, 108	Konofal, Eric	83, 99
Jordan, Kaya	106	Koob, George	96
Jordan, Robyn	82	Koopman, Jacob	88
Jordan, Sheldon	91, 106	Kopcznski, Anika	96
Joshaghani, Narges	93, 110	Koralnik, Igor	86
Joshi, Kruti	85, 87, 104	Korann, Vittal	90
Kahn, René	104	Kornstein, Susan	26, 29
Kallepalli, Rajesh	110	Kostantinis, Georgios	82
Kando, Judith	105	Kott, Alan	101, 108
Kandukuri, Lakshmi	84	Kozauer, Susan G.	87, 102
Kane, Gary	85, 104	Kozel, F. Andrew	103
Kane, John M.	7, 68, 80, 107	Kratter, lan H.	84
Kanes, Stephen	93	Kreitzer, Anatol C.	101
Kantrowitz, Joshua	97	Kritzer, Michael	96
Kapadia, Shivani	98	Kroger, Cornelia	92
Kaplita, Stephen	95	Krystal, Andrew D.	89, 110
Karas, Sarah	84, 108	Krystal, John H.	100
Karim, Alina	98	Kuhn, Taylor	91, 106
Karlin, Daniel	84, 108	Kumar, Rakesh	94
Karnovsky, Alla	85	Kung, Simon	80, 94
Karp, Jordan F.	26, 83	Kupfer, David	99
Katzman, Martin	68, 110	Kwak, Hannah	86, 102
Kaul, Inder	83, 88, 108	LaGasse, Katlin	83
Kealy, John	108	Lakhan, Shaheen E.	84, 100, 110
Keleher, Madeline	102	Laliberté, François	84
Kelly, Ryan	89	Lamon-Fava, Stefania	82
Kelmendi, Benjamin	86, 102, 110	Lane, Rosanne	92
Kemp, David	82	Larsen, Frank	87
Kendrick, Jeremy	99	Larsen, Klaus Groes	81, 97
Kenny, Paul	16, 65	Lassen, Elizabeth	104
Kerolous, Majid	100	Lathia, Chetan	91
Keshavan, Matcheri	80	Laughren, Thomas	89
Keshishyan, Anahit	106	Lauriello, John	104
Kettner, Hannes	86	Lavigne, Gordon	46
Khatib, Rasha	82	Lawson, William	80
Killenberg, Parker	81, 97	Leary, Eileen B.	102
Killingsworth, Randall	95	Lederman, Seth	59, 98, 100
King, James	82	Lee, Daniel Lee, Ellen	81, 97
Kinkead, Becky	82	,	86
Kinon, Bruce	28, 39	Lee, Janet	80
Kirby, Michelle	110	Lee, Jiwon	84, 85
Kirson, Noam	87	Lee, Yoojin	9, 60
Kitay, Brandon	106	Leggio, Lorenzo	96

Leitschuh, Caroline	102	Marrocu, Alessia	86
Lejeune, Dominique	84	Martinez, Antonio	104
Lennek, Lisa	90	Martinez, Cristina	84
Leopold, Karolina	108	Martínez-González, Karen	86
Leow, Alex	102	Martin, Margaret	102
Lerner, Jason	88	Martin, Michael	82, 98, 110
· · · · · · · · · · · · · · · · · · ·	88	Martin-Willett, Renee	61
Lesanpezeshki, Mohammad Levine, Steven			
,	88	Marwood, Lindsey	87
Levin, Jennifer	77, 88	Massé, Fabienne	99
Lewis, Benjamin	106	Mathai, David	92
Lew, Robert	90, 105	Mathalon, Daniel	80
Li, Qiang	71, 89	Mathew, Sanjay J.	90, 91, 107
Li, Qingqin	103	Mattarei, Andrea	85, 92
Li, Yan	81	Matthew, Sanjay	29
Liang, Katharine	44	Matthews-Hayes, Tina	84, 104
Licht, Ava	96	Mattingly, Gregory W.	103
Lillie, James	101	Mayer, Megan	97
Lines, Katherine	106	Mayes, Taryn	96
Lipunova, Nadezda	70	McCall, William Vaughn	90
Liu, Kevin	97	McCarthy, Michael	84
Loebel, Antony	97	McCormack, Tim	95
Lofwall, Michelle	87	McCue, Maggie	82, 98, 110
Loo, Bradford	87	McCutcheon, Robert	90
Loomer, Stephanie	99	McDonnell, David	103, 104
Looper, Karl J.	83	McGrory, James	103, 104
Lopez, Daniela	107	McInnes, Lynne	75, 85, 104
Lorberg, Gunter	68, 110	McInnis, Melvin	107
Lormier, Anh-Tuan	83	McIntosh, Joseph	50
Lund, Bryce	94	McIntyre, Roger S.	69, 75, 82, 98, 102,
Lyden, Kate	109		103
Lynum, Karimah S. Bell	87	McLean, Samuel A	100
Macaluso, Matthew	29, 51, 82, 99	McNamara, Cynthia	80
Macarayan, Erlyn	98	McVoy, Molly	77
MacKenzie, Nicole	85	Measom, Michael	100
Madaj, Zachary	81	Medapati, Rajesh Babu	110
Madera-McDonough, Jessica	87, 99	Medeiros, Gustavo	46, 81
Madore, Michelle	103	Meli, Alicia	105
Mahdavi, Kennedy	91, 106	Mendoza, Brenda Cabrera	93, 109
Maheshwari, Priya	85	Meyer, Chip	102
Maiboe, Katarina	101	Micheelsen, Arun	99
Maixner, Dan	107	Mickey, Brian	91, 99
Majd, Marzieh	103	Mick, Thomas	84, 110
Makhlouf, Ahmed	61	Miecznikowski, Kara	109
Maksyutynska, Kateryna	84, 105	Milanovic, Snezana	90, 105
Mandell, Ally	106	Miller, Jennifer	70
Mandell, Blake	86, 102, 110	Miller, Paul W	86, 102
Manfredi, Paolo	85, 92	Mills, James	106
Mantua, Valentina	11, 26, 58	Mills, Jeffrey	47
Marci, Carl	85	Minhajuddin, Abu	53, 79, 94, 96, 109
Marcus, Ronald	93	Mintz, Council	100
Marder, Stephen R.	29, 85, 100	Miola, Alessandro	94
Margolese, Howard C.	83	Mischoulon, David	82, 93
Mariano, Timothy Y.	88	Moazen-Zadeh, Ehsan	83
Markota, Matej	26	Modirrousta, Mandana	90
Marquez, Sebastian	101	Mohammed, Abdul Rasheed	94, 110
marquoz, oobuotian		monaninou, ribuui riuolloou	0., 110

Moline, Margaret	89, 102	Odontiadis, Michael	86, 101
Monteiro, Jonathan	84	Ogirala, Ajay	79
Montero, Judith	89, 93	Ohayon, Maurice	110
Monti, Louis	92	Ohtani, Yohei	83
Montoya, Ivan	19, 28, 39, 66	Oladini, Bolu	99
Moodie, Erica	83	Olagunju, Andrew	96, 109
Morel, Anne-Laure	99	Olagunju, Andrew T.	93
Moreno, Francisco	27, 29, 70, 93, 109	Olson, Christopher	104
Morin, Pamela	85	Olson-Marszewski, Rachael	104
Moskal, Joseph R	98, 99	Onwuameze, Obiora E.	93, 109
Mueller, Daniel	85	Opler, Mark	51, 93, 98
Munivar, Azim	49, 95	Orsini, Lucinda	87, 88
Murata, Stephen	81	Ortiz-Pena, Melissa	86
Murphy, Nicholas	27, 53, 76	Palacharla, Veera Raghava Chow	
Murrough, James	44, 52, 53, 76	Paladino, Michael	82
Muse, Nina	88	Pandey, Santosh Kumar	94
Muzyk, Andrew	86	Pandina, Gahan	59, 89, 103
Nabulsi, Nadia	84, 104	Panganiban, Kristoffer	84, 85, 105
Nagai, Nobuhiro	83	Pani, Luca	27, 80, 92
Nagornaya, Sophia	80	Papakostas, George	29, 43, 90
Nag, Soma	79, 97, 98, 99	Papanastasiou, Evangelos	81, 98, 101
Nakajima, Shinichiro	83	Papapetropoulos, Spyros	50, 86, 101
Nakajima, Waki	83	Pappagallo, Marco	85, 92
Nandy, Karabi	79	Pappa, Sofia	108
Nasca, Carla	27	Parikh, Mousam	84, 104
Nasrallah, Henry	109	Parikh, Sagar V.	81, 82, 83, 98, 107
Navarro, Natalie	101	Parker-Guilbert, Kelly	86, 102
Nayak, Sandeep	86	Parks, Gregory	102
Neal, Reem	107	Passarell, Julie	87
Nelson, Erik	81	Patel, Tejendra	108
Nemeroff, Charles	93	Patterson, Jonathan	79, 97, 98
Neugebauer, Nichole	105	Paul, Dharam	86, 101
Newcorn, Jeffrey	12, 58	Pavlicova, Martina	17, 65
Neylan, Thomas	48	Payne, Jennifer	47
Nguyen, Huy-Binh	80, 103	Pazdernik, Vanessa	94
Nguyen, Jacqueline	106	Pederson, Aderonke Bamgbose	61
Nguyen, Tram	60	Pedrelli, Paola	96
Nguyen, Veronica	102	Pendergrass, J. Cara	109
Nicoloro-SantaBarbara, Jennifer		Pereira, Sandra	84
Nierenberg, Andrew	15, 65, 85, 94	Perkins, Diana	80
Nierenberg, Andrew Alan	27	Petrova, Mariya	110
Nirogi, Ramakrishna	94, 110	Peyron, Christelle	99
Njuguna, Moses	71, 96	Philip, Noah	103
Nomoto-Takahashi, Kie	83	Phillips, Katharine	28, 39
Nordbeck, Elin Banke	87	Phillips, Luann	87
Norred, Michael	103	Piiwaa, Kayla	93
Novak, Keisha	93	Pinard, Georges-F.	83
Nunes, Edward	87	Pollack, Mark	14, 59
Nunez, Nicolas	82, 94, 109	Polymeropoulos, Christos	103
Nykamp, Louis	107	Polymeropoulos, Mihael	103
Oberbarnscheidt, Thersilla	107	Pontoglio, Francesca	109
O'Brien, Brittany	43	Posse, Patricio Riva	106
Ochman, Francis	93	Potter, William	89
O'Connor, Shane	88	Powell, Jessica	101, 105
O'Donnell, Carolyn	104	Powell, Margret	82

Prasad, Femin	84, 90	Rush, A.	70, 104
Pratap, Abhishek	49, 84, 110	Rush, Megan	107
Prensky, Zachary	107	Rutigliano, Grazia	90
Prestwood, Tyler	84	Sabé, Michel	6
Procyshyn, Ric M.	87	Sachs, Gary S.	87
Pype, Steve	89	Sajatovic, Martha	77, 88
Qiu, Xin	92	Samadani, Ali	103
Qorri, Bessi	80	Sanacora, Gerard	27, 29, 75
Qu, Alice	87	Sanches, Marcos	106
Qureshi, Irfan	95	Sandoval, Veronica	70
Rajachandran, Lavanya	107	Sapko, Michael	94
Raj, Edwin	88	Sapra, Mamta	83
Ramsay, Ian	88, 108	Sarampote, Christopher	18, 25, 28, 66
Ramu, Aashraya	90	Sarkar, Joydeep	104
Rapaport, Mark H.	25, 28, 53, 67, 82	Saucier, Cory	83
Raskind, Murray	108	Sauder, Colin	83, 88, 93, 108
Raskin, Joel	90	Saunders, Erika	27, 29
Ravichandran, Bharath	79, 97, 98	Saunders-Lustick, Joshua	107
Ravidran, Akshay	101	Savitz, Adam	49, 51, 101, 105, 108
Ravula, Jyothsna	94	Saxby, Brian	80
Reardon, Claire	106	Schatzberg, Alan F.	84
Rege, Bhaskar	103	Schettler, Pamela	82
Rehman, Sonia	103	Schmid, Karin	81, 98, 101
Rej, Soham	83	Schooler, Nina	28, 39, 46
Remington, Gary	85, 90	Schork, Nicholas	67
Renshaw, Perry	109	Sembower, Mark A.	89
Rentsch, Christopher	96	Serrano, Alyssa	94
Reuman, Audrey	97	Severe, Jennifer	107
Reuteman-Fowler, Corey	85, 100	Severtson, Stevan Geoffrey	85
Riddle, Julia	13, 58	Sevinsky, Heather	95
Riesenberg, Robert	90	Shah, Alpesh	81
Risinger, Robert	50, 91, 107	Shanahan, Megan	103
Rive, Benoit	87	Sharp, Harlow	104
Rizk, Mina	60	Shekhar, Anantha	98, 99
Roberts, Daniel	86	Shelton, Richard	51, 90
Robin, Jessica	100	Shempp, Priscilla Driscoll	98, 110
Robin, Maxime	83	Shen, Li	101, 108
Robinson, Delbert	68	Shen, Yifeng	106
Robinson, lan	98	Sheridan, Pam	81
Robison, Heather	91, 107	Shinde, Anil	94
Robison, Reid	84, 108	Shoultz, Audrey	94
Rodriguez, Edith Liliana P.	80	Shtrahman, Matthew	86
Rogerson, Olivia	108	Silva, Rob	84
Rolan, Paul	101	Simpson, Carra	100
Rosa, Melissa	109	Simpson, William	100
Rose, Maimon	101, 105	Singh, Anand	94
Rosipal, Roman	99	Singh, Balwinder	76, 80, 81, 94, 107
Rossa, Ella	81	Singh, Manpreet Kaur	27, 47, 69
Rosser, Aaron	108	Sinha, Rajita	77
Roy, Anit	82	Sirbu, Cristian	80
Rucker, Sloan	83	Siskind, Dan	90
Ruiz, Patricia	89	Sisley, Stephanie	106
Runnalls, David	110	Skubiak, Taisa	81, 97
Ruschel, Sandra	89	Slater, Holli	47, 79
,		, -	, -

0	0.4	Tandan Obandan	00
Slettebo, Teresa	94	Taylor, Charles	86
Smid, Marcela	91	Taylor, Jerome H.	93
Smieszek, Sandra	103	Taylor, Rachael W.	87, 88
Smith, Deborah	95	Taylor, Stephan	85
Smith, Emily	84, 93, 105, 109	Tcheremissine, Oleg V.	16, 27, 65
Smith, Mark A.	86, 101	Teeple, Amanda	87
Snipes, Cassandra	84, 100, 110	Teixeira, Antonio Lucio	27
Soares, Jair C.	27, 79	Teoh, Emma	88
Sojka, Ellen	81, 97	Terry, Garth	108
Solages, Martine	23, 78	Thase, Michael E.	89, 90
Solomon, Todd	108	Thilakarathne, Pushpike	87
Sonnenberg, John	52	Thipphawong, John	89
Sorajja, Natali	104	Thomas, Jillian	92
Soria, Maritza	101	Thomas, Zachariah	82
Soudavari, Romina	100	Thompson, Kimberly R.	101
Spear, Matthew	93	Tiberg, Fredrik	87
Spilka, Michael	100	Toft, Sam	96
Sriram, Nivedita	80	Tohen, Mauricio	103
Stahl, Stephen	102	Toll, Russell	96
Stanton, Patric	98	Tomasi, Dardo	83
Steinberg, Louisa	27	Torres, Rosarelis	103
Steiner, Warren	83	Toumeh, Elssa	110
Stein, Murray B.	86	Tow, Amanda	82
Sternat, Tia	69, 110	Traversa, Sergio	92
Stogios, Nicolette	44, 93, 109	Tredici, Andria Del	85
Stogniew, Martin	86, 102, 110	Trejo, Leonardo	99
Stone, William	80	Trivedi, Madhukar H.	44, 47, 78, 79, 90, 94,
Strand, Lauren	104		96, 108, 109
Strawn, Jeffrey	47	Trombello, Joseph M.	89
Streicher, Caroline	87	Truong, Thanh Thuy	92
Stringer, Kathleen	85	Tsai, Joyce	87
Strote, Caren	81, 98, 101	Tsigankova, Valeriya	106
Subramanian, Ramkumar	94, 110	Tso, Ivy	85
Such, Pedro	87, 99	Tsuang, Ming	80
Sullivan, Gregory	98, 100	Tsugawa, Sakiko	83
Sundar, Guhan	101	Tucciarone, Jason	84
Sung, Young-Hoon	109	Tye, Susannah	107
Suppes, Trisha	29	Uchida, Hiroyuki	83
Surya, Jean	106	Ung, Eehwa	84, 100
Sutton, Heather	70	Vaino, Andrew R.	107
Swartz, Holly	28, 29, 39	Vaishnavi, Sandeep	102
Syed, Fatima Zahara	86	Vance, Alex	70
Szabo, Steven T.	79	Van der Vaart, Andrew	94
-		Vande Voort, Jennifer	46
Szegedi, Armin	81, 97	· · · · · · · · · · · · · · · · · · ·	
Szpunar, Mercedes	81	Van Dongen, Hans	102
Taber, Katie Johansen	85	Vano, Luke	90
Tabuteau, Herriot	86, 87, 102	van Oort, Jasper	9, 60
Ta, Jamie	84	Vaughn, Ben	98
Takahashi, Takuya	83	Velligan, Dawn	68
Tang, Sunny	100	Vendruscolo, Leandro	96
Tani, Hideaki	83	Venkatramen, Victoria	91
Taquet, Maxime	70	Verghese, Maya	97
Targum, Steven	93	Vieta, Eduard	103
Tarnal, Vijay	107	Viguera, Adele	81, 97
Taubman, Danielle	107	Villsbøll, Tina	90

Visitacion, Nicole	91, 107	Woods, Scott	80
Vitolo, Ottavio Valerio	27	Worley, Matt	85, 104
Vivo, Michael De	91	Worthington, Michelle	108
Vogeley, Abigail	105	Wu, Wei	101
Vong, Kathy	104	Wyka, Katarzyna	93
Voort, Jennifer Vande	80, 81, 94, 107	Xiao, Changfu	103
Wadhwa, Abhishek	82	Xu, Haiyan	89, 103
Wajs, Ewa	89	Xu, Mengdan	100
Wakhlu, Sidarth	80, 94	Yadav, Vijay	108
Walker, Elaine	80	Yakubu, Amin	103
Wallace, Meredith	99	Yala, Joy	88
Walling, David	93	Yang, Zhiyi	107
Walsh, Sharon	87	Yatham, Lakshmi N.	102
Wang, Chao	101, 105	Yatomi, Taisuke	9, 83
Wang, Jocelyn	103	Yavi, Mani	105
Wang, Ken	89	Yee, Tracy	84
Wang, Tracy Y.	21, 66	Yildirim, Murat	87, 99, 108
Wang, Xiaofeng	87	Yocum, Anastasia	107
Wang, Xingmei	101	Yoon, Hannah	97
Waninger, Shani	108	Young, Matthew	88
Waraich, Simranpreet	100	Yuan, Jason	91, 107
Ward, Kristen	85	Yucebas, Defne	82
Warner-Schmidt, Jennifer	86, 102, 110	Yu, Jun	80, 103
Washington, Krishan	80	Yu, Philip	96
Watson, Carolyn	93	Yurgelun-Todd, Deborah	109
Weaver, Shelley	81, 97	Zadourian, Allison	96
Weiden, Peter J.	45, 61, 83, 103	Zaki, Lara	82
Weijers, Laure	104	Zammit, Gary K.	89, 102
Weise, Celeste	88	Zanardo, Enrico	84
Weiss, Brandon	86	Zandi, Hasiba	96
Wernli, Miri Halperin	108	Zang, Xiao-lei	98
Wexler, Eric	27	Zarate, Carlos	27, 29, 49, 105
White, David	101	Zeifman, Richard	86
White, Samantha	99	Zemel, Babette	106
Whitmore, Kate	83	Zeng, Hui	81, 97
Wicken, Cassie	82, 99	Zhang, Fan	89
Wilcox, Charles	88	Zhang, Yun	89, 103
Wilkinson, Samuel	75, 76	Zhao, Yang	86
Williams, Andre	88	Zhou, Carl	96
Wing, Vicki	88	Zhou, Huanxue	86
Winokur, Andrew	89	Zhu, Kaitlly	105
Wittenberg, Gayle	71, 103	Zhukovsky, Peter	76
Wolkowitz, Owen	89	Zielinski, Margaret	91
Wong, Dean F.	107	Zimmerman, Mark	100
Wong, Joshua	104	zu Eulenburg, Christine	81, 98, 101
Wood, Michael W	101	Zuschlag, Zachary David	27, 103
Woodside, Leana	90		

Notes ASCP

ASCP Notes

SEE YOUNEXT YEAR!

2025 ASCP ANNUAL MEETING MAY 27 – MAY 30, 2025 IN SCOTTSDALE, ARIZONA

